Efficacy of Potassium Nitrate in HFpEF    Page 1 of 79 
V12 – Date 07Oct2021  
 
 . C O N F I D E N T I A L   
 
CLINICAL TRIAL PROTOCOL, R01 HL121510  
Effect of KNO 3 Compared to K Cl on O xygen UpTake in H eart Failure with  
Preserved Ejection Fraction (KNO 3CK OUT HFpEF)  
Version: V12 Date: 07-Oct-2021  
Sponsor: University of Pennsylvania  
Sponsor Representative: Emma A. Meagher, MD  
Sponsor email: psom -ind-ide@pobox.upenn.edu 
 
Funding Sponsor:  National Heart, Lung and Blood Institute (NHLBI)  
Study Chair / Grant Principal Investigator:  
Julio A. Chirinos, M.D., Ph.D.  
 
Site Principal Investigators (alphabetical order)  
Sanjiv Shah, M.D. (P.I., Northwestern Site)  
Sujith Kuruvilla (P.I., Corporal Michael J. Crescenz VAMC Site)  
Payman Zamani, M.D. (P.I., Penn Site)  
 
Sub-Investigators (alphabetical order)  
Thomas Cappola, M.D.  
Jesse Chittams, M.Sc.  
Alexandra Hanlon., Ph.D.  
Kenneth Margulies, M.D.  
Ravinder Reddy, MD, PhD  
Srinath Adusumalli, MD, M.Sc.  
 
Data Coordinating Center:  
Alexandra Hanlon, Ph.D. (Direc tor) and Jesse Chittams, M.Sc.  
NIH Program Officer:  
Patrice Desvigne -Nickens, M.D.   
Efficacy of Potassium Nitrate in HFpEF    Page 2 of 79 
V12 – Date 07Oct2021  
 
 Table of Contents  
1. SPECIFIC AIMS .................................................................................................................................. 5 
2. TRIAL SUMMARY TABLE (OBJECTIVES AND ENDPOINTS)  ........................................................... 8 
3. BACKGROUND AND SIGNIFICANCE  ................................................................................................ 9 
3.1. The nitrate– nitrite –NO activation pathway  .................................................................................. 10 
3.2. Peripheral mechanisms of exercise intolerance in HFpEF .......................................................... 11 
exercise capacity  ............................................................................................................................... 13 
3.4. Rationale behind the use of inorganic nitrate as a therapeutic approach in HFpEF .................... 14 
3.5. Preliminary data: effects of a single- dose of inorganic nitrate in HFpEF ..................................... 15 
3.6 Effect on Myocardial Perfusion Reserve in HFpEF (“Cardiac MRI sub- study”)  ............................. 18 
4. STUDY DESIGN AND POPULATION  ............................................................................................... 18 
4.1. Overview of study des ign ............................................................................................................ 18 
4.2 Study Sites  .................................................................................................................................. 19 
4.3. Study Population ........................................................................................................................ 19 
4.4 Randomized intervention ............................................................................................................. 22 
5. STUDY VISITS AND PROCEDURES  ............................................................................................... 22 
5.1. Initial Visit  ................................................................................................................................... 23 
5.2. Randomization procedure  ........................................................................................................... 25 
5.3. Intervention Phase 1  ................................................................................................................... 25 
5.4. 1- week washout period ............................................................................................................... 27 
5.5. Intervention Phase 2  ................................................................................................................... 27 
5.6 Adverse Event Reporting ............................................................................................................. 29 
5.7. Subject withdrawal / Early termination ........................................................................................ 29 
5.8. Concomitant Medication ............................................................................................................. 29 
6. DRUG DISPENSING, ACCOUNTABILITY, AND DESTRUCTION  .................................................... 30 
6.1. Rules for un -blinding ................................................................................................................... 30 
7. ADVERSE EVENTS  .......................................................................................................................... 30 
7.1. Key definitions  ............................................................................................................................ 30 
7.2. Classification of AE/ADEs  ........................................................................................................... 31 
7.3. Recording and Reporting of Adverse Events  .............................................................................. 33 
7.4. Follow -up .................................................................................................................................... 34 
7.5. Management of Suspected Unexpected Serious Adverse Reaction  ........................................... 34 
7.6. Pregnancy  .................................................................................................................................. 34 
8. STUDY MEASUREMENTS AND DATA COLLECTION  ..................................................................... 35 
Efficacy of Potassium Nitrate in HFpEF    Page 3 of 79 
V12 – Date 07Oct2021  
 
 8.1. Assessment of exercise capacity  ................................................................................................ 35 
8.2. Quality of life assessment  ........................................................................................................... 35 
8.3. Assessment of the systemic vasodilatory response to exercise .................................................. 35 
8.4. Assessment of muscle perfusion and energetics  ........................................................................ 36 
8.5. Doppler Echocardiography  ......................................................................................................... 37 
8.6. Measurement of late systolic load and arterial wave reflections:  ................................................. 37 
8.7. Blood nitrate/nitrite level measurements:  .................................................................................... 38 
8.8 Cognitive Assessment  ................................................................................................................. 38 
8.9. Other assessments  ..................................................................................................................... 40 
9. MULTICENTER MANAGEMENT PLAN  ............................................................................................  41 
9.1. Study Chair/Grant Principal Investigator  ..................................................................................... 41 
9.2. Site Principal Investigators  ......................................................................................................... 41 
9.3. Investigators Commi ttee ............................................................................................................. 41 
9.4. Operational Affairs Committee  .................................................................................................... 42 
9.5. Data Management  ...................................................................................................................... 42 
9.6. Quantification Core Laboratories  ................................................................................................ 43 
9.7 Conflict of Interest Management  .................................................................................................. 44 
10. STATISTICAL CONSIDERATIONS  .................................................................................................  44 
10.1. Power calculations  .................................................................................................................... 44 
10.2. Data Analysis Plan  ................................................................................................................... 45 
10.3. Subgroup analyses and considerations about sex  .................................................................... 46 
10.4 Cardiac MRI sub- study analysis and power calculations  ............................................................ 47 
11. PROTECTION OF HUMAN SUBJECTS .......................................................................................... 47 
11.1. Potential benefits of the proposed research, importance of the knowledge to be gained, and 
risk/benefit ratio  .................................................................................................................................  47 
11.2. Risks to study subjects  ............................................................................................................. 48 
11.3. Adequacy of Protection Against Risks  ...................................................................................... 53 
12. REGULATORY  STANDARDS  ......................................................................................................... 57 
12.1. Informed consent  ...................................................................................................................... 57 
12.2. Institutional Review Board (IRB)  ............................................................................................... 57 
12.3. Investigational New Drug (IND) application ............................................................................... 57 
12.4. Source document handling and archiving ................................................................................. 57 
13. DATA AND SAFETY MONITORING PLAN:  .................................................................................... 57 
14. REFERENCES  ................................................................................................................................ 58 
15. APPENDIX 1. SCHEDULE OF EVENTS ......................................................................................... 75 
Efficacy of Potassium Nitrate in HFpEF    Page 4 of 79 
V12 – Date 07Oct2021  
 
 16. APPENDIX 2. ANTICIPATED STUDY TIMELINE AND KEY DATES  .............................................. 76 
KEY DATES .......................................................................................................................................... 76 
17. APPENDIX 3 Instructions for wearing the Aurora Device (Pulse Watch ) ......................................... 76 
18. APPENDIX 4. HISTORY OF CHANGES  ......................................................................................... 77 
Version 2 (Feb 2016): Amended to specifically include ...................................................................... 77 
Version 3 (July 2016):  ........................................................................................................................ 77 
Version 4 (July 2016)  ......................................................................................................................... 78 
Version 5 (August 2016)  ....................................................................................................................  78 
Version 6 (October 2016)  .................................................................................................................. 78 
Version 7 (January 2017)  .................................................................................................................. 78 
Version 8 (July 20177)  .......................................................................................................................  79 
Version 9 (November 2017)  ............................................................................................................... 79 
Version 10 (October 2018)  ................................................................................................................ 79 
Version 11 (March 2020)  ................................................................................................................... 79 
Version 12 (07- Oct-2021)  .................................................................................................................. 79 
 
  
Efficacy of Potassium Nitrate in HFpEF    Page 5 of 79 
V12 – Date 07Oct2021  
 
 1. SPECIFIC AIMS  
Heart failure (HF) affects ~2% of the population and ~10% of adults aged >75 years. 
Approximately 50% of HF patients demonstrate a preserved left ventricular (LV) ejection fraction 
(EF), and thus have HF with preserved EF (HFpEF). Many therapeutic interventions are available 
for HF with reduced EF, but there are currently no proven effective pharmacologic interventions 
for HFpEF. Given its enormous public health, clinical and societal burden, finding effective 
therapies for HFpEF is a top priority. Accumulating evidence implicates various peripheral abnormalities in the pathophys iology of HFpEF.  
Exercise intolerance with reduced aerobic capacity is t he hallmark of HFpEF and greatly impairs 
quality of life (QOL). Effective O
2 extraction requires cardiac output redistribution towards and 
within exercising muscle, mediated by vasodilation in active muscle tissue. Dietary nitrate increases plasma nitrite,  an endothelium -independent source of the potent vasodilator nitric oxide 
(NO). Importantly, the conversion of nitrite to NO occurs preferentially in the setting of hypoxia, as 
occurs in exercising muscle. Furthermore, nitrate- nitrite -derived NO has been s hown to enhance 
mitochondrial function, representing an additional pathway to improve exercise tolerance. 
Therefore, nitrate supplementation represents a logical intervention to improve exercise tolerance in HFpEF. Our preliminary data from a double- blinded cross -over placebo- controlled trial 
demonstrates that a single dose of inorganic nitrate increases aerobic capacity (peak O
2 
consumption during a symptom -limited maximal effort exercise test), enhances the peripheral 
vasodilator response to exercise, and improves skeletal muscle mit ochondrial oxidative function.  
Late systolic LV load is an important determinant of LV dysfunction and remodeling. Wave 
reflections arise in peripheral arterial sites and travel back to the heart, arriving while the LV is still 
ejecting blood, increasing the late systolic workload of the LV. Available evidence causally link 
late systolic load with LV remodeling, diastolic dysfunction, and HF risk. Wave reflections are highly sensitive to NO. Our preliminary data demonstrates that a single oral dose of inorganic nitrate reduces late systolic load in HFpEF. Thus, in addition to an exercise- enhancing effects, 
augmentation of the nitrate- nitrite -NO pathway has the potential for chronic “disease  modifying” 
benefits in HFpEF.  
Based on preliminary data demonstrating the effects of a single oral dose of inorganic nitrate in 
HFpEF, the current trial was designed to assess the efficacy of sustained oral administration of inorganic nitrate in a more diverse and representative sample of HFpEF patients and to further 
assess the mechanisms by which inor ganic nitrate enhances oxygen uptake and exercise 
capacity. This is a randomized double- blind crossover clinical trial, in which 84 subjects with 
HFpEF will receive the following 2 interventions, in randomized order: (1) Potassium nitrate 
(KNO
3), at a dose  of 12- 18 mmol/d by mouth for approximately 6 weeks, or; (2) Potassium chloride 
(KCl), at a dose of 12- 18 mmol/d by mouth for approximately 6 weeks. A 1 -week washout period 
will be introduced between the 2 interventions. The purpose of the trial is to test  the efficacy of 
KNO 3 on a number of clinical and physiologic endpoints in subjects with HFpEF.  
 
Our specific aims ar e: 
Efficacy of Potassium Nitrate in HFpEF    Page 6 of 79 
V12 – Date 07Oct2021  
 
 Specific Aim 1:  To assess whether KNO 3 therapy improves endpoints with direct clinical 
relevance: aerobic capac ity and quality of life ( QOL). 
Hypothesis 1a:  KNO 3 will improve exercise capacity, quantified as: (1) Total work 
performed during a maximal -effort exercise test; (2) Peak oxygen consumption (VO 2) 
during a symptom -limited maximal effort exercise test. These will be the co -primary 
endpoints of the trial.  
Hypothesis 1b:  KNO 3 will improve QOL, assessed using the Kansas City  Cardiomyopathy 
Questionnaire.  
Specific Aim 2:  To dissect the effects of KNO 3 on specific physi ologic adaptations to exercise 
Hypothesis 2a:  KNO 3 improves the syste mic vasodilator response to exercise, measured 
as the change in systemic vascular resistance during a symptom -limited  maximal effort 
exercise test.  
Hypothesis 2b:  KNO 3 improves muscle blood flow during exercise, measured with 
flowsensitive PC -MRI during a standardized plantar flexion exercise test.  
Hypothesis 2c : KNO 3 improves muscle Cr recovery kinetics  (a marker of oxidative 
capacity), measured with MRI. We will also assess the exercise- induced spatial  matching 
(i.e., within muscle) of blood flow and oxidative capacity using a highly novel method 
(chemical exchange saturation transfer) that allows, for the first time, for highresolution spatial mapping of Cr in muscle.  
Hypotheses 2d- e: Since nitrates may exert venodilating effects and/or myocardial effects , 
we will test the hypotheses that KNO 3 impacts LV diastolic filling parameters  (measured 
with echocardiography at rest and after peak exercise) and improves myocardial strain 
(assessed with spec kle-tracking echocardiography).  
Specific Aim 3 : To assess whether KNO 3 reduces late systolic LV load from wave reflections 
(assessed via comprehensive aortic pressure -flow relations, using arterial tonometry and Doppler 
echocardiography).  
We will explicitly ensure that a balanced sex distribution is present in ou r sample, and that African -
Americans are adequately represented. We will pre- specify stratified analyses of men vs. women 
and African American vs. non- African American subjects. We will also perform analyses to assess 
whether sex or race modify the effects  of KNO 3 on our endpoints. This is important, because sex 
differences have been demonstrated in responses to inorganic nitrate in other populations.1, 2 
Similarly, African Americans have been shown to have more pronounced wave reflections,3 and 
have been s hown to demonstrate differential responses to other NO donors (organic nitrates) in 
the presence of HF with reduced ejection fraction (HFrEF).4, 5 
This trial has the potential to establish a novel, inexpensive, and readily implementable therapeutic 
paradigm for HFpEF and to characterize specific mechanisms involved, enhancing our  
understanding of this disease.  
Efficacy of Potassium Nitrate in HFpEF    Page 7 of 79 
V12 – Date 07Oct2021  
 
 At 2 enrolling centers (Corporal Michael J. Crescenz Veterans Affairs Medical Center and 
University of Pennsylvania), we will perform an ancillary st udy (“Cardiac MRI sub -study”) to 
assess the effect of KNO 3 on myocardial perfusion (MP) and myocardial perfusion reserve (MPR). 
This ancillary study will be funded by a grant from the Department of Veterans Affairs VISN -4 
Competitive Pilot Project Fund (CP PF) obtained by Dr. Sujith Kuruvilla (VA site PI and co-
Investigator in the ancillary studytrial). We will assess myocardial perfusi on using novel MRI 
techniques.  
The sub -study will test the hypothesis that KNO 3 administered over a period of ~4 -6 weeks, wi ll 
improve MP and MPR in subjects with HFpEF as compared to KCl. We will also explore whether 
MPR (measured during the placebo intervention, KCl) correlates with increased myocardial fibrosis (measured as the extracellular volume [ECV] ) using cardiac MRI) , and with subclinical 
myocardial dysfunction (measured by impaired systolic/diastolic strain) in this population.  
We plan to enroll up to 20 subjects in this ancillary study. Subjects participating in the ancillary 
study will undergo all procedures per the parent trial, but in addition, will undergo a stress perfusion cardiac MRI study during the last 2 weeks of phase 1 and phase 2, during which MP, MPR values, myocardial fibrosis and myocardial strain measurements will be obtained.  Of note, 
this may occur  either before or after the exercise endpoint assessment, based on schedule 
availability.  We anticipate that this substudy will contribute to a better characterization of the 
effects of inorganic nitr ate therapy on the myocardium.  
  
Efficacy of Potassium Nitrate in HFpEF    Page 8 of 79 
V12 – Date 07Oct2021  
 
 2. TRIAL SUMMARY T ABLE (OBJECTIVES AND ENDPOINTS)  
Trial Title / Acronym  Effects of KNO 3 Compared to KCl on Oxygen UpTake in Heart Failure 
with Preserved Ejection Fraction (KNO 3CK OUT HFpEFp)  
Funding Agency  National Heart, Lung and Blood Institute,  National Institutes of Health  
Phase  Phase IIb Randomized Clinical Trial (RCT)  
Number of subjects  84 
Study Sites  University of Pennsylvania, Northwestern University, and the Corporal 
Michael J. Crescenz V eterans Affairs Medical Center  
Study Design  Randomized, double -blinded, placebo- controlled crossover study  
Randomized  
Intervention  Potassium Nitrate (KNO 3) capsules, at a dose of 6 mEq (1 capsule) 
three times daily for approximately 6 weeks, versus, potassium chloride 
(KCl) capsules administered at a dose of 6 mEq  (1 capsule) three times 
daily for  approximately 6 weeks  
Primary Aim  To assess whether KNO 3 therapy improves exercise capacity, 
quantified as: (1) Total work performed during a maximal -effort exercise 
test; (2) Peak oxygen consumption (VO 2) during a sym ptomlimited 
maximal effort exercise test. These will be the co -primary endpoints of 
the trial.  
Secondary Aims  1. To assess whether KNO 3 improves quality of life  
2. To assess whether KNO 3 improves the systemic vasodilator  
response to exercise  
3. To assess whether KNO 3 improves muscle blood flow during  
exercise.  
4. To assess whether KNO 3 improves muscle PCr recovery kinetics  
(a marker of oxidative capacity)  
5. To assess whether KNO 3 improves LV diastolic function and 
myocardial systolic strain  
6. To assess whether KNO 3 reduces late systolic LV load from wave 
reflections  
 
Exploratory Aims  1. To assess whether KNO 3 improves the exercise -induced spatial 
matching (i.e., within muscle) of blood flow and oxidative capacity 
(assessed by chemical  exchange saturation transfer).  
2. To assess whether KNO 3 has different effects in men vs. women and 
in African -American vs . non -African American subjects  
3. To assess whether KNO 3 improves:  
 •  Ventilatory threshold, VO 2 kinetics  
• Natriuretic peptide levels  
Efficacy of Potassium Nitrate in HFpEF    Page 9 of 79 
V12 – Date 07Oct2021  
 
 • Physical activi ty (measured via accelerometry)  
• 24-hour late systolic pressure augmentation, measured with the 
Aurora device 
4. To assess the relationship between nitrate and nitrite levels achieved 
and the therapeutic response achieved in each subject  
(improvement in endpoints in response to KNO 3 vs. placebo)  
 
Primary Endpoint  Total work performed and peak oxygen uptake (VO 2) during a 
symptom -limited maximal effort exercise test after  approximately 6 
weeks of KNO 3 vs. KCl. 
Secondary Endpoints  1. Quality of life score,  assessed using the Kansas Ci ty 
Cardiomyopathy Questionnaire.  
2. The change in systemic vascular resistance reserve during exercise  
during a symptom -limite d maximal effort exercise test.  
3. Muscle blood flow during exercise, measured with flow sensitive PC -
MRI during a standardized plantar flexion exercise test.  
4. The time constant of Cr recovery  after a pl antar flexor exercise 
protocol.  
5. Measures of LV diastolic function (E/e’, left atrial volume index) and 
peak global systolic myocardial longitudinal and circumferential 
strain . 
6. Augmentation index, late systolic wall stress and aortic input  
impedance.  
Ancillary Study  Up to 20 subjects will be enrolled at the  CMC VA Medic al Center and 
the University of Pennsylvania  into an ancillary study. The sub -study 
will test the hypothesis that KNO 3 administered over a period of ~4 -6 
weeks will improve myocardial perfusion and myocardial perfusion 
reserve in subjects with HFpEF as com pared to KCl. Participation in the 
ancillary study will not change any  of the main trial procedures.  
 
3. BACKGROUND AND SIGNIFICANCE  
Heart failure (HF) affects ~2% of the western population and 10% of adults age 75 years or older.6 
HF is the most common cause of hospitalization in adults >65 years of age.6 Approximately 46-
54% of patients with HF have HFpEF.6-18 The burden of HF has increased dramatically over the 
last several years.6, 19 The number of new HF cases increased from 348,000 in 2000 to 670,000 
in 2007, a 93% increase over this time period. Not only is HF already an epidemic, but with the 
aging of the population, a dramatic further increase in its prevalence is expected. Furthermore, the relative prevalence of HFpEF (as a  proportion of the total burden of HF) appears to be 
increasing as the population ages.
1, 14 Therefore, although already a huge epidemic, a further 
dramatic increase in the prevalence of HFpEF is expected.6 HFpEF is a malignant disease with a 
high mortalit y rate, high hospitalization risk and poor quality of life (QOL). Studies consistently 
demonstrate higher mortality rates in HFpEF patients compared with age - and sex -matched 
controls. Annual mortality rates ranged from ~3.5- 6% in randomized trials20-22 to ~15% in 
Efficacy of Potassium Nitrate in HFpEF    Page 10 of 79 
V12 – Date 07Oct2021  
 
 community -based studies.23 Approximately 50% of such deaths occur from cardiovascular 
causes.24 In addition to its high morbidity and mortality, HFpEF has been shown to be associated 
with an impaired QOL.25, 26 
Multiple therapies that provide subs tantial clinical benefit in HF with reduced ejection fraction are 
available. In contrast, there are currently no effective pharmacologic interventions that improve 
outcomes in patients with HFpEF.27 Thus, there is an urgent need to develop novel treatment 
strategies. Our trial will test a novel intervention (inorganic nitrate) to modify key physiologic abnormalities (arterial vasodilator reserve, muscle O
2 delivery and utilization, mitochondrial 
function and late systolic LV load from arterial wave reflections), which have the potential for both 
immediate -term improvements in exercise tolerance and long -term “diseasemodifying” effects. 
The trial is designed to address the potential clinical benefit of thi s approach in HFpEF using 
endpoints with direct clinical relevance, and also to characterize the specific physiologic 
mechanisms involved. This would identify a new therapeutic paradigm and a readily 
implementable therapeutic intervention in HFpEF.  
 
3.1. T he nitrate– nitrite –NO activation pathway  
NO formation occurs via 2 pathways in mammals (Figure 1): (1) NO synthases (NOS) catalyze 
the formation of NO from L -arginine and O 2;28 (2) Circulating nitrate (previously considered an 
inert product of NO metabolis m) can be converted to NO through the nitrate- nitrite -NO pathway, 
which is independent of NOS.28-33 
The nitrate -nitrite -NO pathway is dependent primarily on dietary inorganic nitrate intake. 
Vegetables (leafy green vegetables and beetroot, in particular)28, 33 -36 are the main source of 
inorganic nitrate in the diet (>80%). Oral cavity commensal bacteria reduce nitrate to nitrite, which 
has a high oral bioavailability (>90%).33, 35, 36 Nitrite present in the blood stream is reduced directly 
to NO, a reaction catalyzed by several molecules, particularly deoxygenated myoglobin,37-40 and 
deoxygenated hemoglobin,41 but also xanthine oxidoreductase,42 mitochondrial respiratory chain 
enzymes43, aldehyde oxidase44, carbonic anhydrase,45 vitamin C46, polyphenols47, 48 and even 
endothelial NO synthase.49, 50 Nitrate is also directly absorbed in the gastrointestinal tract (without 
requiring conversion to nitrite), with high bioavailability (>90%)51 and circulates in plasma with a 
half-life of ~6- 8 hours, in contrast to nitrite, which has a very short half -life (~30 -40 minutes).52-54 
Circulating nitrate is taken up by the salivary glands and secreted in the saliva (thus being susceptible to both direct reabsorption as nitrate or to conversion to nitrite followed by absorpt ion). 
This entero- salivary cycle provides a natural, “slow” and sustained  source of nitrite from ingested 
nitrate, thus allowing for favorable pharmacokinetics and for safe oral administration of 
“pharmacologic” doses in HFpEF (as discussed further in this  application). Most (65%) inorganic 
nitrate  eventual ly undergoes renal excretion.  
Efficacy of Potassium Nitrate in HFpEF    Page 11 of 79 
V12 – Date 07Oct2021  
 
 NO production by the nitrate- nitrite -NO pathway is enhanced under hypoxic conditions: exercising 
muscle is characterized by a low pO 2,33 which favors the formation of NO from circulating nitrite.  
Deoxyhemoglobin supports the reduction of nitrite to NO and is thought to play a key role in 
modulating small resistance vessels (particularly of skeletal muscle), where O 2 extraction from the 
circulation to the tissues is most marked. Here, the O 2 saturation of hemoglobin approaches the 
P50 (the O 2 concentration at which half the heme is saturated), an optimum balance point between 
the greater reductive potential of heme in the R (oxy) state tetr amer and the number of un -ligated 
deoxy -heme sites necessary for nitrite binding (which are more plentiful in the T- state tetramer). 
This results in near -maximal conversion rates of nitrite to NO and hence vasodilatation.55, 56 
Similarly, NO by deoxy -myogl obin enhances blood flow to skeletal muscle and matches O 2 supply 
to increased metabolic demands under hypoxic conditions.37 Xanthine oxido- reductase also 
converts nitrite to NO when O 2 levels are low.42 In sharp contrast to NO production from the nitrate-
nitrite -NO pathway, which is enhanced in the presence of hypoxia, NO production via the classic 
L-arginine pathway is strongly inhibited by hypoxia50 (Figure 1). In summary, the endogenous 
nitrate -nitrite pathway is a physiological effector of hypoxic vasodilation via NO release, which is 
independent of the L- arginine pathway and largely independent of NO synthase.  
 
3.2. Peripheral mechanisms of exercise intolerance in HFpEF 
Exercise intolerance is the hallmark of HFpEF and determines a poor quality of life.25, 26, 57, 58 
Therefore, enhancing exercise capacity in this population is a  key objective with immediate clinical 
relevance. We believe that new attempts to achieve this unmet goal should be based on careful 
considerations regarding the pathophysiology of exercise intolerance in HFpEF. The early pathophysiologic paradigm was that increases in LV filling pressure during exercise were not accompanied by increases in end -diastolic volume, failing to recruit the Frank -Starling mechanism 
and to augment stroke volume.
59 Studies also reported the presence of chronotropic 
incompetence, leading to an abnormal cardiac output reserve.60-62 However, various studies have 
not found abnormal end -diastolic LV volume during exercise,60, 63 stroke volume reserve (i.e., 

Efficacy of Potassium Nitrate in HFpEF    Page 12 of 79 
V12 – Date 07Oct2021  
 
 increase during exercise),60-62 chronotropic incompetence63 or cardiac output reserve.61 Thus, 
rather than resulting exclusively from cardiac abnormalities, HFpEF is now seen a complex 
disease and there is a need to address not only cardiac, but also peripher al abnormalities in this 
condition.64, 65 
Reduced O 2 utilization is a key abnormality in the pathophysiology of exercise intolerance in 
HFpEF. Peak O 2 uptake (VO 2) during exercise, the most widely accepted index of aerobic 
capacity, is consistently reduced in HFpEF.59-62, 66 Peripheral O 2 utilization requires not only an 
adequate cardiac output during exercise, but also an adequate flow distribution, characterized by 
blood flow being preferentially directed to exercising skeletal muscle, in order to  achieve an 
adequate matching of perfusion with metabolic demands. This preferential flow distribution is 
dependent on the exercise- induced reduction in the local resistance of skeletal muscle arterioles 
(i.e., exercise- induced vasodilation). Therefore, as  discussed below, the normal exercise induced 
vasodilation in exercising muscle serves 2 important roles: (1) To reduce the “total” (i.e., systemic) 
vascular resistance during exercise, which reduces LV afterload, promoting a greater cardiac 
output for any  given contractile state; (2) To preferentially divert flow to highly oxidative muscle, 
promoting matching between metabolic needs and oxygenated blood delivery, thus allowing the “periphery” to optimally “utilize”  the cardiac output to maximize O
2 consumption.  
Exercise arterial vasodilatory reserve is abnormal in HFpEF, leading to excessive LV afterload. 
During exercise, LV afterload must decrease to accommodate increases in cardiac output without 
excessive rise in arterial pressure.  In several studies, co mpared to age- matched hypertensive 
subjects   during exercise allows the local vasculature to overcome humoral and reflex -mediated 
vasoconstriction.67 NO bioavailability and release is a key mechanism mediating this response.67, 
68 Importantly, impaired vascular responses within skeletal muscle can have dramatic 
consequences for O 2 extraction, creating a marked imbalance between O 2 delivery and 
requirement in muscle which results in a large O 2 deficit, accentuated intracellular metabolic 
perturbations and enhanced glycogenolysis even at low levels of activity (reviewed in 67). The 
vasodilator response in exercising muscle is dependent on both endothelium and endotheliumindependent pathways.
67 As will be discussed below, nitrite -derived NO is a potent 
endotheliumindependent mediator of hypoxic vasodilation.37, 68, 69 and increase muscle blood flow 
during exercise.29, 70 Of note, HFpEF patients exhibit endothelial dysfunction71, 72 and may be 
particularly dependent on endothelium -independent NO to enhance skeleta l muscle flow during 
exercise.  
Importance of flow distribution within muscle is also important. Although blood flow toward 
locomotive muscle groups is clearly important during exercise, blood flow (Q) within active muscles is not homogeneous, being great er in highly oxidative muscles, which normally 
demonstrate greater vasodilatation.
73, 74 Hypoxic vasodilation favors preferential vasodilation in 
tissues with high oxidative capacity, which optimizes supply -demand matching (reviewed in 67, 68). 
Dysregulati on of these control processes provides an excess flow and therefore O 2 delivery to 
muscles with less oxidative capacity, reducing muscle and whole- body fractional O 2 extraction.74 
Nitrite -derived NO -mediated hypoxic vasodilation37, 68, 69 thus may not only  enhance overall 
muscle bulk flow, but also optimize flow distribution within muscle. Therefore, we believe that it is important for a study that targets muscle hypoxic vasodilation to not only address “overall” bulk 
muscle flow as a mechanistic endpoint, but also flow distribution within muscle. This important 
Efficacy of Potassium Nitrate in HFpEF    Page 13 of 79 
V12 – Date 07Oct2021  
 
 and elusive goal, although well characterized in animal models,67 has been limited in human 
studies by the lack of techniques to spatially map (i.e., image) oxidative capacity. Our group has 
recently  developed and validated an ad hoc technique75, 76 which, for the first time, allows for non-
invasive high- resolution spatial mapping (i.e., producing an anatomic image) of phosphocreatine 
kinetics (a marker of oxidative capacity). Therefore, our study wil l not only assess the effects of 
our intervention on exercise- induced bulk muscle flow and muscle oxidative capacity , but also on 
the matching of blood flow distribution and oxidative capacity within locomotive muscle.  
 
3.3. Importance of wave reflections and late systolic load: beyond improvements in  
exercise capacity  
While addressing exercise intolerance in HFpEF is a key therapeutic goal, there is also a need to 
address long -term underlying abnormalities that contribute to chronic LV remodeling and the long-
term course of the disease. As discussed below, a large body of evidence now indicates that late systolic pulsatile load from wave reflections (which are increased in HFpEF)
77, have adverse long-
term consequences on LV remodeling and function. Our pr eliminary data suggests that enhancing 
nitrate -nitrite -pathway -derived NO production favorably impacts these systemic arterial 
abnormalities. Therefore, in addition to their exercise- enhancing mechanistic effects, interventions 
that enhance the nitrate -nitrite-NO pathway exert peripheral arterial effects with a potential for 
chronic “diseas e-modifying” benefits in HFpEF.  
The pulse wave generated by the LV travels forward in arteries and is partially reflected at sites 
of impedance mismatch (i.e., bifurcations, points of change in arterial size or wall stiffness, 
predominantly in middle- sized conduit arteries).78-80 Wave reflections travel back to the heart, 
merging into a discrete reflected wave and arrive while the LV is still ejecting blood in mid- to-late 
systole.80, 81 Wave reflections increase the late systolic workload of the LV and profoundly impact 
the LV loading sequence (late relative to early systolic load).78, 79, 82 -84 
Late systolic load from wave reflections leads to LV hypertrophy. For any given level of systolic 
pressure, late- systolic load exerts deleterious effects on the LV.80, 85, 86 Kobayashi et al85 used a 
Wistar rat model and performed constriction of either the ascending aorta (which increased LV 
early systolic load) or suprarenal abdomi nal aorta (which caused prominent late systolic loading 
from a reflected wave at the distal aortic constriction site arriving at the heart in mid- to-late 
systole).85 Despite an identical peak LV pressure in rats that underwent ascending vs. descending 
aortic constriction, rats that underwent descending aortic banding (and were thus exposed to 
greater late systolic load) demonstrated much greater LV hypertrophy and fibrosis than those 
undergoing ascending aortic banding (which were exposed to increased early  systolic load).85 
These animal causal findings are supported by our observational human data demonstrating an association between reflected wave amplitude an LV hypertrophy in the general population
87 and 
by Hashimoto’s study demonstrating that changes in reflection magnitude during antihypertensive 
therapy strongly predicted regression of LV mass independent of blood pressure reduction.88 Of 
note, effects of standard antihypertensive therapy on wave reflections are unpredictable, with reflections actually  increasing in some patients.
88 
Efficacy of Potassium Nitrate in HFpEF    Page 14 of 79 
V12 – Date 07Oct2021  
 
 Late systolic load promotes diastolic dysfunction. Gillebert  et al studied the effect of the timing of 
systolic load on LV relaxation in dogs by inflating balloons in the ascending aorta during either 
early or late systole. They found that late systolic inflation of an aortic balloon increases the LV relaxation constant tau much more than early systolic inflation, demonstrating a cause -effect 
relationship between late systolic load and diastolic dysfunction.
89 In support of these causal 
findings, wave reflections have been shown to be independently associated with diastolic dysfunction in clinical cohorts.
90, 91 We have developed a novel technique to assess timeresolved 
LV wall stress during ejection,92 and more recently showed in the population- based Asklepios 
study  83, 92- 95 that wave reflections selectively increase late LV myocardial wall stress83, 96 and that 
late systolic wall stress was associated with lower mitral annular relaxation velocities, in sharp contrast to early systolic wall stress which was associated with greater relaxation velocities.
95 
Therefore,  available data implicates the loading sequence as an independent correlate of 
myocardial relaxation in humans. Wave reflection magnitude was a strong predictor of incident heart failure among 5,934 participants in the Multiethnic Study of Atherosclerosis,  who were free 
of clinically apparent cardiovascular disease
84, 97 during 7.61 years of follow -up (and after 
adjustment for multiple confounders, including blood pressure), reflection magnitude strongly predicted incident HF (Hazard ratio per 10% -increase= 2.69; 95%CI=1.79 -4.04; P<0.0001), and 
was a stronger predictor of HF than blood pressure and any other standard modifiable risk factor. Similarly, for any given level of systolic and diastolic blood pressure, a greater area under the pressure curve in late  systole (relative to early systole) is strongly predictive of incident HF.
98 Our 
findings implicate late systolic load from arterial wave reflections as a novel strong risk factor for 
HF, strongly supporting animal and human mechanistic findings from prev ious studies and 
demonstrating the relevance of  late systolic load in humans.  
 
3.4. Rationale behind the use of inorganic nitrate as a therapeutic approach in HFpEF  
The arterial hemodynamic characteristics of HFpEF patients (stiff arteries with wide pulse 
pressure,77 reduced exercise- induced vasodilation62, 63, 66, enhanced wave reflections77 dictate a 
set of “ideal” characteristics for a vasoactive intervention in this condition, namely, one that: (1) 
Does not significantly reduce mean arterial pressure at  rest, avoiding hypotension; (2) Enhances 
exercise- induced vasodilation to reduce LV afterload during exercise; (3) Has selectivity for 
enhancing local vasodilation in hypoxic/acidotic environments, in order to match blood flow to 
metabolic demands (i.e., directing blood flow to exercising muscle); (4) Reduces wave reflections 
and late systolic load, which likely contribute to LV diastolic dysfunction and maladaptive 
remodeling.80, 85, 86, 88 -91, 95 Inorganic nitrate precisely satisfies these characteristic s. Inorganic 
nitrate exerts weak vasodilator effects in the absence of hypoxia but acts as a potent arterial vasodilator in the presence of local hypoxemia. Concentrations of nitrite (for which nitrate is a 
precursor) as high as 100- 1000 µmol/L are typical ly required to induce relaxation of arterial rings 
in vitro.
99 Similarly, a lack of vasodilator activity was seen with a concentration of 200 µmol/L of 
nitrite in the forearms of healthy volunteers.100 This situation is, however, different under hypoxic 
conditions. Maher et al studied 40 volunteers and demonstrated that, during normoxia, forearm 
arterial blood flow during local infusions of nitrite at incremental doses (from 40 nmol/min to 7.84 µmol/min) increased by a maximum of 64% during normoxia, but it  increased by as much as 121% 
during hypoxia.
101 The nitrate -nitrite pathway thus seems ideal for enhancing vasodilation, O 2 
extraction and utilization in HFpEF. By virtue of enhancing hypoxia- mediated vasodilation, the 
Efficacy of Potassium Nitrate in HFpEF    Page 15 of 79 
V12 – Date 07Oct2021  
 
 vasodilatory reserve would be increa sed, reducing LV afterload during exercise and directing 
blood flow “where and when it is needed”, enhancing O 2 delivery and this utilization. Indeed, 
inorganic nitrate improves muscle blood flow during exercise.29, 70 Our preliminary data support 
the prom ise of inorganic nitrate in HFpEF, via promotion of exercise- induced vasodilation, 
ultimately leading to enhanced aerobic capacity, in the absence of blood pressure reductions at 
rest, while at the same time reducing LV late systolic load. This represents an optimal “tailored” approach to abnormal hemodynamics in HFpEF.  
 
3.5. Preliminary data: effects of a single- dose of inorganic nitrate in HFpEF 
We performed a randomized double- blind cross -over trial (clinicaltrials.gov [STUDY_ID_REMOVED]) of a 
single dose of 12 .9 mmol of inorganic nitrate given as 140 mL of concentrated nitrate -rich beetroot 
juice (NR- BR; Beet it; Sport, James White Drinks Ltd., Ipswich, UK) versus an otherwise identical 
beetroot juice which had been nitrate- depleted (used as the control or “placebo” juice, PB), 
allowing for a genuine double- blinded design.
102 The intervention was given before a maximal -
effort cardiopulmonary exercise test, with both experiments separated by a wash out period of at least 5 days (mean=11.8 days). We administered N R-BR 3 hours prior to testing because this 
period of time has been shown to correspond to peak circulating nitrite levels after oral nitrate administration. We tested the hypothesis that a single dose of inorganic nitrate would increase 
exercise capacity i n HFpEF and assessed key physiologic adaptations to exercise. Specifically, 
we assessed: (1) Peak oxygen consumption (VO
2); (2) Total work performed; (3) Exercise 
efficiency, defined as the ratio of total work performed to total O 2 consumed (efficiency has  been 
improved by inorganic nitrate in young athletes)70, 103 -107; (4) Exercise vasodilatory reserve (the 
change in peripheral vascular resistance from rest to peak exercise, normalized to the resting 
value); (5) Skeletal muscle mitochondrial oxidative function; (6) Aortic augmentation index, a  
metric of late systolic load.  
We included subjects with symptomatic HF who had a preserved LV EF (>50%) and who were 
required to have a ratio of the early mitral inflow velocity (E) to septal tissue Doppler velocity (e’) 
>8 and at least one other sign of chronically -elevated filling pressures including: (1) left atrial 
volume index >34 mL/m2; (2) elevated NT- pro-BNP level; or (3) elevated filling pressures 
(pulmonary capillary wedge pressure > 12 mmHg) on prior cardiac catheterization. Subjects had to be on stable medical therapy. Exclusion criteria included non- cardiac conditions limiting 
exercise tolerance (i.e. orthopedic issues, peripheral arterial disease with claudication, neuromuscular disorders); gait instabili ty; rhythm other than sinus; infiltrative or hypertrophic 
cardiomyopathy; pericardial disease; primary pulmonary arteriopathy; coronary revascularization within 60 days; clinically significant valvular disease; clinically significant lung disease felt to contribute to exercise intolerance; significant ischemia seen on stress testing within the past  year 
and not revascularized.  
After each intervention, we performed a resting echocardiogram and arterial tonometry, followed 
by a maximal -effort supine- bicycle c ardiopulmonary stress test using a graded exercise protocol, 
beginning at 15 Watts (W) for 3 minutes, increasing to 25 W for 3 minutes, then increasing by 25 W every 3 minutes thereafter.
108 Measurements during exercise included expired gas analyses 
(Parvo Medics True One 2400; Parvomedics, Utah, USA), echocardiographic assessments of 
stroke volume and continuous interrogation of muscle oxygenation of the left gastrocnemius 
Efficacy of Potassium Nitrate in HFpEF    Page 16 of 79 
V12 – Date 07Oct2021  
 
 muscle with near -infrared spectroscopy (Portamon MkII device, Artinis medical systems ; The 
Netherlands). We also assessed mitochondrial oxidative function measured via the recovery of 
oxygen consumption (measured with near -infrared spectroscopy) in forearm skeletal muscle after 
a bout of handgrip exercise, which corresponds to the phosphoc reatine recovery kinetics, as 
previously described and validated against 31PMRI.109, 110 Details of the procedure may be found 
in previous publications. 108,109- 111 In brief, the procedure measures the rate of oxyhemoglobin 
decline during brief high pressure inflations (at 200 mHg using a rapid inflation system), during which the decline in local muscle O
2 is due exclusively to consumption, as the arterial occlusion 
removes the confounding impact of arterial inflow. After a brief bout of forearm exerc ise, several 
of such brief occlusions are performed, allowing for assessments of the rate of O 2 consumption 
at various time points after exercise. Exercise induces increases in the rate of O 2 consumption, 
which upon cessation of exercise, declines towards baseline in a mono- exponential fashion. This 
is characterized by a time constant (τ, tau) that corresponds to the time constant of PCr recovery kinetics.
109, 110 Although we used this relatively inexpensive near -infrared spectroscopy procedure 
in our pilot  trial, we will use more informative MR I techniques in this proposal.  
Participants’ mean age was 66±9 years. The population was enrolled from the Philadelphia VA 
Medical Center and was 88% male and 82% African- American (we will explicitly assure adequate 
representation of women in the KNO 3CK OUT HFpEF trial). Subjects were obese (BMI 35.4±5.4), 
had a high prevalence of hypertension (100%). Median NT -pro-BNP was 326 (IQR=290 -352) 
pg/mL. Mean LA volume index was 35.7±10.9 mL/m2. Serum NO metabolites were mark edly 
greater after NO 3- supplementation (median 326.0 [IQR 290.0 -352.0] versus 10.0 [IQR 9.0- 13.0] 
µM, P=0.0003).  
3.5.1. Changes in exercise capacity and oxygen uptake:  Nitrate supplementation resulted in 
a greater peak VO 2 (12.6±3.7 versus 11.6±3.1 mL O 2/kg/min; P=0.005) and total work performed 
(55.6±35.3 vs. 49.2±28.9 kJ; P =0.04). Ventilatory threshold (a marker of the cellular anaerobic 
threshold) was greater following NO 3- supplementation (7.6±1.8 versus 7.0±1.4 mL O 2/kg/min, 
P=0.03). Because total wor k performed and O 2 consumption increased in tandem, exercise 
efficiency was no different. This is interestingly, different than the effect seen in athletes and younger subjects, among whom exercise efficiency increases
70, 103- 107, demonstrating the 
importance of characterizing specific adaptations to exercise in this  particular patient population.  
3.5.2. Exercise vasodilatory reserve:  NR-BRJ led to a significant fall in systemic vascular 
resistance (SVR) at peak exercise ( -42±17%) compared to PB ( -32±20%; P =0.03). This was 
accompanied by an increase in cardiac output (% change in NR -BRJ 122±60 vs PB: 89±53%, 
P=0.006), increased heart rate (78.0±24.1 versus 65.6±21.0%, P=0.001) and a trend towards 
greater stroke volume (22.6±22 .4 versus 12.7±25.4%, P=0.13).  
3.5.3. Effects on filling parameters:  Interestingly, we found no evidence of reduced preload, 
since end- diastolic volume (EDV) significantly increased with beetroot supplementation (112±12 
mL vs 93±6 mL; P=0.04), whereas the E/E’ ratio did not change (NR -BRJ: 12.1±0.9 vs. PB: 
11.5±0.8; P=0.90). The increased LV EDV may suggest improvements in diastolic function, which 
we plan to further assess in this proposal using measurements of intraventricular pressure gradients.  
Efficacy of Potassium Nitrate in HFpEF    Page 17 of 79 
V12 – Date 07Oct2021  
 
 3.5.4. Augmentation index:  The aortic AI x (derived from radial tonometry) was significantly 
decreased by NO 3- supplementation (NO 3- 132.2±16.7 versus PB 141.4±21.9%, P= 0.03).  
3.5.5. Changes in resting blood pressure:  There was no s ignificant change in resting BP  
 
(mean arterial pressure change=0.17 mmHg; systolic BP change=0.7 mmHg; both P>0.85) with 
NO 3- supplementation. This is in contrast to BP -lowering effect in healthy volunteers and drug  
naïve hypertensive subjects112, 113 and likely explained by recent data indicating that the 
BPlowering effect of inorganic nitrate is mediated by its renal effects in pathways downstream of 
the AT1 -receptor.114 These effects are likely attenuated in patients who are treated with ACE 
inhibitors/angiotensin receptor blockers for  BP control (such  as occurs in HFpEF patients).  
In summary, a single dose of inorganic nitrate increased peak VO 2 and total work during a 
symptom -limited maximal effort exercise test. It enhanced the exercise vasodilatory reserve, 
without affecting SVR or blood pressure at rest. It also reduced late systolic LV load, which is 
implicated in diastolic dysfunction and LV remodeling. Nitrate also led to increased cardiac output during exercise, likely from a reduced afterload, but potentially also mediated by i ncreased EDV 
(suggesting effects on diastolic function). Finally, in accordance with other studies, our pilot data suggest an improvement in mitochondrial oxidative function, suggesting improved ATP production.
115, 116 However, nitrate did not affect the O 2 cost of exercise, as has been 
demonstrated in younger and/or healthier populations.70, 105, 106, 117, 118 This demonstrates the 
importance of having disease- specific and agent -specific data to design our phase IIb trial. Our 
pilot trial was limited by it s small sample size, inclusion of mostly men (we will explicitly assure 

Efficacy of Potassium Nitrate in HFpEF    Page 18 of 79 
V12 – Date 07Oct2021  
 
 adequate representation of women in this trial). However, it does support the need for a larger 
phase IIb randomized trial of prolonged nit rate supplementation in HFpEFp.  
3.6 Effect on Myocardial Perfusion Reserve in H FpEF (“Cardiac MRI sub- study”)  
Myocardial biopsy studies in HFpEF  patients have revealed cardiomyocyte hypertrophy, interstitial 
myocardial fibrosis, incomplete myocardial strip relaxation,  increased cardiomy ocyte stiffness,  
increased production of reactive oxygen species at the coronary endothelial cell level , along with 
increased expression of adhesion molecules and production of pro-inflammatory cytokines.119-122 
In view of these findings , a new paradigm has been suggested in the pathophysiology of HFpEF 
(Figure  3). The paradigm proposes that the co -morbidities seen in HF pEF patients induce a 
proinflammatory state which activates coronary microvascular endothelial cells to produce 
reactive oxygen species and induces cardiomyocyte hypertrophy resulting in concentric LV 
remodeling and increased interstitial collagen deposition proceeding to diastolic dysfunction.  
 
Figure 3: Adapted from Paulus et al. Novel paradigm in HFpEF patients. JACC Volume 62, Issue4 (236 -271)  
MRI is an ideal tool to assess these pathophysiological phenotypes and assess the effect of KNO 3 
on microvascular myocardial function. Coronary microvascular dysfunction which is proposed to 
underlay this disease process can be estimated by measurin g MPR by means of quantitative 
vasodilator stress cardiac MRI. MPR is calculated by a ratio of stress coronary perfusion over rest 
perfusion. Myocardial fibrosis  can be quantitatively assessed by the measurement of ECV by myocardial T1 mapping. 
123 
The an cillary study of the KNO 3CK OUT HFpEF trial represents a unique opportunity to assess 
the effect of inorganic nitrates on MPR values in this patient population.  
4. STUDY DESIGN AND POPULATION  
4.1. Overview of study design  
In this phase IIb, double -blind, c ross-over placebo -controlled trial, we will assign 84 subjects with 
HFpEF to: (A) Potassium nitrate administered by mouth at a dose of 6 mEq three times daily for 
approximately 6 weeks, or (B) Potassium chloride (KCl) at identical doses. The order of the 
interventions (AB -BA design) will be randomized, with a 1 -week washout period separating each 

Efficacy of Potassium Nitrate in HFpEF    Page 19 of 79 
V12 – Date 07Oct2021  
 
 intervention. A crossover design will enable each subject to receive both treatments, reducing 
inter-individual variability and maximizing our power to detect effects of potassium nitrate vs. 
placebo  (KCl). The active drug (KNO 3-) and control (KCl) will be prepared at the Investigational 
Drug Pharmacy at the University of Pennsylvania and dispensed by an investigational drug 
pharmacist, blinded to both the s ubjects  and the investigators.  
4.2 Study Sites  
The three sites for this trial will be the Hospital of the University of Pennsylvania, Northwestern 
University and the Corporal Michael J. Crescenz VA Medical Center.  
4.3. Study Population  
We will enroll 84 subjects meeting the following criteria.  Eligibility will be determined by the site 
PI according to the criteria outlined below . 
4.3.1. Inclusion Criteria:  
1. Adults aged 18 -90 years of age  
2. A diagnosis of heart failure with NYHA Class II -III symptoms  
3. LV ejection fraction >50% during baseline echocardiography  
4. Stable medical therapy: no addition/removal/changes in antihypertensive medications, or beta -
blockers in the preceding 30 days  
5. Elevated filling pressures as evidenced by at least 1 of the following:  
a. Mitral E/e ’ ratio > 8 (either lateral or septal), with low e’ velocity (septal e’<7 cm/sec or 
lateral e’< 10 cm/sec), in addition to one of the following:    
i   Enlarged left atrium (LA volume index >34 ml/m2)    
ii   Chronic loop diure tic use for control of symptoms  
iii  Elevated natriuretic peptides (BNP levels >100 ng/L or NT -proBNP levels >300 
ng/L)  
b. Mitral E/e’ ratio > 14 (either lateral or septal)  
c. Elevated invasively -determined filling pressures previously (resting LVEDP>16 mmHg 
or mean pulmonary capillary wedge pressur e [PCWP] > 12 mmHg; or 
PCW P/LVEDP≥25 mmHg with exercise)  
d. Acute heart failure decompensation requiring IV diuretics  
 
4.3.2. Exclusion Criteria:  
1. Supine sys tolic blood pressure <100 mm Hg 
2. Pregnancy : Women of childbearing potential will undergo a pregnancy test during the 
screening visit  
3. Orthostatic hypotension defined as >20 mm Hg decrease in systolic blood pressure 3 -5 
minutes following the transition from the supine to standing position 
4. Uncontrolled atrial fibrillation, as defined by a resting heart rate>100 beats per m inute  
5. Hemoglobin < 10 g/dL  
6. Inability/unwillingness to exercise  
7. Moderate or greater left sided valvular disease (mitral regurgitation, aortic stenosis, aortic 
regurgitation), any degre e of mitral stenosis, severe right -sided valvular disease, or presenc e 
of a prosthetic valve in the mitral position  
Efficacy of Potassium Nitrate in HFpEF    Page 20 of 79 
V12 – Date 07Oct2021  
 
 8. Hypertrophic, infiltrative,  or inflammatory cardiomyopathy  
9. Clinically significant pericardial disease, as per investigator judgement.  
10. Current angina  
11. Acute coronary syndrome or coronary interv ention within the past 2 months  
12. Primary pulmonary arteriopathy  
13. Clinically significant lung disease as defined by: Chronic Obstructive P ulmonary Disease  
meeting Stage III or greater GOLD criteria, treatment with oral steroids within the past 6 
months for an exacerbation of obstructive lung disease, or the use  of daytime supplemental 
oxygen 
14. Ischemia on stress testing without either (1) subsequent revascularization, or; (2) a 
subsequent angiogram demonstrating the absence of clinically significant epicardial coronary 
artery disease, as per investigator judgement.  
15. Left ventricular ejection fraction <45% in any prior  echocardiogram or cardiac MRI , unless this 
was in t he setting of uncontrolled atrial fibrillation . 
16. Treatment with phosphodiesterase inhibitors that cannot be withheld  
17. Treatment with organic nitrates  
18. Significant liver disease impacting synthetic function or volume control (ALT/A ST > 3x ULN, 
Albumin <3.0 g/dL)  
19. eGFR < 30 mL/min/1.73m2 
20. G6PD deficiency. In males of African, Asian or Mediterranean decent, this will be formally 
evaluated by enzyme testing prior to drug administration. A negative screening test for G6PD 
will be required in these subjects for inc lusion in the study. If a quantitative test is being 
performed, a clinically significant reduction in G6PD activity (<60% of normal) will exclude 
subjects . 
21. Methemoglobinemia – baseline methemoglobin level >5%  
22. Serum K>5.0 mEq/L  
23. Severe right ventricular dysf unction 
24. Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the study.  
25. Contraindications to MRI (except as noted below), including the presence of a pacemaker, metal implants, claustrophobia, or that have known medical conditions which can be 
exacerbated by stress such as anxiety or panic attacks. Inability to lie flat in the MRI scanner 
for 90 minutes is also an exclusion criterion.  
Participants who have contraindications for MRI but are otherwise good candidates for the study, 
may be enrolled. In this case, participants will undergo all study procedures except for the MRI 
scans.** (See paragraph below for more detail)  
In addition, specific exclusion criteria for undergoing scanning in the 7 -Telsa MRI s canning system 
include (these will only apply when the 7T scanner is used. In addition, a 3T scanner is also 
available at Penn, allowing the choice of the scanner depending on availability (to maximize 
safety, exclusion criteria for 7T will be applied at P enn for all participants, even if they ultimately 
are scanned at 3T):**  
– ANY intra -luminal implant, fil ter, stent,  or valve replacement  
– ANY type of life ass ist device, pump, or prosthetic  
– ANY vascular clip or clamp  
Efficacy of Potassium Nitrate in HFpEF    Page 21 of 79 
V12 – Date 07Oct2021  
 
 – ANY surgically placed clips or clamps or bands on visceral organs  
– ANY intracranial implants of any type other than dent al fillings  
– ANY non -removable piercings, jewelry, or medicinal patch  
– ANY personal history of intraocular injury or fragment in or around the orbit that cannot 
be cleared through radiologic examination  
– ANY personal history of bullet, shrapnel, or stabbing wounds that cannot be cleared 
through radiologic evaluation.  
 
** If any of the above apply, we may investigate the issue further to ensure subject safety. This 
may include obtaini ng X -rays or obtaining reports from prior radiographic studies. We may also 
discuss the case with our radiologists and MRI technicians. In these circumstances, an MRI will 
only be performed if deemed safe by an attending radiologist on a case- by-case basis . 
Subjects that qualify for a 3T  or 7T scanner (for the leg MRI study) also qualify for scanning in a 
1.5T scanner (for the cardiac MRI substudy). However, the opposite is not necessarily true. 
Subjects who are determined eligible to undergo scanning in a 3T or 7T scanner (in the primary 
study) are eligible to undergo scanning in the 1.5T scanner (for the cardiac MRI study). Some situations (such as many intraluminal stents and prosthetic valves) which would exclude scanning at high field (7T or 3T) are considered safe for 1.5T scanning. Subjects who are deemed ineligible to undergo 7T or 3T scanning in the parent trial, may still be enrolled in the ancillary myocardial perfusion study and undergo a cardiac MRI study (at 1.5T). In all cases, participation in  the 
myocardial perfusion / cardiac MRI ancillary study will be approved by Dr. Kuruvilla, who has 
appropriate clinical expertise to assess the safety of this test, according to current clinical 
standards. Dr. Kuruvilla is the Director of Advanced Cardiac Imaging at the CMJC  Philadelphia 
VA Medical Center and Assistant Professor at t he University of Pennsylvania.  
4.3.3.  Criteria that will prompt exclusion from the trial at the 6 week visit  
Subjects will be discontinued from study participation if they meet any of the following crit eria at 
the 6 -week study visit:  
1. Acute coronary syndrome or coronary intervention for unstable cor onary disease after 
enrollment  
2. New onset ischemia on stress testi ng since the time of enrollment , including clinically 
significant reversible ischemia in a coronary distribution identified during the cardiac MRI 
substudy . 
3. New treatment with organic nitrates or phosphodiesterase inhi bitors that cannot be withheld  
4. Serum K>5. 5 mEq/L 
5. Any medical condition that, in the opinion o f the investigator, will interfere with the safe 
completion of the study, or the validity of endpoint assessments. Although the ultimate authority/decision making will rely on each site PI, these ad- hoc discontinuations will be 
discussed with the other sit e PIs, the chair of the trial and the medical director of the IND 
for input.  
Subjects who meet the criteria below will not be immediately discontinued, but will be scheduled 
for an ad hoc additional visit for reassessment of values prior  to drug initiation in phase 2:  
Efficacy of Potassium Nitrate in HFpEF    Page 22 of 79 
V12 – Date 07Oct2021  
 
 1. Supine sy stolic blood pressure <90 mm Hg 
2. Acute kidney injur y with eGFR < 30 mL/min/1.73m2  
3. Methemoglobinemia – baseline methemoglobin level >5%  
 
If these criteria persist during the ad- hoc visit, the subject will be discontinued from the study.  
4.3.4  Conditions that will preclude participation in the myocardial perfusion ancillary study  
include:  
1. Prior allergic reactions to gadolinium -based contrast agents.  
2. Allergy, or prior severe adverse reactions t o regadenoson or aminophylline.  
3. 2nd degree AV block, 3rd degree AV  block or high- grade AV block.  
 
4.4 Randomized intervention  
The randomized interventions will be the following (in random order, separated by a 1 -week 
washout period)  
(A) Potassium nitrate: Potassium nitrate crystals will be purc hased and placed into oral gelatin 
capsules with an inert filler (lactose monohydrate). Capsules will be prepared at the University of 
Pennsylvania Investigational Drug Service [3600 Spruce Street, Ground floor Maloney Building, 
Philadelphia, PA 19104]. Each capsule will contain 610 mg KNO 3-, corresponding to 6.03 mmoles 
of NO 3-, plus 190mg of lactose monohydrate, spray dried, NF. The dose for this trial will be 18 
mmoles of NO 3-per day, given as one capsul e (6 mmoles) three times a day.  
(B) Control drug: For t he purpose of conducting this clinical trial, a control capsule will be made 
consisting of potassium chloride, granular, USP (450mg) plus lactose monohydrate, spray dried, NF (300mg) combined and packed into an identical capsule shell. We chose potassium c hloride 
in order to isolate the effects of nitrate from any potential effect of potassium supplementation. The dose for this trial will be 18 mmoles of KCl  per day, given as one capsule (6 mmoles) three times a day.  
5. STUDY VISITS AND PROCEDURES  
A letter  may be sent to potential subjects prior to initial contact. An overview of the study design 
and flow of study v isits is presented in Figure 4.  
 
 
Figure 4. Overview of the study design and procedures.  
Efficacy of Potassium Nitrate in HFpEF    Page 23 of 79 
V12 – Date 07Oct2021  
 
  
 
The following investigational devices  will be used during the study:  
• Aurora device: wearable pulse collection device (watch)  
• Portalite: continuous wave near infrared spectroscopy (NIRS) system to measure 
oxygenation of muscle t issue  
• Portamon: continuous wave near infrared spectroscopy (NIRS) system to measure 
oxygenation of muscle tissue 
5.1. Initial Visit  
During the baseline study visit, inclusion and exclusion criteria will be reviewed to ensure subject 
suitability. After  subject eligibility is confirmed, written informed consent will be obtained from the 
subject using Institutional Review Board (IRB) -approved documents. Informed consent will be 
obtained before any study procedures. Subjects will be given the opportunity to have all questions 
regarding their participation answered in detail in a private sett ing before entering the study.  
Informed consent may be obtained in- person or virtually.  
Following informed consent, a physical examination, with measurement of orthostatic blood 
pressures, will be performed. A urine pregnancy test will be performed in women with childbearing 

Efficacy of Potassium Nitrate in HFpEF    Page 24 of 79 
V12 – Date 07Oct2021  
 
 potential. Blood will be collected for measurement of (a) comprehensive metabolic panel; (b) 
complete blood count; (c) NT- pro-BNP; and (d) methemoglobin. A pregnancy test (women of 
childbearing potential) and Glucose- 6-phosphate dehydrogenase (G6PD) deficiency screening 
(males of males of African, Asian or Mediterranean decent) will be performed as needed. Blood, 
urine, and saliva samples will be collected and frozen for nitrate/nitrite level determination. 
Following the  collection of baseline labs and biomarker samples, subjects will be provided with a 
standard low nitrate breakfast.The Kansas City Cardiomyopathy Questionnaire (KCCQ) will be administered. Subjects will also be given an informational brochure regarding foods that are high in nitrate/nitrite and will be instructed to avoid such foods whi le participating in the study.  
Computerized cognitive assessment testing will be performed using cogstate software (Cogstate; 
New Haven, CT).  The assessment includes a customized battery of seven tests that measure 
various cognitive domains. The batter y includes the following tests:  
• International Shopping List Test  
• Gorton Maze Learning Test  
• Detection Test  
• Identification Test  
• One Card Learning Test  
• One Back Test  
• International Shopping Lis t Test - Delayed Recall (memory)  
The system works with an internet server administered and maintained by Cogstate, which 
quantifies the subject’s performance/responses and calculates cognitive scores. No personal identifiable information will be entered/uploaded into the server.  
Echocardiography will then be performed using a standardized protocol. Images will be obtained 
from the parasternal long axis, short axis, apical 5- , 4-, 3-, and 2- chamber, subcostal, and 
suprasternal views for offline analysis of myocardial strain. Dedicated ventricular chamber images will be obtained in the 4-  and 2 -chamber apical positions for determination of left ventricular 
volumes. Mitral inflow velocities, including color M -mode interrogation, will be assessed in t he 4-
chamber view. Tissue Doppler imaging will be performed at the mitral septal position, 
approximately 1- cm apical to the mitral valve plane. Additional images will be obtained in the 
parasternal short axis at the level of the papillary muscles, 2 -chamber, and 4- chamber apical 
views for assessment of myocardial strain. Pulse- wave Doppler interrogation of the left ventricular 
outflow tract (LVOT) will be performed in the apical 5- chamber view.  
Concurrent arterial tonometry will be performed using a high- fidelity tonometer at the carotid, 
femoral, and radial arteries, using a Sphygmocor device. Waveforms will be calibrated using the 
brachial artery blood pressures, obtained using a validated oscillometric device. Waveforms will be digitally -stored for off -line analysis. Where available, we will also measure blood pressure using 
a BP+ device (Uscom, Sydney, Australia), which is an FDA -approved device that measures 
brachial and central blood pressure using a standard brachial blood pressure cuff. Body surface 
measurements will be made to determine distance between the suprasternal notch to the carotid, 
radial, and femoral arteries. A 6 -minute walk test will also be performed during this visit. Patients 
who demonstrate significant desaturation during exercise (<= 94% or a fall in Spo2 >= 5%) w ill be 
excluded from the study  
Efficacy of Potassium Nitrate in HFpEF    Page 25 of 79 
V12 – Date 07Oct2021  
 
  
Initial Visit Procedures  
 
• Informed Consent a 
• Eligibility assessment  
• Medical History, Concomitant Medications  
• Dietary counseling 
• KCCQ  
•Physical Exam (including orthostatic vital signs a nd anthropometric measurements)  
•ECG, Laboratory tests (CBC, comprehensive metabolic panel, NTproBNP or proBNP, 
methemoglobin; pregnancy test and G6PD deficiency screening as needed)  
• Blood, urine and saliva collection 
• Cognit ive assessment  
• 2D echocardiogram, a rterial tonometry  
• Device (A urora and Actigraph) education  
• 6 minute walk test with O 2 saturation and Aurora device  
 
a Informed consent will be obtained before any study procedures  
 
  
5.2. Randomization procedure 
A stratified blocked randomization will be performed based on enrollment site 
(UPenn/Northwestern/ VAMC), sex , and ethnicity. A sufficient number of complete blocks will be 
generated for each stratum so that randomized assignments are available for every eligible 
subject. Strata -specific treatment order assignments and will be provided by a member of the data 
management team. Each block will contain an equal number of allocations to KNO 3 followed by 
KCl versus KCL followed by KNO 3. The order of treatment sequences within each block will be 
randomized.  
To preserve blinding, the strata- specific treatment order assignments and the associated 
studyspecific  patient identification number will be provided to each study IDS representative site 
in electronic format (excel spreadsheet ) pre-sealed envelopes.  
Upon determination of subject eligibility into the trial, the IDS representative will break the seal of 
the next envelope for the appropriate stratum to determine the treatment group assignment based on the appropriate stratum -specific scheme and will record the patient identification number for 
that study subject.  
5.3. Intervention Phase 1  
Subjects will be randomized to either active drug (KNO
3) or placebo (KCl) as the “first” drug for 
phase A. The initial dose will be one 6 mmol capsule administered twice daily, to be taken with meals. We will provide subjects with a 14- day supply of study medication to account for potential 
delays in the shipment of the 2
nd batch of medication (i.e., after the 1 -week call).  
Efficacy of Potassium Nitrate in HFpEF    Page 26 of 79 
V12 – Date 07Oct2021  
 
 1-week call:  Subjects will be called by telephone ~1 week later for side- effect assessment. 
Subjects will receive reinforcement of the dietary restrictions imposed during the study. Subjects 
will be interrogated about headaches and dizziness. If these symptoms are not present, or are not worse compared to  the subject’s baseline, the drug dose will be up titrated to 18 mmol daily (One 
6-mmol capsule taken 3 times per day). The presence of orthostatic symptoms (i.e. sustained 
lightheadedness upon standing) will prompt a visit to assess for orthostatic vital signs. The presence of symptomatic orthostatic hypotension (20 mmHg reduction in systolic blood pressure with associated symptoms such as dizziness) will prompt exclus ion of patients from the trial.  
Subjects may experience symptoms upon dose uptitration that do not prompt exclusion from the 
trial, as per the criteria noted above (for example, but not limited to, mild dizziness, gastrointestinal symptoms, fatigue). In these instances, the Site Principal Investigator can reduce the dose back to 6-mmol capsule taken twice per day, for the remainder of the treatment phase.  For subjects 
who have a baseline serum K between 4.7 and 5.0 mEq/L in the presence of either: (a) potassium -
sparing diuretic use, or (b) e stimated glomerular filtration rate of 30- 39 mL/min/1. 73m
2, we will 
check a serum potassium 1 week after the implementation of the 18 mmol/d dose as a safety measure . A serum potassium >5.5 mEq/L will prompt exclusion at this point.  
At approximately 5 weeks into each interventional phase, the Aurora and Actigraph devices will 
be given to the subjects. The goal will be for the subjects to wear these devices during the final week of each interventional phase to look for differences with each therapy. The devices will be 
brought back by the subject at his/her nex t visit.  
6-week endpoint assessment:  Following ~6 -weeks of therapy with KNO
3/KCl, subjects will 
return for endpoint assessments. Physical examination with measurement of orthostatic blood 
pressure, pill count, KCCQ, dietary counseling, cognitive assessment , and side effect 
assessments will be performed. A urine pregnancy test will be performed in women with 
childbearing potential. An intravenous catheter will be placed in the antecubital vein and securely fixed in place. Blood, urine,  and saliva samples wil l be collected prior to, and approximately 2 
hours after the morning dose administration, given with a standardized low -nitrate breakfast. 
Blood RNA samples will be collected prior to the morning dose administration using Paxgene 
tubes (BD Biosciences, Franklin Lakes, NJ). Subjects will then undergo repeat echocardiography, arterial tonometry , and blood pressure measurements (including BP+ central blood pressure 
measurements). Subjects will then perform a maximal -effort peak oxygen consumption (VO
2) test 
using a supine bicycle exercise test with expired gas analysis. Cardiac output at rest will be 
measured immediately prior to exercise using pulsed wave Doppler echocardiography. Exercise cardiac outputs will also be obtained using the same technique. An addi tional blood sample will 
be obtained at peak exercise. The Aurora watch will be worn during exercise when possible. 
Subjects enrolled at Penn or the VA will undergo an assessment of skeletal muscle mitochondrial oxidative capacity using MRI either before, or at least 3 hours after, peak VO
2 testing. Based on 
scheduling and availability, the MRI may be performed on a different day than the exercise study. The Kansas City Cardiomyopathy Questionnair e (KCCQ) will be administered.  
 
Phase 1: 6- week Visit Procedures  
 
• Interim medical hi story, concomitant medications  
Efficacy of Potassium Nitrate in HFpEF    Page 27 of 79 
V12 – Date 07Oct2021  
 
 • Physical exam (inc luding orthostatic vital signs)  
• Pill count  
• Blood, urine and sputum collection, blinded drug administration 
• ECG, labs (CBC, comprehensive metabolic panel, methemoglobin, pregnancy test as needed, 
BD PAXgene RNA samples)  
• KCCQ  
• Blood, urine,  and saliva collection approximat ely 2 hours post -administration  
• Cognitive assessment  
• 2D echocardi ogram, arterial tonometry  
•Cardiopulmonary test with resting and exercise cardiac output measurements, blood draw at 
peak exercise 
• If feasible, plantar flexor exercise / MRI (fat/water imaging / Creatine CEST / PC -MRI); these 
measurements are not perfo rmed at the Northwestern site  
• Data dow nload of the Aurora device and Actigraph 
 
Additional visit for subjects participating in the Cardiac MRI sub -study:  Subjects who 
participate in the MPR ancillary study will undergo a cardiac MRI with regadenoson administration. 
This will be scheduled duri ng the last 2 weeks of the study intervention (4- 6 weeks after initiation 
of drug administration in Phase 1), such that it will not interfere with the scheduling of the main 
trial visits. The cardiac MRI may take place on a different day than the exercise study o r the lower 
extremity MRI scan and may occur either before or after the exercise endpoint study visit.  
5.4. 1- week washout period  
Following the endpoint assessment, subjects will enter a 1- week washout period during which 
they will not receive any s tudy medications.  
5.5. Intervention Phase 2  
Following the washout period, subjects will receive either active drug (KNO 3) or placebo (KCl) 
during phase 2 of the trial. Subjects will receive the intervention (KNO 3 or KCl) that was not 
administered in phase 1, such that each subject will receive both study interventions in this cross -
over design. The ~1- week call and the ~6 -week study visit will be repeated as above. We will 
provide subjects with a 14- day supply of study medication to account for potential delays in the 
shipment of the 2nd batch of medication (i.e., after the 1 -week call).  
1-week call:  Subjects will be called by telephone ~1 week later for side- effect assessment. 
Subjects will receive reinforcement of the dietary restrictions imposed during the study. Subjects will be asked about headaches and dizziness. If these symptoms are not present , or are not 
different than the subject’s baseline, the drug dose will be up- titrated to 18 mmol daily (One 6mmol 
capsule taken 3 times per day). The presence of orthostatic symptoms will prompt a visit to assess for orthostatic vital signs. The presence o f symptomatic orthostatic hypotension (20 mmHg 
reduction in systolic blood pressure with associated symptoms such as dizziness) will prompt exclusion of patients from the trial.  
Subjects may experience symptoms upon dose uptitration that do not prompt excl usion from the 
trial, as per the criteria noted above (for example, but not limited to, mild dizziness, gastrointestinal 
Efficacy of Potassium Nitrate in HFpEF    Page 28 of 79 
V12 – Date 07Oct2021  
 
 symptoms, fatigue). In these instances, the Site Principal Investigator can reduce the dose back 
to 6-mmol capsule taken twice per day,  for the re mainder of the treatment phase.  
At approximately 5 weeks into each interventional phase, the Aurora and Actigraph devices will 
be given to the subjects. The goal will be for the subjects to wear these devices during the final week of each interv entional phase to look for differences with each therapy. The devices will be 
brought back by the subject at his/her next visit.  
6-week endpoint assessment:  Following ~6 -weeks of therapy with KNO
3/KCl, subjects will 
return for a repeat endpoint assessment.  Physical examination with measurement of orthostatic 
blood pressure, pill count, KCCQ, dietary counseling, cognitive assessment , and side effect 
assessments will be performed. A urine pregnancy test will be performed in women with childbearing potential. An intravenous catheter will be placed in the antecubital vein and securely 
fixed in place. Blood, urine,  and saliva samples will be collected prior to, and approximately 2 
hours after, morning dose administration, given with a standardized low -nitrate bre akfast. Blood 
RNA samples will be collected prior to the morning dose administration using Paxgene tubes (BD 
Biosciences, Franklin Lakes, NJ). Subjects will then undergo repeat echocardiography, arterial 
tonometry , and blood pressure measurements (including BP+ central blood pressure 
measurements). Subjects will then perform a maximal -effort peak oxygen consumption (VO
2) test 
using a supine bicycle exercise test with expired gas analysis. Cardiac output at rest will be 
measured immediately prior to exercise using pulsed wave Doppler echocardiography. Exercise 
cardiac outputs will also be obtained using the same technique. An additional blood sample will 
be obtained at peak exercise. The Aurora watch will be worn during exercise when possible. 
Subjects enroll ed at Penn or the VA will undergo repeat assessment of skeletal muscle 
mitochondrial oxidative capacity using MRI either before, or at least 3 hours after, peak VO 2 
testing. Based on scheduling and availability, the MRI may be performed on a different day than 
the exercise study. The Kansas City Cardiomyopathy Questionnaire (KCCQ) will be administered. Following the final endpoint assessment, subjects’ participation in the study will be ov er. 
 
Phase 2: 6- Week  Visit (final visit) Procedures  
 
• Interim medical history, concomitant medications  
• Physical exam (inc luding orthostatic vital signs)  
• Pill c ount and side effect assessment  
• Blood, urine,  and sputum measurements, followed by blinded drug administration  
• ECG, labs (CBC, comprehensive metabolic panel, methem oglobin, pregnancy test as needed, 
BD PAXgene RNA samples)  
• KCCQ  
• Blood, urine and , saliva collection approximately 2 hours post -administration  
• Cognitive assessment  
• 2D echocardiogram, arterial tonometry  
• Cardiopulmonary test with resting and exercise cardiac  output measurements, blood draw at 
peak exercise 
• If feasible, plantar flexor exercise / MRI (fat/water imaging / Creatine CEST / PC - 
MRI); these measurements are not perf ormed at the Northwestern site  
• Data download of the Aurora device and Actigraph 
Efficacy of Potassium Nitrate in HFpEF    Page 29 of 79 
V12 – Date 07Oct2021  
 
  
Additional visit for subjects participating in the Cardiac MRI Sub -study:  Subjects who are to 
participate in cardiac MRI sub- study will undergo a Stress Cardiac MRI with regadenoson 
administration. This will be scheduled during the  last 2 weeks of the study intervention (4- 6 weeks 
after initiation of drug administration in phase 2), such that it will not interfere with the scheduling 
of the main trial visits. The cardiac MRI may take place on a different day than the exercise study 
or the lower extremity MR I scan  and may be performed either after or before the exercise 
assessment.  
5.6 Adverse Event Reporting  
All adverse events will be reported following FDA guidelines. The research team will keep a log 
of all adverse events that occur in the trial, and any r eportable events will be reported per Section 
7 in this protocol. The study team in charge of the conduct of the trial is up to date on all trainings pertaining to safety guidelines and adverse event reporting. Adverse Events will be reported to the site I RB, the Data Safety Monitoring Board, the Sponsor andand the NIH Program Office in a 
timely fashio n, as specified in S ection 7.  
5.7. Subject  withdrawal / Early termination  
Subjects may voluntarily withdraw from the study at any time and for any reason, or this may be 
at the investigator’s discretion. The investigator may withdraw a patient from the study due to 
protocol non -compliance, incorrect enrollment or randomization, or for any other reasons related 
to subject safety. The reason for study discontinuation will be recorded on the source documents 
and all such subjects will be asked to compl ete an early termination visit.  
During this visit, we will document: (1) vital signs; (2) compliance with the medications, including 
pill count; (3) adverse effects , (4) specific reason for withdrawal.  
Early Termination Visit Procedures  
• Vital signs and physical exam 
• Pill cou nt and medication adherence log 
• Safety labs 
• Adverse event assessment  
• Documentation of reason for withdrawal  
• Retrieval of Aurora and Acti graph devices and data download 
 
5.8. Concomitant Medication  
Subjects should be treated with standard of care medications for HFpEF or associated 
comorbidities. As per inclusion criteria, subjects should be on a stable medical regimen for HFpEF  
prior to entry. Further adjustment of diuretics or blood pressure medications during the study 
period is discouraged and should only be performed according to new and clinically compelling 
worsening of clinical status. Therapy with organic nitrates or phosphodiesterase -5 inhibitors is 
contra -indicated during the study period.  
Efficacy of Potassium Nitrate in HFpEF    Page 30 of 79 
V12 – Date 07Oct2021  
 
 6. DRUG DISPENSING,  ACCOUNTABILITY , AND DESTRUCTION 
Drug dispensing will be managed  by the Penn Investigational Drug Pharmacy, in collaboration 
with the Northwestern Investigational D rug Pharmacy. KNO 3 and KCl capsules will be 
compounded at the Penn IDS. Penn IDS will bottle, label , and dispense product for the Penn and 
VA sites. Penn IDS will ship product to Northwestern IDS for bottling, labeling , and dispensing of 
product at the Nor thwestern site. Prior to initiation of each phase, participants will receive a 
sufficient supply of KNO 3 or placebo capsules to last until the end of each treatment phase, 
allowing for 100% compliance with the regimen for the entire treatment phase, including a window 
of ±7 days for the 1- week up -titration (to ensure an adequate supply of medication) and ±1 week 
for the 6- week endpoint assessment visit.  
Subjects will be instructed to take the medication as required by the protocol, and compliance will 
be as sessed via  pill count performed by IDS.  
Subjects will be instructed to return unused capsules at the end of each treatment phase. A pill 
count will be performed prior to destruction of the drug. Returned trial capsules will be stored separately from the non -allocated trial capsules until returned trial capsules are disposed of. The 
IDS personnel will keep track of all received, used, partly used and unused trial products.  
Used and unused study drug will be destroyed at the instruction of the sponsor. A copy  of the drug 
destruction SOP should be maintained in the pharmacy sec tion of the Regulatory Binder.  Study 
drug should not be destroyed until drug accountability has been completed and the Sponsor has 
authorized it . 
 6.1. Rules for un- blinding  
Randomization data will be kept strictly confidential, accessible only to authorized IDS personnel, 
until the time of un -blinding. The investigators will be given access to the treatment code for their 
patients for emergency un- blinding by calling the respective IDS. T his is considered to be a very 
unlikely occurrence. Any suspected study drug- related events will be treated as though the patient 
received active (KNO
3). Nevertheless, in the rare event ofemergency un- blinding, the site PI and  
the Sponsor must be notified.  
7. ADVE RSE EVENTS  
7.1. Key definitions  
Adverse Event:  An adverse event (AE) is any untoward medical occurrence associated with the 
use of a drug in a subject whether or not  considered drug or biologic related. An AE can therefore 
be any unfavorable and unintended sign, symptom , or disease temporally associated with the use 
of the pharmaceutical product.  
Suspected Adverse Reaction : A suspected adverse reaction (SAR) is any adverse event for 
which there is a reasonable possibility that the drug caused the event. “Reasonable possibility” suggests there is a causal relationship between the drug and the adverse event. “Suspected adverse reaction” implies a lesser degree of certainty about causality than adverse reaction, which 
means any adverse event caused by a drug . 
Efficacy of Potassium Nitrate in HFpEF    Page 31 of 79 
V12 – Date 07Oct2021  
 
 Serious Adverse Events (SAE):  An adverse event or suspected adverse reaction is considered 
serious if the investigator or  sponsor believes any of the following outcomes may occur:  
• Death 
• Life-threatening AE: Places the subject at immediate risk of death at the time of the event 
as it occurred. It does not include an AE that, had it occurred in a more severe form, might 
have c aused death.  
• Persistent or significant incapacity or substantial disruption of the ability to  conduct normal 
life functions.  
• Inpatient hospitalization or pr olongation of hospitalization.  
• Congenital anomaly or birth defect.  
• Important medical events that may  not result in death, be life threatening, or require 
hospitalization may be considered a serious adverse event when, based upon appropriate 
medical judgment, they may jeopardize the subject and may require medical or surgical 
intervention to prevent one o f the outcomes l isted in this definition above.  
This determination is based on the opinion of either the investigator, or sponsor (i. e., if any  one of 
these believes it is serious, it must be considered serious).  
Unanticipated Adverse Device Effect (ADE):  Any serious adverse effect on health or safety, 
any life -threatening problem or death caused by, or associated with a device, if that effect, 
problem, or death was not previously identified in nature, severity, or degree of incidence in the 
application; or  any other unanticipated serious problem associated with a device that relates to 
the rights, safety, or welfare of s ubjects.  
7.2. Classification of AE/ADEs  
A medically -qualified investigator must assess all AEs in terms of causal relationship to 
intervention, severity, and “expectedness”  using the following guidelines . 
Classification of Adverse Events for Causal Relationship to Study Interventions 
Not related  There is not a reasonable causal relationship to the investigationa l 
product and the adverse event.  
Unlikely related  No temporal association or the cause of the event has been identified, or 
the drug or device is unlikely to be implicated, but there is a low  
likelihood that a causal relationship exists.  
Possibly related There is reasonable evidence to suggest a causal relationship betw een 
the drug and adverse event.  
Related There is evidence to suggest a causal relationship, and the influence of other factors is unlikely.  
 
 
 
 
Efficacy of Potassium Nitrate in HFpEF    Page 32 of 79 
V12 – Date 07Oct2021  
 
  
1 Mild AE : Awareness of sign, symptom, or event, but easily t olerated; no 
treatment required  
2 Moderate AE : Discomfort enough t o cause interference with usual activity 
and may warrant intervention. In the latter sce nario, AE responds to 
treatment  
3 Severe AE : Incapacitating, limiting usual/normal activities or significantly 
affects clinical status requiring hospitalization or pr olongation of 
hospitalization.  
4 Life-threatening or disabling 
5 Fatal AE  
 
 
Expectedness:  The expectedness of an AE/ADE or SAR shall be determined according to the 
specified reference document containing safety information (e.g., most current investigator’s 
brochure or product label). Any AE/ADE that is not identified in nature, severity, or specificity in the current study reference docum ent(s) (e.g. protocol or investigator’s brochure) is considered 
unexpected. Events that are mentioned in the investigator's brochure as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but not specifically mentioned as occurring with the particular drug under investigat ion, are considered unexpected.  
The following AEs are expected, disease -related events in patients with HF with prese rved 
ejection fraction (HFpEF).  
1. Unplanned hospitalization, ER visit or clin ic visit for worsening HF 
2. Arrhythmias, particularly atrial fibrillation  
3. Sudden cardiac death  
4. Acute coronary syndrome 
5. Cerebrovascular event  
6. Venous thromboembolis m 
7. Lightheadedness  
8. Worsening renal function  
9. Shortness of breath at rest or during/after exercise  
10. Fatigue at rest or during/after exercise  
The following are potential expected side effects of KNO
3: 
1. Stomach discomfort  
2. Slight headache  
3. Dizziness  
Classification of Adverse Events Regarding Severity Scale  
Efficacy of Potassium Nitrate in HFpEF    Page 33 of 79 
V12 – Date 07Oct2021  
 
 4. New ons et or worsening lightheadedness  
5. Low blood pressure  
6. Stomach ache, diarrhea, nausea, or vomiting 
7. Worsening shortness of breath  
8. Worsening fatigue  
9. Flushing  
10. Rash  
11. Mild orthostatic hypotension 
Clinically significant methemoglobinemia or significant symptomatic orthostatic hypotension (20 
mmHg or greater reduction in systolic blood pressure with associated symptom s such as dizziness  
upon standing ) are potential expected side effects to KNO 3, although we will consider them 
unexpected given prior data in this patient population with this part icular drug and dosing scheme.  
The following are potential expected side effects of regadenoson administration (for subjects 
participating  in the cardiac MRI sub- study):  
1. Headache 
2. Dizziness  
3. Nausea or stomach discomfort  
4. Decreased sense of taste 
5. Mild chest discomfort  
6. Shortness of breath  
7. Flushing (warmth, redness, or  tingly feeling under the skin)  
These side effects are transient and generally resolve upon clearance of the drug and/or 
reversal of drug effects with dypiridamole.  
The following are potential expected side effects of gadolinium -based contrast administration (for 
subjects participating  in the cardiac MRI sub- study):  
1. Inject ion site pain (from the needle)  
2. Burning at injection site  (if the dye contacts the skin)  
3. Headache 
4. Dizziness or faintness  
5. A decrease in blood pressure  
6. Nausea 
7. Vomiting  
8. Sweating  
9. Paresthesias  
 
These side effects occur in a small minority of patients, but if they do occur they will be noticed 
within minutes of the injection and are transient in nat ure. 
7.3. Recording and Reporting of Adverse Events 
The site PIs will continuously supervise all aspects of the trial and review the records of the study 
subjects following each visit and at the end of their participation. The site PIs will be responsible 
Efficacy of Potassium Nitrate in HFpEF    Page 34 of 79 
V12 – Date 07Oct2021  
 
 for ensuring that all adverse events are noted, followed and reported to the  Sponsor  database  
and IRB as per local requirements . 
SAEs occurring from the time of signed informed consent to the Week 15 phone visit will be 
captured on a CIOMS form. AEs will be classified according to the guidelines/definitions specifi ed 
in section 7 of the protocol. Any AE rated >=3 in severity and all  SAEs must be reported by the 
site investigator or qualified designee within 1 working day of first becoming aware of the event, 
to the Sponsor via email  (at psom -ind-ide@pobox.upenn.edu) , and the medical director (Dr. 
Townsend), with CC to the study chair (Dr. Chirinos). The IRB should be notified as per institutional guidelines at each respective site. The medical director  will make an immediate determination about the necessity to modi fy the protocol, include additional information in the 
consent form, inform previous participants, temporarily hold enrollment of patients, or terminate 
the study.  
The investigator or qualified designee will enter the required information regarding the AE  into the 
appropriate module of the eCRF, All study procedures and cumulative adverse events are subject to full IRB review at least yearly and DSMB review every 6 months.  
Events significant enough to necessitate modification of study drug dosing will be c aptured on an 
appropriate eCRF module (“Study Drug Dosing” page). Should the PI determine that a modification to study drug is appropriate, the PI must obtain written approval from the Sponsor to 
proceed with this exception to the protocol.  
7.4. Follow -up 
The Investigator will record follow -up safety information according to the same process used for 
reporting the initial event as described above. The Investigator will follow all safety events until resolution, stabilization or the event is othe rwise explai ned. 
The DSMB will review detailed safety data approximately every 6 months throughout the study, 
as detailed in the Data Safety Monitoring Section of this protocol and in the D ata Safety Monitoring 
Charter.  
7.5. Management of Suspected Unexpected Serious Adverse Reaction 
AEs that meet the criteria of serious, related to study intervention, and unexpected for the study 
intervention, qualify for expedited reporting by the Sponsor to the regulatory authorities. The Site Investigator will assess all SAEs occur ring at his/her site and evaluate for “unexpectedness” and 
relationship to study drug. The Site Investigator is required to complete a report for any event identified as serious, study drug related and unexpected, using the CIOMS format , and to submit 
it to the Sponsor within 1 working day of the PI or site personnel being aware of it . The sponsor 
will submit a safety report according to regulations.  
A copy of the  report sent by the PI to the Sponsor should be kept at the site Regulatory Binder  
7.6. Pregnancy  
Pregnancy is a contraindication to enrollment in the study. Pregnancy occurring during the study 
period, although not considered an SAE, must be reported to the Sponsor within the same 
Efficacy of Potassium Nitrate in HFpEF    Page 35 of 79 
V12 – Date 07Oct2021  
 
 timelines as an SAE, and to the  IRB per local requirements  . The pr egnancy will be recorded on 
the appropriate note to file. The drug will be discontinued immediately and subject terminated from 
the trial, but t he pregnancy will be followed until final outcome. Any associated AEs or SAEs that 
occur to the mother or fetus/ child will be recorded in t he AE or SAE case report form.  
8. STUDY MEASUREMENTS AND DATA COLLECTION 
8.1. A ssessment of exercise capacity  
We will use a supine bicycle exercise protocol in conjunction with expired gas analysis to assess 
oxygen consumption (V O2) during exercise. Subjects will perform a maximal exertion limited 
exercise test using a graded- exercise protocol. We will use a supine cycle ergometer designed 
for stress echocardiography (Stress Echo Ergometer 1505, Medical Positioning, Inc, Kansas Ci ty, 
MO). Subjects will undergo expired gas analysis with a Parvo Medics True One 2400 device (Parvo Medics, Sandy, UT), an Innocor device (Innovision Inc) or equivalent. Resistance began at 15 W for 3 minutes, increasing to 25 W for 3 minutes, and then inc reasing by 25 W every 3 
minutes thereafter. Breath- by-breath information will be recorded. We will use custom -designed 
software already developed in Matlab (MathWorks, Natick, MA) at our lab for offline processing and quantification of all exercise data.
111 All data quantification will be blinded to treatment. Total 
work performed will be computed and exercise efficiency will be defined as (total work/total oxygen consumed). Exercise efficiency is not a formal endpoint of the trial, but will be used to interpret 
changes in the co -primary outcomes.  
 
8.2. Quality of life assessment  
This will be assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ).
124 We will 
administer the KCCQ to subjects prior to randomization and at the end of each intervention phase 
(6-week time point in both phases). This is a validated 23 -item questionnaire that assess physical 
function, symptoms, social function, self -efficacy and knowledge, and quality of life. It has been 
used extensively in heart failure studies (ht tp://c voutcomes.org/pages/3214) . 
8.3. Assessment of the systemic vasodilatory response to exercise  
Blood pressure will be measured with a validated oscillometric device at rest,  at each stage of 
exercise and after exercise. Cardiac output will be measured at rest and at each stage of exercise using echocardiography. Systemic vascular resistance (SVR) will be calculated at rest and at peak 
exercise as mean arterial pressure / cardi ac output. Systemic vasodilatory reserve will be 
measured as the reduction in SVR during exercise, relative to SVR at rest ([rest SVR – peak 
exercise SVR] / rest SVR ).
111 Depending on equipment availability at each site, we may also 
monitor and record muscl e oxygenation in the calf (lateral aspect of left gastrocnemius) and 
forearm (flexor digitorum superficialis) during exercise non- invasively using a Portamon or 
Portalite near -infrared spectroscopy device (Artinis Medical Systems; The Netherlands). Both the 
Portamon and Portalite are investigational devices and not currently approv ed medical devices in 
the U.S.  
Efficacy of Potassium Nitrate in HFpEF    Page 36 of 79 
V12 – Date 07Oct2021  
 
 8.4. Assessment of m uscle perfusion and energetics  
If available equipment and personnel are available at the time of enrollment, MRI studies will be  
performed at rest and immediately after a standardized plantar flexion exercise test using a 3T or 
a 7T scanner equipped with a 15-channel transmit/ receive radiofrequency coil  and an MR  
compatible pneumatically controlled foot pedal. Phase contrast MRI  using a fast 1D projection 
technique125 will be used to image blood flow  with high temporal resolution  (Figure 5a- c) .  
 
 
The primary measure of recovery kinetics will be measured with creatine chemical exchange 
saturation transfer (CrCEST) , except for subjects enrolled at the Northwestern site. Sample 
CrCEST recovery images of the calf are shown in figure 5d. The first 2 acquisitions are pre-
exercise (red box), with the remainder representing sequential acquisition immediately after 
cessation of exercise. Recovery kinetics of creatine levels will be quantified. Phosphorus 
spectroscopy is limited by the lack of anatomic information, being able only to assess PCr levels 
in a large voxel of tissue. In contrast, the chemical exchange saturation transfer (CEST) technique, a novel sensitivity enhancement method developed by our group,
75, 126 -128 can dete ct metabolite 
content based on exchangerelated properties at either 7T127, 128 or 3T,126 utilizing hydrogen signal 
  
  
Efficacy of Potassium Nitrate in HFpEF    Page 37 of 79 
V12 – Date 07Oct2021  
 
 (thus not depending on the much weaker phosphorus signal). Creatinine exhibits a concentration 
dependent CEST effect between its amine ( -NH 2) and bulk water protons (CrCEST )75 which allows 
for the monitoring of Cr concentration changes with high spatial and temporal resolution. In 
contrast to phosphorus spectroscopy, this technique allows for spatial mapping (creation of an 
highresolution anato mic image) of PCr levels (figure 3D). This cannot be accomplished with 
phosphorus spectroscopy. This novel technique can be used to assess PCr recovery kinetics 
following exercise, allowing for accurate selection of muscle tissue (rather than fat or bone).  More 
importantly, the serial anatomically mapped PCr information can be used to assess oxidative 
capacity of muscle tissue from specific pixels in the image.  We will also assess muscle fat using 
a 3-point Dixon separation technique and hydrogen spectroscopy. We will exclude fat from 
CrCEST computations.  
 
8.5. Doppler Echocardiography  
This procedure is similar to clinical cardiac echocardiograms. An ultrasound probe will be placed 
on the surface of the skin to obtain images of the heart. This takes approximately 60 minutes. This 
will oc cur at all three visits.  
Measurement of LV filling and myocardial strain : Given that inorganic nitrate may also induce 
venodilation and myocardial effects, we will also assess the effects of potassium nitrate on (1) Early mitral annular early diastolic tissue velocity; (2) The ratio of early diastolic mitral inflow velocity to mitral  annular tissue velocity (a surrogate of LV filling pressures); (3) Peak early 
diastolic intraventricular pressure gradient, a marker of ventricular relaxation, assessed with color 
M-mode interrogations of mitral inflow.
129, 130 We note that the latter is not simply based on the 
inflow propagation velocity, but rather on solving Euler momentum equation.129 This method is 
able to accurately assess LV relaxation.129 Systolic function will be assessed via systolic 
myocardial strain (using speckle tracking echocardiography), which we have successfully applied 
in previous studies.92, 95, 131  
 
8.6. Measurement of late systolic load and arterial wave reflections:  
We will use a high -fidelity Millar applanation tonometer80 to record carotid pressure waveforms, 
which will be calibrated using brachial artery pressures. Central arterial tonometric recordings and 
Doppler flow velocity files will be processed off -line using custom -designed software written in 
Matlab (The Mathworks, Natick, MA) as previously described.92, 132 We have successfully 
implemented this method in multiple previous studies79, 83, 92, 93, 133 and have published a tutorial 
detailing our analysis methods.78, 79 After signal -averaging of pressure and flow, time alignment of 
carotid pressure and LV outfl ow curves will be performed to maximize concordance of the rapid 
systolic upstroke of pressure and flow, concordance of the dicrotic notch and cessation of flow, 
zero value of the phase angle of higher -frequency harmonics (7th to 10th) of input impedance, and 
linearity of the early systolic pressure -flow relationship.132 After computation of aortic input 
impedance, proximal aortic characteristic impedance (Zc) will be computed in the frequency 
domain as previously described.132 Pressure and flow harmonics w ere separated into forward and 
backward components using standard wave separation analysis.78, 79, 132, 134 The sum of forward 
and backward pressure harmonics yields the forward and backward waves, respectively. We will 
Efficacy of Potassium Nitrate in HFpEF    Page 38 of 79 
V12 – Date 07Oct2021  
 
 assess the reflection coefficient in the first 3 harmonics. As reflection coefficient is derived from 
the ratio of two sine waves, it is a complex number with an amplitude and phase- angle, which can 
correspond to different degrees of destructive or constructive interference between forward and 
backward waves. Therefore, the net -effect of reflections will be expressed as the real part of Γ, 
which becomes increasingly positive as pressure from wave reflections increases (constructive interference), and negative when destructive interference leads to a net decrease in pressure by wave reflections at a given harmonic.
135 Since all harmonics of wave reflection contribute variably 
to systolic LV load, our primary measure of late systolic load will be the net pressure related to wave reflections duri ng ejection in the time domain, which better represents the impact of 
reflections on LV afterload. We will first compute the product of flow and aortic Zc (QZc product), 
which represents the pressure resulting from the interaction of blood flow with aortic  root Zc.
79, 80 
The relation between QZc and measured pressure reveals the direct effect of wave reflections on 
the arterial system.136 We will therefore quantify the additional ejection- phase pressure load from 
wave reflections arising distal to the root (i.e., reflection -related pressure time integral during 
ejection, as the difference between measured pressure and the QZc product). Carotid- femoral 
pulse wave velocity (PWV), an index of large artery stiffness,137, 138 will also be measured80, 139 
using a Sphygmocor device (Atcor Medical).137 We will also measure carotid -radial PWV using 
the Sphygmocor device. PWV is not a formal endpoint of this trial, since our pilot trial did not demonstrate an effect of nitrate -rich beetroot juice on this endpoint (unpublished data). However, 
it may aid in interpreting changes in pulsatile hemodynamics in the trial. Similarly, when available, arterial tonometry may be performed during and immediately after exer cise for exploratory 
purposes.  
8.7. Blood nitrate/nitrite level measurements : 
We will document an intervention- related change in blood nitrate and nitrite. Nitrate and nitrite 
levels will be sampled before and approximately 2 hours after the last oral dose on the morning of the exercise test, after the patient ha s been on each intervention for approximately 6 weeks. 
Measurements will be performed at Dr. Harry Ischiropoulos’ lab at the University of Pennsylvania. Venous blood samples will be drawn into lithium -heparin tubes (which have very low levels of 
nitrate/ni trite) and centrifuged at 4,000 rpm for 10 min within 3 min of collection and frozen at -
80°C for later analysis. Blood will also be obtained at peak exercise. After thawing at room 
temperature, blood samples will be deproteinized using cold ethanol precipitation as previously 
described.
118 The nitrate and nitrite content of deproteinized blood will be determined using a 
modified detection chemiluminescence technique using a Ionics/Sievers nitric oxide analyzer (NOA 280), as first described by Dr. Ischiropoulos’ lab
140 and later adapted by Allen et al for human 
blood.141 
8.8 Cognitive Assessment  
Computerized cognitive assessment testing will be performed using cogstate software (Cogstate; 
New Haven, CT). These tests will be administered to subjects prior to randomization and at the 
end of each intervention phase (6- week time point in both phases).The assessment includes a 
customized battery of seven tests that measure various cognitive domains. The batter y includes 
the following tests:  
 
Efficacy of Potassium Nitrate in HFpEF    Page 39 of 79 
V12 – Date 07Oct2021  
 
 COGNITIVE ASSESSMENT T ESTS    
TEST NAME AND 
INSTRUCTIONS  COGNITIVE DOMAIN  PRIMARY OUTCOME  INTERPRETATION  
International Shopping 
List Test  
Tell me the items on the 
shopping list.  Verbal learning  Number of correct 
responses remembering 
the word l ist on three 
consecutive trials  Higher score = Better 
performance  
Gorton Maze Learning 
Test 
Find the hidden pathway.  Executive function  Number of errors 
learning the same 
hidden pathway across 
the consecutive learning 
trials Lower score = Better 
performance  
Detection Test  
Has the card turned over?  Psychomotor function  Speed of performance; 
mean of the log 10 
transformed reaction 
times for correct 
responses  Lower score = Better 
performance  
Identification Test  
 Is the card red? 
 Attention  Speed of performance; 
transformed reaction 
times for correct 
responses  Lower score = Better 
performance  
One Card Learning Test  
Have you seen this card 
before in this test?  Visual learning  Accuracy of 
performance  Higher score = Better 
performance  
One Back Test  
Is the card the same as  
the previous card?  Working memory  Speed of performance; 
transformed reaction 
times for correct 
responses  Lower score = Better 
performance  
Intern ational Shopping 
List Test  - Delayed Recall  
 
Tell me the items on the shopping list that you 
learned earlier.
 Memory  Number of correct 
responses  Higher score = Better 
performance  
 
Efficacy of Potassium Nitrate in HFpEF    Page 40 of 79 
V12 – Date 07Oct2021  
 
 8.9. Other assessments 
Weight and Height : Weight will be measured to the nearest 0.1 kg with the use of calibrated 
scales, while the subjects are wearing light clothing and no shoes. Height will be measured at 
baseline to the nearest 0.1 cm usi ng a wall -mounted stadiometer.  
Physical Activity:  We will measure activity level in all subjects with the Actigraph device, which 
has been previously validated. This device can be worn on the wrist, and measures acceleration 
each minute in the anterior -posterior, mediolateral, and vertical axis, and summarizes that 
information as a vector magnitude. The software will use this data to calculate physical activity in 
METS and steps. The accelerometer will be provided during both phase 1 and phase 2. We will 
give the devices (Aurora [see below] and Actigraph) to the subjects during approximately the final 
week of each interventional phase. We will ask the subjects to put the devices on and will provide informational materials to assist with device placement. We will also discuss device placement 
with the subjects at the study visits as well as over the phone as needed. Subjects will bring the devices to the endpoint assessment visits. Subjects will be fully oriented i n the use of this device. 
The device may be removed for showering or swimming but otherwise should be worn continuously. The specific details in the use of this device will be provided to study subjects. We will use the average METS of activity over this t ime period as an estimate of physical activity. We 
will also records steps taken.  
Ambulatory Pulse Wave Analysis:  Ambulatory pulse wave analysis  will be performed, when 
feasible, with a novel watch research device (Microsoft Aurora device). This device is not 
commercially available or FDA  approved and is investigational. It continuously measures the 
radial pulse via a watch- mounted tonometer. The device also measures transit time from the heart 
to the wrist in an ambulatory fashion. The device will be worn outside of the exercise lab, as well 
as during the exercise studies themselves. The specific details in the use of this device will be 
provided to study subjects.  
Genetic Expression Analysis:  Blood RNA samples will be collected using BD PAXgene blood 
RNA t ubes (BD Biosciences) in order to explore changes in genetic expression in response to the 
study medication (potassium nitrate) and whether patterns of genetic expression predict response 
to the study medication. Two 2.5 mL samples (total of 5 mL of blood)  will be collected at each 6-
week endpoint assessment visit.  
Myocardial Perfusion Reserve:  Subjects who agree to participate in the cardiac MRI sub -study 
will undergo a Stress Cardiac MRI during the last 2 weeks of each cross -over treatment phase. 
Study parameters assessed during this MRI scan will include: assessment of myocardial perfusion, 
assessment of myocardial fibrosis , and myoc ardial strain.  
Myocardial perfusion:  Stress perfusion images will be obtained following IV injection of 
regadenoson. Three t o four short -axis perfusion images will be acquired each heart beat during 
the injection of the gadolinium -based contrast agent at a rate of 3 to 4 mL/s via a power injector 
during first pass of the contrast agent. Forty to sixty image frames will be obtai ned. Following 
reversal of regadenoson with intravenous aminophylline, cine images and delayed enhancement 
images (for focal fibrosis) will be obtained. At the end of the study , perfusion images will be 
obtained at rest using the same imaging protocol. Myocardial  perfusion will be assessed from the 
time-intensity curves of the myocardium and blood pool. Overall  MPR will be obtained as the ratio 
Efficacy of Potassium Nitrate in HFpEF    Page 41 of 79 
V12 – Date 07Oct2021  
 
 of myocardial perfusion after vasodilator administration divided by the myocardial perfusion after 
reversal of the  vasodilator (“rest” images).  
Myocardial fibrosis:  We will use cardiac MRI to assess diffuse myocardial fibrosis by computing 
the extracellular volume fraction from pre - and post -gadolinium normalized myocardial 1/T1 and 
blood 1/T1 changes , after correction for hematocrit. T1 mapping pre - and post - administration of 
a macrocycic gadolinium -based contrast agent  (i.e., Gadobutrol 0.1 mmol/kg or an equivalent 
dose of Dotarem ) will be performed using a modified Look -Locker inversion recovery (MOLLI) 
sequence with image analysis using CMR42 software (Cir cle CVI, Calgary, AB, Canada).  
Myocardial strain : We will assess myocardial longitudinal and circumferential strain using Cine 
Displacement ENcoding with Stimu lated Echoes (DENSE) sequences.  
 
9. MULTICE NTER MANAGEMENT PLAN  
9.1. Study Chair/Grant Principal Investigator  
Dr. Chirinos will serve as the Study Chair and grant Principal Investigator for this protocol. In this 
role, he will administer the grant, and communicate with the NIH about study progress.  He will 
communicate with site PIs regarding the science and any operational issues that arise during the trial, establish subcommittees and working groups to complete specific activities, monitor study 
implementation across sites (Penn, Northwestern,  and Corporal Michael J. Crescenz VAMC), and 
hold regular investigator calls/meetings. As DSMB coordinator, he will convene an independent 
DSMB, communicate with the DSMB , and participate in open DSMB meetings. Dr. Chirinos will 
supervise the investigative team  to develop and coordinate procedures and generate reports and 
presentations. He will maintain communication with the DSMB and will provide central fiscal management and reporting. Other roles of Dr. Chirinos will include directing the echocardiography 
and arterial hemodynamics co re laboratory for this trial.  
9.2. Site Principal Investigator s 
A principal investigator will lead operations at each enrollment site (Penn, Northwestern , and 
Corporal Michael J. Crescenz VAMC) and will be responsible for various aspects of the study, 
including data collection, adherence to all policies and procedures, and maintenance of study protocol to ensure that the specific objectives are being met. In conjunction with the Sponsor , they 
will oversee the safety of study partici pants. They will interact with the Sponsor team, including 
the Medical Director, the data management team, the study chair and the IND sponsor  regulatory 
lead,  as needed.  
9.3. Investigators Committee  
An Investigators Committee will hold a monthly call and discuss aspects of the study, including 
enrollment, retention, data management, quality assurance, and other issues as they arise. Dr. Chirinos will chair the committee, which will include the following members: Julio Chirinos, Payman Zamani, Sanjiv Shah, Sujith Kuruvilla, and Jesse Chittams. Minutes of these meetings 
will be distributed and kept on file. The study chair and the site PIs will have authority to make 
Efficacy of Potassium Nitrate in HFpEF    Page 42 of 79 
V12 – Date 07Oct2021  
 
 decisions that require immediate attention when the committee is unavailable to meet. The study 
chair will adjudicate disagreements within the committee. The sponsor has the final responsibi lity 
for all study decisions.  
9.4. Operational Affairs Committee  
This committee will be responsible for oversight and coordination of the day -to-day activities  of 
the project. Committee members will include the site PIs, the study coordinators at both enrollment sites, the post -doctoral researcher in charge of processing the MRI fat/water imaging, creatine-
CEST and PC -MRI data, the echocardiography/tonometry quantification technician and staff 
members of the biostatistical team. This group, along with all of the members of the Investigators Committee, will hold an in- person meeting at the beginning of the project to review the study 
protocol and the policies and procedures for its implementation. Members of the Operational Affairs Committee will participate in the Investigators Committee, but may hold additional 
meetings/calls throughout the project to review subject recruitment, retention, data transfer, 
quality of data, etc. Minutes of these meetings will be distributed and kept on file.  
9.5. Data Management  
The UPENN site will serve as the data coordinating center (DCC) and will play a fundamental role 
in overseeing randomization, data entry, data coordination, data transfer, and DSMB meetings. Dr. Alexandra Hanlon will be director of the DCC. Within the UPENN School of Nursing, DCC will have access to state- of-the-art computing resources capable of supporting studies ranging in size 
from one to more than 100,000 subjects. The equipment is fully supported by the Office of 
Technology and Information Systems (OTIS), which has complete business continuity and 
disaster recovery via redundant, distributed data centers and backup processes, in addition to 
traditional of fice a nd project management software.  
The data for this trial will be collected in ad hoc source documents by the research staff during 
each study visit, using trial -specific and visit -specific data collection forms. All source documents 
collected in this trial will be housed inside of a locked cabinet in the offices of the research staff, 
located at each study site. Data capture and storage will be accomplished within the framework 
of the Research Electronic Data Capture (REDCap) project. REDCap is a secur e, web -based 
application designed exclusively to support data capture for research studies. It provides an intuitive interface for data entry with data validation, audit trails for tracking data manipulation and export procedures, automated export procedur es for seamless data downloads to common 
statistical packages, including SAS, and procedures for importing data from external sources. As of March 2015, REDCap was in production use or prototype build- status for more than 99,000 
studies spanning numerous r esearch focus areas across a consortium of 940 active institutional 
partners, including the University of Pennsylvania. Once the DCC launches the REDCap 
database into production mode, the study coordinators will be responsible for transmitting the 
particip ant coded electronic data using standardized data collection instruments to the database 
manager who will check the data for accuracy and completeness and follow -up with the research 
assistants as needed. The research coordinators will perform manual data entry from source 
documents and self -administered participant questionnaires (such as quality of life 
questionnaires), and the DCC will perform com prehensive data quality checks.  
Efficacy of Potassium Nitrate in HFpEF    Page 43 of 79 
V12 – Date 07Oct2021  
 
 9.6. Q uantification Core Laboratories  
Various physiologic core laboratory uni ts will be in charge of analyzing ph ysiologic data from the 
trial. 
9.6.1 Echocardiography Core Laboratory : The echocardiography core lab, directed by Dr. 
Chirinos, has extensive experience in analyzing echocardiographic data for multicenter trials. The 
lab functions as the core lab for 2 ongoing international multicenter trials in heart failure (CVRx HOPE4HF a nd CVRx NeoHF) and one US -based multicenter study focused on HFpEF and 
HFrEF (BMS CV002004). The core lab has all the capabilities required for echocardiographic data management and quantification in this study. The core lab has well  established standard 
procedures for receiving and logging imaging data, quantitative analyses, quality control, audit 
trails, and communication with study sites (queries about individual issues, feedback for quality control). The core lab will be responsible for generating and updating manuals for echocardiographic data acquisition, which will standardize procedures across the sites. The core lab will certify individual technicians performing measurements for the study after reviewing of 
sample scans (from normal volunteers) acr oss the 2 sites, and will review and update certification 
as needed. The core lab will have the capacity to veto individual technicians from performing 
studies for the trial, based on data quality. The echocardiographic core lab will hold monthly calls with a representative of the data management core to discuss issues regarding core lab data 
management.  
 
9.6.2 Arterial hemodynamics and exercise physiology core laboratory:  The arterial 
hemodynamics core lab, directed by Dr. Chirinos, has experience in analy zing hemodynamic data 
for various large cohort studies (MESA, Asklepios )83, 93, 95, 97, 142 -145 and currently functions as the 
core lab for physiologic data for several ongoing multicenter studies (ACRIN 4008, BMS CV002004, iCAP study, CREST study). The co re lab has specific experience in assessing specific 
exercise- related phenotypes relevant to inorganic nitrate effects
102 and has adequate capabilities 
required for physiologic data management and quantification in this study. The core lab will have ad hoc  teleconference calls with Dr. David Poole (consultant in this grant). Dr. Poole will provide 
input about specific datasets in which there may be questions about physiologic phenomena. In 
addition to enhancing the interpretation of our human datasets, this  will facilitate scientific 
interactions and will spark new ideas that will facilitate the translation of human observations to animal models and vice- versa. The physiology core lab will hold monthly calls with a 
representative of the data management core to discuss issues regarding core lab data 
management.  
 
9.6.3  MRI core laboratory : The MRI quantification core lab will be directed by Dr. Ravinder 
Reddy and will include a designated post -doctoral researcher (35% effort throughout the grant 
duration) who will be in charge of implementing the scans, performing QC of data as the study 
progresses, and performing standardized quantification of MRI images. Dr. Reddy’s laboratory has extensive experience in MRI quantification, with >100 publications in quantitat ive MRI and 14 
completed studies using CEST imaging in the last 5 years .
75, 126, 128, 146 -155 The MRI core lab will 
hold monthly calls with a representative of the data management core to discuss issues regarding core lab data management.  
 
Efficacy of Potassium Nitrate in HFpEF    Page 44 of 79 
V12 – Date 07Oct2021  
 
 9.6.4 Imaging data management : All imaging electronic data will be stored within a secure 
HIPAA- compliant network -attached storage server, and is accessible only to those who are 
specifically given access by the core lab director. The secure server has mechanisms for 
redundant storage and data backup at different physical locations, to prevent data loss from 
disasters (such  as a fire).  
 
9.6.5 Data Safety Monitoring Board : The DSMB will provide independent oversight of the 
project. The DSMB will be responsible for assessing: 1) baseline comparability between groups; 
2) participant accrual rate and retention; 3) resource availability; 4) data quality with special emphasis on eligibility data; and 5) patient safety. The board will make recommendations regarding: study continua tion, protocol modification, and review of additional data. The conference 
call meetings and progress r eports will be set by the DSMB.  
9.6.6 Cardiac MRI core laboratory:  Cardiac MRI quantification will be supervised by Dr. Kuruvilla, 
with support from Dr. Chirinos. Dr. Kuruvilla will have access to software available in Dr. Chirinos’ core laboratory, including CMR 42 software and Matlab software.  
9.7 Conflict of Interest Management  
Dr. Chirinos is named as inventor on a patent application which has been assigned to the 
University of Pennsylvania. This constitutes Clinical trial intellectual property (as defined under University of Pennsylvania policy) relevant to this trial. Therefor e, the Offices of Research 
Services and Vice Provost for Research have formulated a management plan for Dr. Chirinos’ participation in the trial as Study Chair and Grant PI. Notification of this t management plan will be 
distributed to DSMB members, site PI s and Sub- Investigators and the operations of the trial will 
adhere to this plan.  
 
10. STATISTICAL CONSIDERATIONS  
10.1. Power calculations 
We will randomize 84 subjects to one of 2 sequences (i), each of which consists of 2 periods 
(AB/BA design). We now have pilot data regarding the distribution of the changes in peak VO
2 
(the primary endpoint of the study) as well as various secondary endpoints, among patients with 
HFpEF. We considered an increase in peak VO 2 of ~0.6 ml/kg/min to be the minimum clinicall y 
significant change. This was based on the fact that even “modest” changes of comparable 
magnitude in peak VO 2 have been associated with improved outcomes.156 The standard deviation 
of the change in peak VO 2 in our pilot trial was 1.23 ml/kg/min. Therefor e, the standardized effect 
size is 0.49 or greater. Assuming a 90% retention rate, enrolling 84 subjects in this cross -over trial 
will have 80% power to detect such an effect size in the intervention induced change of our study 
endpoints, with a two- sided α=0.05. Based on the distribution of the changes in study endpoints 
in our pilot trial or from repeated measurements of the Kansas City Cardiomyopathy Questionnaire in HFpEF patients, we estimated that this trial study is powered (80%) to detect the follow ing 
changes in other endpoints: 4.6 points for the Kansas City Cardiomyopathy Questionnaire, 8.2% for exercise vasodilatory reserve, 19% for cardiac output reserve, 5 seconds for PCr/Cr recovery kinetics , and 4.2% change in reflection magnitude. We note that these differences are well below 
what is considered a clinically significant change in KCCQ (10 points or more, http://cvoutcomes.org/pages/3217) or the effect size that has been observed for these endpoints 
Efficacy of Potassium Nitrate in HFpEF    Page 45 of 79 
V12 – Date 07Oct2021  
 
 in our pilot  trial.111 Therefore, we are con fident that we will achieve adequate power not only for 
our clinical endpoints, but also for our physiologic measures. PASS11157 was used to perform 
power analyses . 
10.2. Data Analysis Plan 
The co -primary outcome variables will be peak VO 2 and work perform ed during a symptom -limited 
maximal effort exercise test. All secondary outcome measures are continuous variables. The 
predictor of interest for all aims will be intervention (KNO 3 therapy vs. placebo), with analyses 
based upon the total number of subjects  randomized. Initial descriptive estimates of all measures 
will be generated for study participants at each time point by treatment group. Statistics will include 
estimates of central tendency, measures of variability, and derived moments of skewness and kurtosis. Analyses of distributional properties will be performed to determine if variance stabilizing 
or normalizing transformations should be applied. Outliers will be assessed via visual inspection of distributions and checked for accuracy. Aim 1 will as sess the effects of potassium nitrate 
therapy on peak O
2 / work performed (co -primary outcomes) and quality of life score (secondary 
outcome). An initial assessment of the treatment effect will be performed using the paired t -test 
and the non -parametric Wi lcoxon sign- rank test on the difference between the paired within 
subject outcome measures. This will be followed by a more comprehensive linear mixed- effects 
model  analysis158 allowing for assessments of the treatment effect on each continuous outcome 
of interest while controlling for effects of other covariates such as period, sequence, and a random 
subject effect nested within sequence. For non -normal distributed outcomes, we will utilize non-
parametric methods or consider distribution- stabilizing transf ormations. The intervention groups 
will initially be compared within each period (time invariant covariates will only be compared for period 1) according to continuous covariates described above using parametric or non- parametric 
one-way ANOVA models, depending upon whether or not normality appears to be in question. 
Levine’s tests will be used to assess homogeneity of variance. Additionally, the intervention groups will be compared within period according to categorical covariates using Fisher’s Exact 
tests. Significant differences between groups on these variables will result in their use as control 
variables in the modeling of outcome. Separate models will be generated for each of the two 
outcome measures, with each outcome measure regressed on interventi on group assignment, 
along with baseline outcome and any other covariates deemed prognostic in preliminary analyses. The linear mixed- effects models will incorporate adjustments for any period effect and include 
data from dropouts .
159-161 The model will include subject -specific intercepts as random effects, and 
assumes independent and identically distributed random errors within subject. Restricted maximum likelihood estimation will be used, and an appropriate covariance matrix will be 
spec ified. Model assumptions will be examined (eg,QQ plots to assess  normally distributed 
residuals for valid Wald tests). All mixed- effects models will be analyzed using the SAS PROC 
MIXED procedure
162 in SAS version 9.3 (SAS Institute, Inc., Cary, NC). We w ill make every 
possible effort to minimize missing data and ensure final assessments for participants opting to 
discontinue study participation. Missing data, however, is an inevitable problem in a longitudinal study. The mechanism for missingness -missing completely at random (MCAR), missing at 
random (MAR), nonignorable or not missing at random (NMAR) -will be evaluated prior to 
implementing methodology intended to minimize bias from missing data .
163 We anticipate that 
~10% of randomized subject s will not c omplete the study.  
Efficacy of Potassium Nitrate in HFpEF    Page 46 of 79 
V12 – Date 07Oct2021  
 
 The intent -to-treat principle of including all randomized participants in the outcome models will be 
followed. SAS software procedures will be used for creating and analyzing multiple imputed data 
sets for incomplete multivariate data. I nstead of filling in a single value for each missing value, 
Rubin's164 multiple imputation procedure replaces each missing value with a set of plausible 
values that represent the uncertainty about the correct value to impute. These multiple imputed data sets are then analyzed using standard procedures for complete data and combining the results from this analysis. Assuming monotone missing data patterns emerge, either a parametric 
regression method that assumes multivariate normality or a nonparametric method that uses 
propensity scores will be implemented, depending upon distributional patterns.  
Analytic methods described above will take advantage of all available data. The possibility of 
systematic bias in the outcomes for those who withdraw exists. Baseli ne characteristics will be 
compared among subjects with and without complete follow -up, recognizing that statistical power 
associated with finding true statistical differences may be limited. To assess potential biases, a comparison of withdrawal rates and  or/time to withdrawal will be included. If the number of 
subjects lost to follow -up is small and the missing observations can be documented as being MAR 
or MCAR, then the primary hypotheses will be tested using the complete observed data. If missing obser vations cannot be assumed to be MAR or MCAR, more complex approaches will be 
considered. Sensitivity analyses for these models will be performed should they be implemented.
165 
Our secondary aims involve exploratory analyses investigating mechanisms of acti on. In addition 
to assessing the effect of our randomized intervention on each mechanistic endpoint, exploratory structural equation modeling will be used to evaluate associations between outcomes and biologic 
mechanistic pathways. The modeling will be car ried out in three sequential steps: (1) exploratory 
factor analysis, (2) confirmatory factor analysis, and (3) structural equation modeling. The 
exploratory factor analysis will be based on principal axis factoring to decrease the number of variables. For both theoretical and empirical reasons, it will be assumed that retained factors are 
correlated and thus an oblique rotation method will be used. Measured and latent variables will 
be examined for co- linearity, and related variables will be combined into s ingle factors with 
individual factor loadings. To determine the number of factors, the model will be evaluated against 
the following four rules: (1) eigenvalues greater than 1.0
166; (2) Glorfeld’s167 extension of parallel 
analysis, where a large number of random correlation matrices are generated  to compare the number of eigenvalues that are significant by chance
168; (3) high internal consistency (an alpha 
coefficient of >  .70) for unit -weighted factors,169 and (4) interpretability.170 The heaviest weight will 
be placed on the Minimum Average Partial and parallel analysis methods, with the scree test as a visual adjunct.
171 The next step involves incorporating the factors into a model using 
confirmatory factor analysis. The model will be tested using goodness of fit tests to assess the overall fit of the model to the data.  Various models will be tested and compared prior to arriving at the best fitting model. And finally, the best fitting model obtained from confirmatory factor 
analysis will incorporate a s tructural equation model designed to examine the links between the 
randomized intervention, the mechanistic variables and the clinical variables assessed in the trial.  
10.3. Subgroup analyses and considerations about sex  
Although women represent 60% of pat ients with HFpEF, our sample will include 50% women and 
50% men. This is due to the fact that we explicitly wish to perform sex -stratified analyses, in 
Efficacy of Potassium Nitrate in HFpEF    Page 47 of 79 
V12 – Date 07Oct2021  
 
 addition to testing for a potential modifying effect of sex on the effects of KNO 3. Having an equal 
balance in terms of the number of males and females maximizes the statistical power to test for 
significant interaction effects between sex and other variables of interest. Furthermore, the slight 
increase in the proportion of males sampled will help to maximi ze the statistical power for sub -
analyses including only males. Balancing the sample on sex will also reduce the chances of 
having confounding between the race effect and other variables in the model. Lastly, since the over sampling of males is only slight ly above the estimated actual population of 40%, the results 
of the analysis of the sample data should still be generalizable to the overall HFpEF population.  
Additional pre- specified subgroup analyses will include diabetes vs. no diabetes, hemoglobin 
value above and below median, and use vs. non -use of calcium channel blockers.  
10.4 Cardiac MRI sub- study analysis and power calculations  
The aim of this ancillary study is to assess the paired difference in myocardial blood flow and 
perfusion reserve in response to KNO
3 or the control intervention (KCl) in a cross -over design. 
We will therefore utilize paired -t tests to estimate the difference. The non- parametric Wilcoxon 
sign-rank test will be considered, as appropriate. For exploration of the relationship between MPR 
and myocardial fibrosis or myocardial function, we will compute Pearson’s correlation coefficients for linear associations, or the Spearman’s Rank Correlation coefficient for monotonic non- linear 
associations. A p- value less than 0.05 w ill be con sidered significant.  
Power calculations: The standard deviation of the change in MPR in repeated measures in prior 
studies is 0.5. Assuming a dropout rate of 10% (effective n=18), the ancillary study will have 85% 
power to detect a standardized effect size of 0.75 or greater. Therefore, our study will be powered 
to detect an improvement of 0.375 in MPR with KNO
3 vs. KCl.  
 
11. PROTECTION OF HUMAN SUBJECTS  
11.1. Potential benefits of the proposed research, im portance of the knowledge to be gained, and 
risk/benefit ratio  
Potential benefits : There are no anticipated direct benefits to the subjects as a result of their 
participation in this study nor will this be implied when obtaining consent. However, if our 
hypothesis is correct, subjects in the active medication groups may experience improvements in 
their functional class and quality of life, although this will not be implied in any way during informed 
consent or enrollment.  
Importance of the knowledge to be gained:  If our hypothesis is correct, this st udy may identify an 
effective specific intervention to treat peripheral mechanistic abnormalities in HFpEF patients. 
Furthermore, if improving these peripheral abnormalities leads to an enhanced exercise capacity in this patient population, this would lead to a new paradigm in the field and a better understanding 
of the mechanisms that lead or contribute to HFpEF, which will accelerate the discovery of new 
treatments for this condition. In addition, if potassium nitrate proves effective in enhancing 
exercis e capacity and/or quality of life in this trial, this would identify a readily implementable, 
inexpens ive therapy for this condition.  
Efficacy of Potassium Nitrate in HFpEF    Page 48 of 79 
V12 – Date 07Oct2021  
 
 Risk/benefit ratio : the results of this study may ultimately lead to an effective treatment for HFpEF, 
which is urgently needed to help millions of patients. Since there is minimal risk and potential 
benefits to medical knowledge and society, the risk / benefit ratio is acceptable.  
11.2. Risks to study subjects 
The conduct of these studies will involve 84 human subjects, each  exposed to both the active 
drug (potassium nitrate) and control (potassium chloride) intervention (cross -over design), and 
therefore studied as their own controls. All subjects will be adults able to give informed consent.  
Subjects will be enrolled with explicit assurance for adequate representation of women and African 
Americans. Assuring representation of women is key for the scientific aspects of this disease (high 
incidence in women). Assuring adequate representation of African- Americans is key for thi s 
intervention with a nitric oxide donor (since African Americans with HF and reduced EF have 
demonstrated differential responses to NO donors compared to Caucasians).172-175 Children will 
not be enrolled. Participants will be recruited from the Hospital o f the University of Pennsylvania, 
Northwestern University Medical Center, and the Corporal Michael J. Crescenz VAMC. Assuring 
this gender and ethnic distribution will not be a problem given the clinical populations in the enrolling medical centers.  
The study involves various tests (arterial tonometry, Doppler echocardiography, a 
cardiopulmonary exercise stress, a lower extremity MRI without gadolinium administration with a standardized plantar flexor exercise protocol, blood draws) and the administration of  randomized 
therapy (potassium nitrate vs. placebo). The ancillary study involes a cardiac MRI with gadolinium and regadenoson administration.  
11.2.1 Potential Risks of study intervention (potassium nitrate) :  
The main potential risks of nitrate administra tion are related to its potential effect on (1) blood 
pressure;  and (2) methemoglobin levels.  
Effects on blood pressure:  Regarding the blood pressure reduction, as described above, many 
studies have demonstrated a reduction in blood pressure in both hypert ensive and normal 
subjects following nitrate supplementation. This was summarized in a recent meta- analysis, 
demonstrating an approximate 4 mm Hg reduction in systolic blood pressure and 1 mm Hg 
reduction in diastolic blood pressure.51 Importantly, in our study of a single dose of inorganic 
nitrate in this specific population (HFpEF), we did not observe any change in blood pressure 
following nitrate ingestion. This suggests that subjects with HFpEF may have a different response 
to nitrate than other populat ions and thus hypotension may be a less pronounced side effect. 
Importantly, the lack of a blood pressure response to nitrate has been shown in both elderly 176 
and diabetic individuals,177 further suggesting that there may be important differences in nitrate 
effect by subgroups. In our pharmacokinetics study, we found a mild (~12 mm Hg) asymptomatic 
reduction in blood pressure recorded at the time of our study visits during 2- week drug 
admi nistration, which occurred in the absence of any hypotensive symptoms.178 We did not find a 
reduction in ambulatory blood pressure. Therefore, although we don’t anticipate major changes in BP or significant hypotension with this dose, we will implement exc lusion criteria and safety 
Efficacy of Potassium Nitrate in HFpEF    Page 49 of 79 
V12 – Date 07Oct2021  
 
 blood pressure checks throughout the conduct of the study to ensure subject safety (see next 
section).  
Impact of NO 3- on methemoglobin levels:  Nitrate supplementation increases serum nitrite levels 
through the actions of an enter osalivary circuit and reduction of nitrate to nitrite by anaerobic 
bacteria in the oral cavity.  28, 33 -36 Methemoglobin is generated by the reaction of nitrite with 
hemoglobin. According to Toxnet, doses between 2- 9 grams of NO 3- have been associated with 
methemoglobinemia. The dose we will use in our study (18 mmol KNO 3-) will provide only 1.11 
grams (18 mmol NO 3- x 62 grams/mol NO 3- x 1mol/1000 mmol), which is well below this threshold. 
Moreover, this level of nitrate supplementation provides less inorganic nitrate than that found in a traditional Japanese diet, which is rich in vegetables (traditional Japanese diet provides 18.8 mg/kg of nitrate per day x 70 kg individual = 1.3 grams of nitrate).
179 Moreover, not a single cases 
of methemoglobinemia was observed in our pharmacokinetics trial , at the same doses used in this trial and in the same patient population. In the pharmacokinetics study we measured 
methemoglobin every half hour after the first administration as well as during steady -state 
continued oral administration at doses of both 12 mmol/d and 18 mmol/d (same dosing scheme 
used in the KNO
3CK OUT HFpEF p trial) and did not find any clinically -significant elevations in 
methemoglobin. We don’t anticipate any significant issues with methemoglobinemia in the 
KNO 3CK OUT HFpEFp study since this is a problem that has been reported with nitrite, but not 
with nitrate at  the doses used in this study.  
Pilot safety data:  In our double- blind randomized controlled trial in HFPEF, in which 12.9 mmol 
of inorganic nitrate were administered to patients with HFpEF, efficacy was demonstrated for the 
study endpoint (please refer to research plan). In this pilot study, no side effects were noted in 
any subject , except for pink urine (which was not different between the nitrate -rich and nitrate -
poor beetroot juice, because this is a consequence of other components of beetroot juice). As the 
body is able to reduce oxidized Fe3+ in methemoglobin back to Fe2+ at a rate of approximately 
15% per hour,180 the gradual increase in  nitrite that occurs after nitrate administration (and the 
consequent formation of methemoglobin), should occur slowly enough to prevent significant rises 
in methemoglobin. To the best of our knowledge, methemoglobinemia has not been reported with oral nit rate administration. In our pharmacokinetic study, we did not observe any clinically -relevant 
elevations in methemoglobin levels .
178 
Other potential safety considerations:  There has been concern regarding whether a high 
nitrate diet may predispose to gastr ic cancer in humans through conversion to nitrite in the 
stomach or through increased urinary excretion of nitrate metabolites. This is a controversial issue derived from animal studies
181, although the relationship between nitrate intake and cancer has 
not been demonstrated in humans.31, 106, 182 In fact, many studies show either no relationship or 
even an inverse relationship between a high intake of nitrate and the occurrence of gastric cancer.
183, 184185, 186 The Joint FAO/WHO Expert Committee on Food r eviewed all the available 
evidence, but failed to establish a definite link between nitrate intake and risk of developing cancer.
189, 190 Furthermore, The World Cancer Research Fund/American Institute of Cancer 
Research found no evidence linking ingestion of vegetables which are known to be high in nitrate with the development of cancer .
191 We note that the highly controversial concern regarding cancer 
risk associated with nitrate intake is related to long- term intake and not a significant issue with our 
6-week administrati on scheme of potassium nitrate.  
Efficacy of Potassium Nitrate in HFpEF    Page 50 of 79 
V12 – Date 07Oct2021  
 
 11.2.2. Potential Risks of study procedures:   
Potential risks are associated with the study tests, the study interventions (potassium nitrate) and 
potential breaches in confidentiality.  
Lower extremity MRI:  The non- invasive nature and the lack of ionizing radiation make the risks 
associated with MRI small. A MRI scan requires the participant to be in a partially enclosed space 
inside the scanner. Some people may find this to be uncomfortable. Claustrophobia i s an 
exclusion criterion for the study. The MRI scanner produces different types of noises during a scan. Participants are given special earplugs to reduce the noise. A MRI scanner has a strong 
magnet which attracts certain metals. If anyone has these types of metal in their body, the MRI’s 
strong magnetic field can cause them to move which may cause injury. Subjects with be thoroughly screened for the presence of body metal and excluded from the study if they are unable to safely undergo the MRI study. If body metal/device may be present, we may investigate the 
issue further by obtaining X -rays or prior radiographic reports. We may also discuss the case with 
our radiologists and MRI technicians. An MRI will only be performed if deemed sa fe by an 
attending r adiologist.  
The greatest risk of MRI scanning is a metallic object flying through the air toward the magnet and 
hitting the subject. To reduce this risk we require that all people involved with the study remove all metal from their clothing and all metal objects from their pockets. No metal objects are allowed 
to be brought into the magnet room anytime. In addition, once the subject is in the magnet, the door to the room will be closed so that no one inadvertently walks into the magnet. Some of the imaging sequences and/or RF coils are not FDA approved but are considered nonsignifican t risk 
investigational devices.  
Risks of 7.0T MRI : To date no persistent adverse effects have been reported by facilities with 
magnetic field strengths at 7.0T. However, there has been an increase in the number of people reporting transient dizziness or nausea upon being moved into the field. This dizziness lasts less than 10 minutes and can be reduced by reducing the speed at which the subject is placed into the magnet. Risks ar e not cumulative and effects are transient. In addition, there has also been an 
increase in the number of subjects reporting a metallic taste in their mouth over that of 1.5 and 3.0T systems. The FDA has approved the use of 7.0T magnets for research imagin g in humans. 
All subjects will be informed of the possibility of having these sensations during the informed consent process.  
If an X -ray is deemed to be necessary to investigate any potential metal in the body, the subject 
will be exposed to minor doses o f radiation:   
Efficacy of Potassium Nitrate in HFpEF    Page 51 of 79 
V12 – Date 07Oct2021  
 
  
(data from http://www.radiologyinfo.org/en/info.cfm?pg=safety -xray, accessed 10/5/2016; this website is maintained by the 
Radiologi cal Society of North America)  
Plain film X -rays expose subjects to very low doses of radiation.  From this table, it can be seen 
that a bone X -ray of an extremity would expose subjects 0.001 mSv, which is less radiation than 
an intraoral X -ray performed at the dentist’s office (0.005 mSv) and less radiation than a chest X -
ray (0.1 mSv).  
Cardiopulmonary stress test : This test is used extensively for research purposes with minimal 
risk to subjects. The most significant risks of the test are dysrhythmias or other cardiovascular 
complications, which are extremely rare. These procedures will be performed by qualified personnel according to established American Heart Association Guidelines.
192, 193 
Nonrevascularized myocardial ischemia, which may increase the risk of complications during exercise testing, is an exclusion criterion for the study. We note that prior studies  in HFpEF also 
enrolled subjects with atrial fibrillation
194 and that rate- controlled atrial fibrillation is not a 
contrai ndication to exercise testing.  

Efficacy of Potassium Nitrate in HFpEF    Page 52 of 79 
V12 – Date 07Oct2021  
 
 Subjects may feel uncomfortable as a result of pushing themselves during the maximal effort 
exercise test. Subjects will likely feel short of breath and fatigued as a result of the exercise test. 
Various other complaints, such as nausea, lightheadedness, and other aches and pains are also possible as a result of the maximal effort exercise study. Although exercise testing may result in 
exhaustion, rarely do people develop abnormal HR or heart complications during exercise tests. 
The risk of this happening is the same as if the participant would exert themselves during stressful situations or during exercise elsewhere.  
We will perform EKG, HR, and blood pressures monitoring during our exercise test. In addition to 
the blood pressure (generally increases) and heart rate (generally increases) changes during exercise, we will also monitor arterial saturation. Thi s will be done non -invasively using a pulse 
oximeter. Of note, oxygen levels can decrease with exercise, even in individuals without significant cardiopulmonary disease.
195, 196 If the arterial saturation falls to below 88% (“severe exercise 
induced hypoxemia”196), we will alert the care provider as this may prompt consideration for 
additional/alternative causes for arterial hypoxemia.  
Venipuncture and IV placement : According to the 2010 WHO guidelines on phlebotomy, major 
risks associated with blood donations include hematoma at the site of venipuncture in 23%, and vasovagal reactions and fainting in 1%. The placement of an intravenous catheter would be anticipated to increase the risk of hematoma and discomfort slightly. Given that the catheter will 
be in place for a short -period of time, infection is an unlikely complication. Of note, the amount of 
blood to be drawn in the study is less than the amount of blood drawn at routine blood donation 
where the risk  of syncope of 1% was defined.  
Arterial tonometry and assessments of oscillometric arterial pressure waveforms are noninvasive 
procedures and do not have any known risks.  
During various procedures (echocardiography, arterial tonometry), we will use adhesive 
electrodes attached to the participant’s skin to record the electrical signal from the heart. These 
may occasionally cause skin itching and irritation.  
Ambulatory pulse wave analysis (Aurora device) may cause mild discomfort in the wrist.  
Pregnancy Risks:  We will not be enrolling subjects who are pregnant in this study. Right now, 
there is not enough research on the potassium nitrate to determine the safety of the mother or unborn child. A pregnancy test will be given to women  of child -bearing potential prior to enrollment 
in the study and administration of the supplement. The pregnancy test will be repeated at the 6-
week visit (prior to initiation of the second treatment period). If a woman is enrolled of child- bearing 
potenti al, we will ask that they use a medically accepted method of birth control (such as an IUD, 
birth control combination pill, patch, ring, progestin- only pills, Depo Provera Shot, Implanon, 
complete abstinence, or condoms) while they participate in the study . In addition, we will test for 
pregnancy at each study visit and discontinue subjects from the study immediately if she becomes pregnant. As subjects with HFpEF are generally older (>55 years old) we do not anticipate this concern to occur with our study population. We will not enroll pregnant women or women who are lactating.  
11.2.3. Potential Risks of Cardiac MRI sub- study procedures:  
Efficacy of Potassium Nitrate in HFpEF    Page 53 of 79 
V12 – Date 07Oct2021  
 
 Subjects who have agreed to participate in the cardiac cardiac  MRI sub -study will undergo a 
cardiac MRI with IV gadolinium and IV regadenoson administration.  The risks entailed with 
performing a MRI scan are described under lower extr emity MRI in the risk section.  
Gadolinium -based contrast agent administration:  Durin g the MRI examination, subjects will 
be administered a gadolinium -based contrast agent (GBCA), which allows for the quantification 
of diffuse interstitial fibrosis and the visualization of focal scars. Gadolinium -based contrast agents 
have been linked to i ncreased risk of nephrogenic systemic fibrosis (NSF), a disease that causes 
fibrosis of the skin and connective tissues throughout the body and that can cause death. There 
is no known treatment for NSF. While there seems no increased risk for NSF in subjec ts with 
normal renal function or only moderate renal insufficiency, risk for NSF seems to increase in 
subjects with severe renal insufficiency (glomerular filtration rate (GFR) <30 mL/min/1.73m2). In 
a retrospective study with Omniscan (one of the five FDA  approved GBCAs), 4% of subjects with 
severe renal insufficiency were estimated to be at risk for NSF.197 Allergic reactions, which may 
include rash, sweating, itching, hives, facial swelling, and anaphylactic shock, may occur with GBCAs independent of renal function. No increased risk of gadolinium administration is 
anticipated among patients taking the study drug.  There is recent data showing that traces of 
gadolinium may remain in the body long -term after contrast administration. However reviews by 
the F DA have not identified adverse health effects from gadolinium retained in the brain or bodily  
tissues after MRI. Further more,  the gadolinium agent that is used in this study belongs to a group 
of macrocyclic gadolinium based agents that are thought to mini mize or eliminate this risk.  
Regadenoson:  Regadenoson will be administered intravenously as part of the stress portion of 
the exam in order to induce coronary vasodilatation. Regadenoson is used as part of both cardiac MRI and cardiac nuclear stress testin g protocols on a daily basis for clinical assessment of 
ischemia. Common side effects of regadenoson include headache, dizziness, nausea, abdominal discomfort, chest discomfort, fl ushing and shortness of breath.  
Venipuncture and IV placement : As described above.  
Potential risk of investigational dev ices:  The Aurora device (pulse wave analysis watch) can 
produce skin irritation at the tonometer site. This usually goes away within few hours of discontinuing use. The version of the device that we will use for exercise studies uses adhesive 
electrodes attached to the participant’s skin to record the electrical signal from the heart. These may occasionally cause skin itching and irritation.  
The Portomon and Portali te (near infrared spectroscopy, or NIRS ) devices have no known risks. 
They are non- invasive devices applied on top ofto the skin to measure the oxy genation of 
underlying tissue.  
As with any clinical research study, there is a potential for breach of confidentiality. Adequate 
measures will be taken to minimize this risk (below).  
11.3. Adequacy of Protection Against Risks  
11.3.1. Recruitment and Informed Consent :  
Efficacy of Potassium Nitrate in HFpEF    Page 54 of 79 
V12 – Date 07Oct2021  
 
 Written informed consent will be obtained from the subjects by the investigators prior to entry into 
the research study. This will be performed in accordance with the guidelines and under the 
supervision of the University of Pennsylvania, Corporal Michael J. Crescenz VAMC, and the 
Northwestern University Institutional Review Boards. The study procedures and interventions and 
the assoc iated risks will be explained to the subjects during the informed consent process. Only 
IRB-approved consent forms and related materials will be used.  
11.3.2. Protection against risks associated with the MRI study :  
Subjects will be thoroughly screened for  the presence of body metal and excluded from the study 
if they are unable to safely undergo an MRI study. We will exclude patients who are not suitable 
candidates for an MRI study by virtue of having the following absolute or relative contraindications: 
(i) Central nervous system aneurysm clips; (ii) Implanted neural stimulators; (iii) Implanted cardiac 
pacemaker or defibrillator; (iv) Cochlear implant; (v) Ocular foreign body (e.g. metal shavings); 
(vi) Other implanted medical devices: (e.g. drug infusion ports); (vii) Insulin pump; (viii) Metal 
shrapnel or bullet; (ix) Claustrophobia; (x) Extreme obesity rendering the patient unable to fit into narrow -bore scanners; (xi) Unwillingness of the patient to undergo an MRI. All patients with 
metallic implants w ill be individually evaluated prior to MRI. Women with child -bearing potential 
will have a serum pregnancy test to exclude pregnancy before each MRI scan. Pregnant women  
will be excluded from the study . Screening for MRI -related exclusion criteria will  done  during a 
phone interview (pre-screen) and  with an on-site questionnaire  at the time of the scan.  
Once subjects are deemed able to safely undergo an MRI study, these will be performed 
according to standard safety practices as per our institutional standards. Voice contact with 
patients will be maintained throughout the scan.  
All people involved with the study remove all metal from their clothing and all metal objects from 
their pockets. No metal objects are allowed to be brought into the magnet room  anytime. In 
addition, once the subject is in the magnet, the door to the room will be closed so that no one 
inadvertently walks into the magnet.  
11.3.3 Protection against risks associated with cardiopulmonary exercise tests :  
These tests will be performed  by qualified personnel according to established American Heart 
Association Guidelines192, under ECG monitoring. Personnel with adequate cardiopulmonary 
resuscitation training and resuscitation equipment (crash cart) will be available during these tests. Similarly, these tests will be performed in a hospital setting where a full code team can be 
deployed immediat ely should complications occur.  
11.3.4 Protection against risks of potassium nitrate administration:  
Subjects will be thoroughly advised regarding the potential risks of the study medication and 
precautions needed during its administration. We will exclude individuals who are taking sildenafil (Viagra®), tadalafil (Cialis®), or vardenafil (Levitra®) and we will instruct them not to take these medicat ions while participating in the study, since it is likely that these medications may 
exaggerate the vasoactive effects of potassium nitrate. Similarly, the use of organic nitrate will be contraindicated duri ng participation in this trial.  
Efficacy of Potassium Nitrate in HFpEF    Page 55 of 79 
V12 – Date 07Oct2021  
 
 Supine and orthostatic blood pressure measurements:  Supine vital signs will be measured at 
the screening visit. The subject will rest in a supine position for a minimum of 3 minutes prior to 
obtaining vital sign measurements. Subjects with a supine systolic blood pressure >110 will be enrolled in the study. The subject will then assume a standing position for 3- 5 minutes. Vital signs 
(BP and pulse rate) will then be measured while the subject is standing. A reduction in systolic blood pressure >20 mmHg will be considered an  exclusion criterion for the study. Blood pressure 
measurements will be repeated after approximately 6 weeks of randomized therapy. 
Measurements will also be prompted by reports of any report of orthostatic symptom by study subjects at any point during the  trial. The presence of symptomatic orthostatic hypotension (20 
mmHg reduction in systolic blood pressure with associated symptom such as dizziness) will prompt exclus ion of patients from the trial.  
Safety Clinical Laboratory Tests:  Laboratory evaluations will be collected prior to study drug 
initiation. Among women who are not surgically sterilized or post -menopausal, a urine pregnancy 
test will be performed at screening (prior to all baseline studies and drug initiation), at the end of the first treatment  phase (prior to the MRI study and initiation of the second treatment phase) and 
immediately before the MRI study performed at the end of the second treatment phase. Methemoglobin levels will be measured before initiation of randomized therapy and approxim ately 
6 weeks after initiation of randomized therapy in both treatment phases (1 and 2). 
Methemoglobinemia (methemoglobin levels >10%) will prompt discontinuation of patients from 
the trial. Other tests, including a complete blood count, liver enzymes, a basic metabolic panel (including serum creatinine for assessments of renal function) will also be performed prior to randomization and approximately 6 weeks after init iation of randomized therapy.  
Significant methemoglobinemia was not observed in our pharmacokinetics trial, at the same doses 
used in this trial, in the same patient population. In this study we measured methemoglobin every 
half hour after the first administration as well as during steady -state continued oral administration 
at doses of both 12 mmol/d and 18 mmol/d (same dosing scheme used in the KNO
3CK OUT 
HFpEFp  trial).  
Side Effect Management  Plan:  No side effects have been observed in our single- dose study or 
our ongoing pharmacokinetics study (in particular, no hypotension or methemoglobinemia). 
However, a plan for management of side effects will be in place. The use of acetaminophen may be used for headaches during the study. Although hypotension is not expected, it should be 
managed as per standard clinical practice. In the unlikely event that methemoglobinemia does 
occur during the trial, we will manage according to best clinical standards.
198 As the endogenous 
rate of reconversion from methemoglobin to hemoglobin is approximately 15% per hour, most asymptomatic patients can be managed conservatively. Generally, methemoglobin levels >20% with symptoms, or > 30% without symptoms, warrant therapy; any patient with levels that are elevated to this range will be referred to the emergency room for management .
198 
11.3.5 Measures to minimize the risk of breach in confidentiality:   
All records will be treated with strict confidentiality according to HIPAA guidelines (all study 
personnel are trained on HIPAA regulations). Blood samples obtained from subjects will be used only for resear ch purposes. Records will be treated with strict confidentiality and stored in a 
secured, limited access area. A randomly assigned number rather than name will identify all 
Efficacy of Potassium Nitrate in HFpEF    Page 56 of 79 
V12 – Date 07Oct2021  
 
 collected samples. A secure database of patient information will be maintained. The investigators 
and the sponsor will have access to research information and will follow IRB and institutional 
HIPAA guidelines. Paper files will be saved under lock in a secure IRB -approved area.  
11.3.6 Other measures to minimize risk:   
Phlebotomy, arterial tonometry, NIRS, MRI studies , and Doppler echocardiographic examinations 
will only be performed by appropriately trained personnel as per our institutional standards. Subjects will receive instructions in Aurora device use, including written instructions  (Appendix  3), 
including instructions to loosen the wrist strap if there is discomfort and discontinue i ts use if 
discomfort persists.  
11.3.7  Protection against risks associated with the MRI study:  
See above (Section 11.3.2). It is worth noting that the risk of a cardiac MRI at 1.5T is in general, 
lower than at 3 T or 7T, given the lower magnetic field. Subjects that qualify for a 3 T or 7T scanner 
(for the leg MRI study) also qualify for scanning in a  1.5T scanner (for cardiac MRI during the 
myocardial perfusion ancillary study). However, the opposite is not necessarily true. Some situations (such as many intraluminal stents and prosthetic valves) which exclude scanning at high field (7T or 3T) are considered safe for 1. 5T scanning. If subjects are deemed to be ineligible 
for 7T or 3T scanning in the parent trial, they may still be enrolled in the ancillary myocardial 
perfusion study and undergo a cardiac MRI study (at 1. 5T). In all cases, participation in the 
myocardial perfusion / cardiac MRI ancillary study will be approved by Dr. Kuruvilla, who has 
appropriate clinical expertise to assess the safety of this test, according to current clinical standards. Dr. Kuruvilla is the Director of Advanced Cardi ac Imaging at the CMC VA Medical 
Center and Assistant Professor at the University of Pennsylvania.  
 
Protection against risks associated with IV gadolinium administration:  The presence of  
eGFR >30 mL/min/1.73m2 is an exclusion criterion from the parent trial. In addition, GFR will be 
assessed within 3 weeks prior to the cardiac MRI. A GBCA will be only administered for the MRI examination if eGFR > 40 mL/min/1.73m
2. Subjects with a prior history of allergic reactions to 
GBCAs will b e excluded from participati on. There is recent data showing that traces of gadolinium 
may remain in the body long- term after contrast administration. However reviews by the FDA have 
not identified adverse health effects from gadolinium retained in the brain or bodily tissues after MRI. Further the gadolinium agent that is used in this study belongs to a group of macrocyclic 
gadolinium based agents that are thought to minimize or eliminate this risk.  
Protection against risks associated with IV regadenoson administration:  Regadenoson 
should be avoided in patients with unstable angina, severe COPD/asthma and patients with advanced cardiac heart block. Subjects with 2
nd degree AV block, 3rd degree AV block or 
highgrade AV block will be excluded from participation in the ancillary study. U nstable coronary 
syndromes or significant lung disease are exclusion criteria for the parent trial. In all cases, screening will be performed as per clinical guidelines prior to all patients receiving regadenoson. Cardiac resuscitation equipment and trained staff including a cardiologist will be available be fore 
administering regadenoson.  
Efficacy of Potassium Nitrate in HFpEF    Page 57 of 79 
V12 – Date 07Oct2021  
 
 12. REGULATORY STANDARDS  
12.1. Informed consent  
The site investigator, or a person designated by the site investigator, will fully inform the subject 
of all pertinent aspects of the clinical trial including the review of the informed consent form 
approved by an Institutional Review Board (IRB). Prior to  a subject's participation in the clinical 
trial, the Informed Consent Form will be signed and personally dated by the subject or by the subject’s legally acceptable representative. Informed consent may be obtained in- person or 
virtually. All subjects will receive a copy  of the informed consent form.  
12.2. I nstitutional Review Board (IRB)  
The site Principal Investigator will submit this protocol to the appropriate IRBs, and will forward to 
the NHLBI a copy of the written and dated approval by the IRB Chairm an and committee. The 
study (study number, protocol title and version number), the document reviewed (protocol, 
Informed Consent Form, etc.) and the date of the review will be clearly stated on the written IRB 
approval opinion. During the study, any amendm ent or modification to the protocol will be sent to 
the IRB. It will also be informed of any event likely to affect the safety of subjects or the continued conduct of the study, in particular any change in safety and all updates to the protocol will be sent 
to IRB.  
12.3. Investigational New Drug (IND) application 
This trial will be done under our currently open Food and Drug Administration IND (IND#123785) 
to study this particular drug and preparation in this particular patient population. The IND Sponsor 
will be responsible for interactions with the FDA, with support from the Sponsor Support Unit within 
the Office of Clinical Research at the Perelman School of Medicine, University of Pennsylvania.  
12.4. Source document handling and archiving 
Hard copies of subject’s study records, including signed informed consent forms, HIPPA forms, 
source documents, and other study related materials will be stored in the subject binders, in a 
locked file cabinet in the research coordinator’s study office until archived. Research records will be retained for at least 2 years after the completion of this study. All study electronic files will be kept for at least 6 years after IRB acknowledgement of study termination. Files are not be 
destroyed or deleted without Sponsor appr oval. Data will be made available to the study sponsor 
National Institute of Health (NIH) members of the Institutional Review Board, and the Food and 
Drug administration, if requested by any of these entities.  
13. DA TA AND SAFETY MONITORING PLAN:  
A data and safety monitoring plan is in place for this study.   
Efficacy of Potassium Nitrate in HFpEF    Page 58 of 79 
V12 – Date 07Oct2021  
 
 14. REFERENCES  
1. IVelmurugan S, Kapil V, Ghosh SM, Davies S, McKnight A, Aboud Z, Khambata RS, Webb 
AJ, Poole A and Ahluwalia A. Antiplatelet effects of dietary nitrate in healthy volunteers: involvement of cGMP and influence of sex. Free Radic Biol Med. 2013;65:1521- 32.  
2. Kapil V, Milsom AB, Okorie M, Maleki- Toyserkani S, Akram F, Rehman F, Arghandawi S, 
Pearl V, Benjamin N, Loukogeorgakis S, Macallister R, Hobbs AJ, Webb AJ and Ahluwalia A. Inorganic nitr ate supplementation lowers blood pressure in humans: role for nitritederived 
NO. Hypertension. 2010;56:274- 81.  
3. Heffernan KS, Jae SY, Wilund KR, Woods JA and Fernhall B. Racial differences in central blood pressure and vascular function in young men. Am J Physiol Heart Circ Physiol. 
2008;295:H2380- 7.  
4. Ferdinand KC, Elkayam U, Mancini D, Ofili E, Pina I, Anand I, Feldman AM, McNamara D and Leggett C. Use of isosorbide dinitrate and hydralazine in African- Americans with heart 
failure 9 years after the African- American Heart Failure Trial. Am J Cardiol . 2014;114:151 -9.  
5. Oliveira -Paula GH. Genetic mechanisms possibly leading to racially different responses to 
nitrate therapy. Am J Cardiol . 2014;114:1126.  
6. Lam CS, Donal E, Kraigher -Krainer E and Vasan RS. Epidemi ology and clinical course of 
heart failure with preserved ejection fraction. Eur J Heart Fail . 2011;13:18- 28.  
7. Vasan RS, Benjamin EJ and Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol . 1995;26:1565- 74.  
8. Redfield MM, Jacobsen SJ, Burnett JC, Jr., Mahoney DW, Bailey KR and Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. Jama . 2003;289: 194-202.  
9. Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G, Marino EK, Lyles M, Cushman M and Enright PL. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol. 2001;87:413 -9.  
10. Devereux RB, Roman MJ, Liu JE, Welty TK, Lee ET, Rodeheffer R, Fabsitz RR and Howard BV. Congestive heart failure despite normal left ventricular systolic function in a populationbased sample: the Strong Hear t Study. Am J Cardiol . 2000;86:1090- 6.  
11. Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A and Oliveira A. Prevalence of 
chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail .  
2002;4:531 -9.  
12. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A and Grobbee DE. 
Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J . 1999;20:447- 55.  
Efficacy of Potassium Nitrate in HFpEF    Page 59 of 79 
V12 – Date 07Oct2021  
 
 13. Morgan S, Smith H, Simpson I, Liddiard GS,  Raphael H, Pickering RM and Mant D. 
Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients 
in general practice setting: cross sectional survey. Bmj . 1999;318:368 -72.  
14. Cortina A, Reguero J, Segovia E, Rodriguez Lambert JL, Cortina R, Arias JC, Vara J and Torre F. Prevalence of heart failure in Asturias (a region in the north of Spain). Am J Cardiol . 
2001;87:1417 -9.  
15. Kupari M, Lindroos M, Iivanainen AM, Heikkila J and Tilvis R. Congestive heart failure in old 
age: prev alence, mechanisms and 4- year prognosis in the Helsinki Ageing Study. Journal of 
internal medicine. 1997;241:387- 94.  
16. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, 
O'Connor CM, Sun JL, Yancy CW and Young JB. Characteristics, tr eatments, and outcomes 
of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE -HF Registry. J Am Coll Cardiol. 2007;50:768- 77.  
17. Yancy CW, Lopatin M, Stevenson LW, De Marco T and Fonarow GC. Clinical presentat ion, 
management, and in- hospital outcomes of patients admitted with acute decompensated 
heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006;47:76- 84.  
18. Lenzen MJ, Scholte op Reimer WJ, Boersma E, Vantrimpont PJ, Follath F, Swedberg K, 
Cleland J and Komajda M. Differences between patients with a preserved and a depressed 
left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J . 
2004;25:1214 -20.  
19. Lloyd- Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, 
Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW and Rosam ond WD. Defining 
and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation . 
2010;121:586 -613.  
20. Cleland JG, Tendera M, Adamus J, Freemant le N, Polonski L and Taylor J. The perindopril 
in elderly people with chronic heart failure (PEP -CHF) study. Eur Heart J . 2006;27:2338 -45.  
21. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, 
Donovan M, Iverson E, Staiger C and P taszynska A. Irbesartan in patients with heart failure 
and preserved ejection fraction. N Engl J Med . 2008;359:2456 -67. 
22. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, 
Olofsson B, Ostergren J, Investigators C and Committees.  Effects of candesartan in patients 
with chronic heart failure and preserved left -ventricular ejection fraction: the 
CHARMPreserved Trial. Lancet . 2003;362:777 -81.  
23. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, Tu JV and Levy D. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection 
Efficacy of Potassium Nitrate in HFpEF    Page 60 of 79 
V12 – Date 07Oct2021  
 
 fraction: insights from the framingham heart study of the national heart, lung, and blood 
institute. Circulation . 2009;119:3070 -7.  
24. Lam CS, Donal E, Kraigher -Krainer E and Vasan RS. Epidemiology and clinical course of 
heart failure with preserved ejection fraction. European journal of heart failure. 2011;13:1828.  
25. Hoekstra T, Lesman- Leegte I, van Veldhuisen DJ, Sanderman R and Jaarsma T. Quality of 
life is impaired similarly in heart failure patients with preserved and reduced ejection fraction. Eur J Heart Fail . 2011;13:1013- 8.  
26. Lewis EF, Lamas GA, O'Meara E, Granger CB, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Halling K, Carlsson J, Olofsson B, Mc Murray JJ, Yusuf S, 
Swedberg K and Pfeffer MA. Characterization of health- related quality of life in heart failure 
patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail . 
2007;9:8391.  
27. Oghlakian GO, Sipahi I and Fang JC. Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm? Mayo Clinic proceedings Mayo Clinic . 
2011;86:531 -9.  
28. Lundberg JO, Weitzberg E and Gladwin MT. The nitrate- nitrite -nitric oxide pathway in 
physiology and therapeuti cs. Nature reviews Drug discovery . 2008;7:156- 67.  
29. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, 
Zalos G, Xu X, Huang KT, Shields H, Kim -Shapiro DB, Schechter AN, Cannon RO, 3rd and 
Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nature medicine. 2003;9:1498- 505.  
30. Machha A and Schechter AN. Inorganic nitrate: a major player in the cardiovascular health benefits of vegetables? Nutrition reviews . 2012;70:367- 72.  
31. Tang  Y, Jiang H and Bryan NS. Nitrite and nitrate: cardiovascular risk -benefit and metabolic 
effect. Current opinion in lipidology . 2011;22:11- 5.  
32. Weitzberg E, Hezel M and Lundberg JO. Nitrate- nitrite -nitric oxide pathway: implications for 
anesthesiology and i ntensive care. Anesthesiology . 2010;113:1460 -75.  
33. Lundberg JO, Carlstrom M, Larsen FJ and Weitzberg E. Roles of dietary inorganic nitrate in cardiovascular health and disease. Cardiovascular research . 2011;89:525- 32.  
34. Dibble CT, Lima JA, Bluemke  DA, Chirinos JA, Chahal H, Bristow MR, Kronmal RA, Barr 
RG, Ferrari VA, Propert KJ and Kawut SM. Regional left ventricular systolic function and the 
right ventricle: the multi -ethnic study of atherosclerosis right ventricle study. Chest . 
2011;140:310 -6.  
35. Rubin MF, Rosas SE, Chirinos JA and Townsend RR. Surrogate markers of cardiovascular 
disease in CKD: what's under the hood? Am J Kidney Dis . 2011;57:488- 97.  
Efficacy of Potassium Nitrate in HFpEF    Page 61 of 79 
V12 – Date 07Oct2021  
 
 36. Durand M, Koistinen R, Chirinos M, Rodriguez JL, Zambrano E, Seppala M and Larrea F. 
Hormonal evaluation and midcycle detection of intrauterine glycodelin in women treated with 
levonorgestrel as in emergency contraception. Contraception. 2010;82:526 -33.  
37. Totzeck M, Hendgen- Cotta UB, Luedike P, Berenbrink M, Klare JP, Steinhoff HJ, Semmler 
D, Shiva S, Williams D, Kipar A, Gladwin MT, Schrader J, Kelm M, Cossins AR and Rassaf T. Nitrite regulates hypoxic vasodilation via myoglobin- dependent nitric oxide generation. 
Circulation . 2012;126:325- 34.  
38. Shiva S, Huang Z, Grubina R, Sun J, Ringwood LA, MacArthur PH, Xu X, Murphy E, DarleyUsmar VM and Gladwin MT. Deoxymyoglobin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration. Circ Res . 2007;100:654 -61.  
39. Rassaf T, Flogel U, Drexhage C, Hendgen -Cotta U, Kelm M and Schrader J. Nitrite 
reductase function of deoxymyoglobin: oxygen sensor and regulator of cardiac energetics and function. Circ Res . 2007;100:1749 -54.  
40. Hendgen- Cotta UB, Merx MW, Shiva S, S chmitz J, Becher S, Klare JP, Steinhoff HJ, 
Goedecke A, Schrader J, Gladwin MT, Kelm M and Rassaf T. Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischemia- reperfusion 
injury. Proc Natl Acad Sci U S A. 2 008;105:10256 -61.  
41. Gladwin MT and Kim -Shapiro DB. The functional nitrite reductase activity of the 
hemeglobins. Blood. 2008;112:2636 -47.  
42. Webb A, Bond R, McLean P, Uppal R, Benjamin N and Ahluwalia A. Reduction of nitrite to nitric oxide during ischemia pr otects against myocardial ischemia- reperfusion damage. Proc 
Natl Acad Sci U S A . 2004;101:13683 -8.  
43. Kozlov AV, Staniek K and Nohl H. Nitrite reductase activity is a novel function of mammalian mitochondria. FEBS letters . 1999;454:127- 30.  
44. Zweier JL, Li H, Samouilov A and Liu X. Mechanisms of nitrite reduction to nitric oxide in the 
heart and vessel wall. Nitric Oxide . 2010;22:83- 90.  
45. Aamand R, Dalsgaard T, Jensen FB, Simonsen U, Roepstorff A and Fago A. Generation of nitric oxide from nitrite by carbonic anhydrase: a possible link between metabolic activity and 
vasodilation. Am J Physiol Heart Circ Physiol. 2009;297:H2068- 74.  
46. Carlsson S, Wiklund NP, Engstrand L, Weitzberg E and Lundberg JO. Effects of pH, nitrite, 
and ascorbic acid on nonenzymatic nitric ox ide generation and bacterial growth in urine. 
Nitric Oxide . 2001;5:580- 6.  
47. Gago B, Lundberg JO, Barbosa RM and Laranjinha J. Red wine- dependent reduction of 
nitrite to nitric oxide in the stomach. Free Radic Biol Med. 2007;43:1233- 42.  
Efficacy of Potassium Nitrate in HFpEF    Page 62 of 79 
V12 – Date 07Oct2021  
 
 48. Gago B, Nystrom T, C avaleiro C, Rocha BS, Barbosa RM, Laranjinha J and Lundberg JO. 
The potent vasodilator ethyl nitrite is formed upon reaction of nitrite and ethanol under gastric 
conditions. Free Radic Biol Med. 2008;45:404 -12.  
49. Gautier C, van Faassen E, Mikula I, Martasek  P and Slama- Schwok A. Endothelial nitric 
oxide synthase reduces nitrite anions to NO under anoxia. Biochemical and biophysical research communications . 2006;341:816 -21.  
50. Vanin AF, Bevers LM, Slama- Schwok A and van Faassen EE. Nitric oxide synthase reduces  
nitrite to NO under anoxia. Cellular and molecular life sciences : CMLS . 2007;64:96 -103.  
51. Siervo M, Lara J, Ogbonmwan I and Mathers JC. Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta- analysis. 
The Journal of nutrition. 2013;143:818 -26.  
52. Hunault CC, van Velzen AG, Sips AJ, Schothorst RC and Meulenbelt J. Bioavailability of sodium nitrite from an aqueous solution in healthy adults. Toxicol Lett . 2009;190:48 -53.  
53. Dejam A, Hunter CJ, Tremonti  C, Pluta RM, Hon YY, Grimes G, Partovi K, Pelletier MM, 
Oldfield EH, Cannon RO, 3rd, Schechter AN and Gladwin MT. Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation . 2007;116:1821- 31.  
54. Pluta RM, Oldfield EH, Bakhtian KD, Fathi AR, Smith RK, Devroom HL, Nahavandi M, Woo S, Figg WD and Lonser RR. Safety and feasibility of long -term intravenous sodium nitrite 
infusion in healthy volunteers. PLoS One. 2011;6:e14504.  
55. Huang Z, Shiva S, Kim -Shapiro DB, Patel RP, Ringwood LA, Irby CE, Huang KT, Ho C, Hogg 
N, Schechter AN and Gladwin MT. Enzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control. J Clin Invest . 2005;115:2099 -107.  
56. Gladwin MT, Raat NJ, Shi va S, Dezfulian C, Hogg N, Kim -Shapiro DB and Patel RP. Nitrite 
as a vascular endocrine nitric oxide reservoir that contributes to hypoxic signaling, 
cytoprotection, and vasodilation. Am J Physiol Heart Circ Physiol. 2006;291:H2026- 35.  
57. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, Brosnihan 
B, Morgan TM and Stewart KP. Pathophysiological characterization of isolated diastolic heart 
failure in comparison to systolic heart failure. Jama . 2002;288:2144 -50.  
58. Phan TT, Shivu GN, Aboz guia K, Sanderson JE and Frenneaux M. The pathophysiology of 
heart failure with preserved ejection fraction: From molecular mechanisms to exercise 
haemodynamics. Int J Cardiol . 2012;158:337 -43.  
59. Kitzman  DW, Higginbotham MB, Cobb FR, Sheikh KH and Sullivan MJ. Exercise intolerance 
in patients with heart failure and preserved left ventricular systolic function: failure of the 
Frank -Starling mechanism. J Am Coll Cardiol. 1991;17:1065 -72.  
Efficacy of Potassium Nitrate in HFpEF    Page 63 of 79 
V12 – Date 07Oct2021  
 
 60. Maeder  MT, Thompson BR, Brunner -La Rocca HP and Kaye DM. Hemodynamic basis of 
exercise limitation in patients with heart failure and normal ejection fraction. J Am Coll 
Cardiol . 2010;56:855- 63.  
61. Bhella PS, Prasad A, Heinicke K, Hastings JL, Arbab- Zadeh A, Adams -Huet B, Pacini EL, 
Shibata S, Palmer MD, Newcomer BR and Levine BD. Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur J Heart Fail . 
2011;13:1296304.  
62. Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC and Kass DA. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation . 2006;114:2138 -47.  
63. Ennezat PV, Lefetz Y, Marechaux S, Six -Carpentier M, Deklunder G , Montaigne D, Bauchart 
JJ, Mounier -Vehier C, Jude B, Neviere R, Bauters C, Asseman P, de Groote P and Lejemtel 
TH. Left ventricular abnormal response during dynamic exercise in patients with heart failure and preserved left ventricular ejection fraction at rest. Journal of cardiac failure. 2008;14:475-
80.  
64. Kitzman DW and Haykowsky MJ. Invited editorial commentary for American Heart Journal mechanisms of exercise training in heart failure with preserved ejection fraction: central disappointment and peripher al promise. Am Heart J . 2012;164:807 -9.  
65. Maurer MS and Schulze PC. Exercise intolerance in heart failure with preserved ejection fraction: shifting focus from the heart to peripheral skeletal muscle. J Am Coll Cardiol. 
2012;60:129 -31.  
66. Borlaug BA, Olson TP , Lam CS, Flood KS, Lerman A, Johnson BD and Redfield MM. Global 
cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. Journal 
of the American College of Cardiology . 2010;56:845- 54.  
67. Poole DC, Hirai DM, Copp SW and Musch TI.  Muscle oxygen transport and utilization in 
heart failure: implications for exercise (in)tolerance. American journal of physiology Heart 
and circulatory physiology . 2012;302:H1050 -63.  
68. Umbrello M, Dyson A, Feelisch M and Singer M. The key role of nitric ox ide in hypoxia:  
hypoxic vasodilation and energy supply -demand matching. Antioxid Redox Signal . 2013.  
69. Dufour SP, Patel RP, Brandon A, Teng X, Pearson J, Barker H, Ali L, Yuen AH, Smolenski RT and Gonzalez -Alonso J. Erythrocyte- dependent regulation of human skeletal muscle 
blood flow: role of varied oxyhemoglobin and exercise on nitrite, S -nitrosohemoglobin, and 
ATP. Am J Physiol Heart Circ Physiol. 2010;299:H1936- 46.  
70. Bailey SJ, Winyard P, Vanhatalo A, Blackwell JR, Dimenna FJ, Wilkerson DP, Tarr J, Benjam in N and Jones AM. Dietary nitrate supplementation reduces the O
2 cost of 
lowintensity exercise and enhances tolerance to high -intensity exercise in humans. J Appl 
Physiol . 2009;107:1144- 55.  
Efficacy of Potassium Nitrate in HFpEF    Page 64 of 79 
V12 – Date 07Oct2021  
 
 71. Lam CS and Brutsaert DL. Endothelial dysfunction: a pathophysiol ogic factor in heart failure 
with preserved ejection fraction. J Am Coll Cardiol. 2012;60:1787 -9.  
72. Akiyama E, Sugiyama S, Matsuzawa Y, Konishi M, Suzuki H, Nozaki T, Ohba K, Matsubara 
J, Maeda H, Horibata Y, Sakamoto K, Sugamura K, Yamamuro M, Sumida H, Kaikita K, 
Iwashita S, Matsui K, Kimura K, Umemura S and Ogawa H. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2012;60:1778 -86.  
73. Muller-Delp JM. Aging -induced adaptations of microvascular reactivity. Microcirculation . 
2006;13:301 -14.  
74. Poole DC and Ferreira LF. Oxygen exchange in muscle of young and old rats: musclevascular -pulmonary coupling. Exp Physiol . 2007;92:341- 6.  
75. Haris M, Nang a RP, Singh A, Cai K, Kogan F, Hariharan H and Reddy R. Exchange rates of 
creatine kinase metabolites: feasibility of imaging creatine by chemical exchange saturation transfer MRI. NMR Biomed . 2012;25:1305 -9.  
76. Kogan F, Haris M, Singh A, Cai K, Debrosse C, Reddy Nanga R, Hariharan H and Reddy R. A Method for High Resolution Imaging of Creatine In vivo using Chemical Exchange Saturation Transfer (CrCEST). Magn Reson Med. 2013;In press.  
77. Weber T, Wassertheurer S, O'Rourke MF, Haiden A, Zweiker R, Rammer M, Ham etner B 
and Eber B. Pulsatile hemodynamics in patients with exertional dyspnea: potentially of value in the diagnostic evaluation of suspected heart failure with preserved ejection fraction. Journal of the American College of Cardiology . 2013;61:1874 -83.  
78. Chirinos JA and Segers P. Noninvasive evaluation of left ventricular afterload: part 1: pressure and flow measurements and basic principles of wave conduction and reflection. Hypertension. 2010;56:555- 62.  
79. Chirinos JA and Segers P. Noninvasive evaluation o f left ventricular afterload: part 2: arterial 
pressure -flow and pressure- volume relations in humans. Hypertension. 2010;56:563 -70.  
80. Nichols WW ORM, Vlachopoulos C. McDonald’s blood flow in arteries. Theoretical, 
Experimental and Clinical Principles. .  6 ed: Hodder Arnold; 2011.  
81. Chirinos JA and Segers P. Noninvasive evaluation of left ventricular afterload: part 2: arterial 
pressure -flow and pressure- volume relations in humans. Hypertension. 56:563- 70.  
82. Chirinos JA, Segers P, Rietzschel ER, De Buyzere ML, Raja MW, Claessens T, De Bacquer 
D, St John Sutton M and Gillebert T. Early and late systolic wall stress differentially relate to 
myocardial contraction and relaxation in middle- aged adults. The Asklepios study. 
Hypertension. 2013;In press.  
Efficacy of Potassium Nitrate in HFpEF    Page 65 of 79 
V12 – Date 07Oct2021  
 
 83. Chirinos JA, Segers P, Gillebert TC, Gupta AK, De Buyzere ML, De Bacquer D, St 
JohnSutton M, Rietzschel ER and Asklepios I. Arterial properties as determinants of time-varying myocardial stress in humans. Hypertension. 2012;60:64 -70.  
84. Shah SJ and Wasserstr om JA. Increased arterial wave reflection magnitude: a novel form of 
stage B heart failure? J Am Coll Cardiol. 2012;60:2178- 81.  
85. Kobayashi S, Yano M, Kohno M, Obayashi M, Hisamatsu Y, Ryoke T, Ohkusa T, Yamakawa K and Matsuzaki M. Influence of aortic impedance on the development of pressure -overload 
left ventricular hypertrophy in rats. Circulation . 1996;94:3362 -8.  
86. Gillebert TC and Lew WY. Influence of systolic pressure profile on rate of left ventricular pressure fall. Am J Physiol . 1991;261:H805- 13.  
87. Zamani P, Bluemke DA, Jacobs DR, Jr., Duprez DA, Kronmal R, Lilly SM, Ferrari VA, 
Townsend RR, Lima JA, Budoff M, Segers P, Hannan P and Chirinos JA. Resistive and Pulsatile Arterial Load as Predictors of Left Ventricular Mass and Geometry: The MultiEthnic Study of Atherosclerosis. Hypertension. 2014.  
88. Hashimoto J, Westerhof BE, Westerhof N, Imai Y and O'Rourke MF. Different role of wave reflection magnitude and timing on left ventricular mass reduction during antihypertensive treatment. J Hypertens . 2008;26:1017 -24.  
89. Gillebert TC and Lew WY. Influence of systolic pressure profile on rate of left ventricular pressure fall. Am J Physiol . 1991;261:H805- 13.  
90. Fukuta H, Ohte N, Wakami K, Asada K, Goto T, Mukai S, Tani T and Kimura G. Impact of 
arterial load on left ventricular diastolic function in patients undergoing cardiac 
catheterization for coronary artery disease. Circulation journal : official journal of the 
Japanese Circulation Society . 2010;74:1900- 5.  
91. Weber T, O'Rourke MF, Ammer M, Kvas E, Punzengruber C and Eber B. Arterial stiffness and arterial wave reflections are associated with systolic and diastolic function in patients 
with normal ejection fraction. American journal of hypertension . 2008;21:1194- 202.  
92. Chirinos JA, Segers P, Gupta AK, Swillens A, Riet zschel ER, De Buyzere ML, Kirkpatrick 
JN, Gillebert TC, Wang Y, Keane MG, Townsend R, Ferrari VA, Wiegers SE and St John 
Sutton M. Time -varying myocardial stress and systolic pressure -stress relationship: role in 
myocardial -arterial coupling in hypertension. Circulation . 2009;119:2798 -807.  
93. Chirinos JA, Rietzschel ER, De Buyzere ML, De Bacquer D, Gillebert TC, Gupta AK, Segers 
P and Asklepios i. Arterial load and ventricular -arterial coupling: physiologic relations with 
body size and effect of obesity. Hype rtension. 2009;54:558 -66.  
94. Chirinos JA, Segers P, De Buyzere ML, Kronmal RA, Raja MW, De Bacquer D, Claessens 
T, Gillebert TC, St John- Sutton M and Rietzschel ER. Left ventricular mass: allometric 
scaling, normative values, effect of obesity, and prognosti c performance. Hypertension . 
2010;56:91 -8.  
Efficacy of Potassium Nitrate in HFpEF    Page 66 of 79 
V12 – Date 07Oct2021  
 
 95. Chirinos JA, Segers P, Rietzschel ER, De Buyzere ML, Raja MW, Claessens T, De Bacquer 
D, St John Sutton M, Gillebert TC and Asklepios I. Early and late systolic wall stress differentially relate to myocardial contraction and relaxation in middle- aged adults: the 
Asklepios study. Hypertension. 2013;61:296 -303.  
96. Chowienczyk P and Shah A. Myocardial wall stress: from hypertension to heart tension. Hypertension. 2012;60:10- 1.  
97. Chirinos JA, Kips JG, Jacobs DR, Jr., Bru mback L, Duprez DA, Kronmal R, Bluemke DA, 
Townsend RR, Vermeersch S and Segers P. Arterial wave reflections and incident cardiovascular events and heart failure: MESA (Multiethnic Study of Atherosclerosis). J Am 
Coll Cardiol. 2012;60:2170- 7.  
98. Chirinos JA SP, Duprez DA, Brumback L, Bluemke DA, Zamani P,  Kronmal R,  Vaidya D,   
Ouyang P, Townsend RR Jacobs DR Jr. Late Systolic Central Hypertension as a Predictor 
of Incident Heart Failure: The Multi -Ethnic Study of Atherosclerosis. JAHA, In press . 2015.  
99. Furchgott RF and Bhadrakom S. Reactions of strips of rabbit aorta to epinephrine, 
isopropylarterenol, sodium nitrite and other drugs. The Journal of pharmacology and experimental therapeutics . 1953;108:129 -43.  
100. Lauer T, Preik M, Rassaf T, Strauer BE, Deussen A, Feelisch M and Kelm M. Plasma nitrite 
rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic 
vasodilator action. Proc Natl Acad Sci U S A. 2001;98:12814 -9.  
101. Maher AR, Milsom AB, Gunaruwan P, Abozguia K, Ahmed I, Weaver RA, Thomas P, 
Ashrafian H, Born GV, James PE and Frenneaux MP. Hypoxic modulation of exogenous nitrite -induced vasodilation in humans. Circulation . 2008;117:670 -7.  
102. Zamani P, Rawat D, Shiva- Kumar P, Geraci S, Bhuva R, Konda P, Doulias PT, Ischi ropoulos 
H, Townsend RR, Margulies KB, Cappola TP, Poole DC and Chirinos JA. Effect of inorganic 
nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation . 
2015;131:371 -80; discussion 380.  
103. Bescos R, Rodriguez FA, Iglesias  X, Ferrer MD, Iborra E and Pons A. Acute administration 
of inorganic nitrate reduces VO(2peak) in endurance athletes. Med Sci Sports Exerc . 
2011;43:1979 -86.  
104. Larsen FJ, Weitzberg E, Lundberg JO and Ekblom B. Dietary nitrate reduces maximal oxygen consumpt ion while maintaining work performance in maximal exercise. Free radical 
biology & medicine. 2010;48:342 -7.  
105. Larsen FJ, Weitzberg E, Lundberg JO and Ekblom B. Effects of dietary nitrate on oxygen 
cost during exercise. Acta Physiol (Oxf) . 2007;191:59- 66.  
106. Vanhatalo A, Bailey SJ, Blackwell JR, DiMenna FJ, Pavey TG, Wilkerson DP, Benjamin N, 
Winyard PG and Jones AM. Acute and chronic effects of dietary nitrate supplementation on 
Efficacy of Potassium Nitrate in HFpEF    Page 67 of 79 
V12 – Date 07Oct2021  
 
 blood pressure and the physiological responses to moderate- intensity and increment al 
exercise. Am J Physiol Regul Integr Comp Physiol . 2010;299:R1121- 31.  
107. Wylie LJ, Kelly J, Bailey SJ, Blackwell JR, Skiba PF, Winyard PG, Jeukendrup AE, Vanhatalo 
A and Jones AM. Beetroot juice and exercise: pharmacodynamic and doseresponse  
relationships. J Appl Physiol . 2013;115:325- 36.  
108. Haykowsky MJ, Brubaker PH, Stewart KP, Morgan TM, Eggebeen J and Kitzman DW. Effect 
of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction. J Am Coll 
Cardiol . 2012;60:120- 8.  
109. Ryan TE, Southern WM, Reynolds MA and Mc Cully KK. A cross -validation of near -infrared 
spectroscopy measurements of skeletal muscle oxidative capacity with phosphorus magnetic resonance spectroscopy. J Appl Physiol . 2013;115:1757 -66.  
110. Van Beekvelt MC, Colier WN, Wevers RA and Van Engelen BG. Perf ormance of nearinfrared 
spectroscopy in measuring local O(2) consumption and blood flow in skeletal muscle. J Appl 
Physiol . 2001;90:511- 9.  
111. Zamani P RD, Shiva- Kumar P, Geraci S, Bhuva R, Konda P, Doulias P, Ischiropoulos H, 
Townsend RR, Margulies KB, Cappola KB, Poole DC, Chirinos JA. The Effect of Inorganic Nitrate on Exercise Capacity in Heart Failure with Preserved Ejection Fraction Circulaiton, In 
press . 2015.  
112. Ghosh SM, Kapil V, Fuentes -Calvo I, Bubb KJ, Pearl V, Milsom AB, Khambata R, 
MalekiToyserkani  S, Yousuf M, Benjamin N, Webb AJ, Caulfield MJ, Hobbs AJ and 
Ahluwalia A. Enhanced vasodilator activity of nitrite in hypertension: critical role for 
erythrocytic xanthine oxidoreductase and translational potential. Hypertension. 
2013;61:1091 -102.  
113. Larsen FJ, Ekblom B, Sahlin K, Lundberg JO and Weitzberg E. Effects of dietary nitrate on 
blood pressure in healthy volunteers. N Engl J Med. 2006;355:2792 -3.  
114. Gao X, Yang T, Liu M, Peleli M, Zollbrecht C, Weitzberg E, Lundberg JO, Persson AE and Carlstrom M. NA DPH Oxidase in the Renal Microvasculature Is a Primary Target for Blood 
Pressure -Lowering Effects by Inorganic Nitrate and Nitrite. Hypertension . 2014.  
115. Larsen FJ, Schiffer TA, Borniquel S, Sahlin K, Ekblom B, Lundberg JO and Weitzberg E. Dietary inorganic  nitrate improves mitochondrial efficiency in humans. Cell metabolism . 
2011;13:149 -59.  
116. Clerc P, Rigoulet M, Leverve X and Fontaine E. Nitric oxide increases oxidative 
phosphorylation efficiency. Journal of bioenergetics and biomembranes . 2007;39:158 -66.  
117. Bailey SJ, Fulford J, Vanhatalo A, Winyard PG, Blackwell JR, DiMenna FJ, Wilkerson DP, Benjamin N and Jones AM. Dietary nitrate supplementation enhances muscle contractile 
efficiency during knee -extensor exercise in humans. J Appl Physiol . 2010;109:135- 48.  
Efficacy of Potassium Nitrate in HFpEF    Page 68 of 79 
V12 – Date 07Oct2021  
 
 118. Lansley KE, Winyard PG, Fulford J, Vanhatalo A, Bailey SJ, Blackwell JR, DiMenna FJ, 
Gilchrist M, Benjamin N and Jones AM. Dietary nitrate supplementation reduces the O 2 cost 
of walking and running: a placebo- controlled study. J Appl Physiol . 2011;110:591 -600.  
119. van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, Linke WA, Laarman GJ and Paulus WJ. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation . 2006;113:1966- 73.  
120. Collier P, Wat son CJ, Voon V, Phelan D, Jan A, Mak G, Martos R, Baugh JA, Ledwidge MT 
and McDonald KM. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Hear t Fail . 2011;13:1087 -95.  
121. Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, von Schlippenbach J, Skurk C, Steendijk P, Riad A, Poller W, Schultheiss HP and Tschope C. Cardiac inflammation contributes to changes in the extracellular matrix  in patients with heart failure 
and normal ejection fraction. Circ Heart Fail. 2011;4:44 -52.  
122. Chaturvedi RR, Herron T, Simmons R, Shore D, Kumar P, Sethia B, Chua F, Vassiliadis E and Kentish JC. Passive stiffness of myocardium from congenital heart diseas e and 
implications for diastole. Circulation . 2010;121:979- 88.  
123. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C and Moon JC. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fi brosis: preliminary validation in humans. Circulation . 2010;122:138 -44.  
124. Green CP, Porter CB, Bresnahan DR and Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol . 2000;35:1245- 55.  
125. Kim SG. Quantification of relative cerebral blood flow change by flow -sensitive alternating 
inversion recovery (FAIR) technique: application to functional mapping. Magn Reson Med. 1995;34:293 -301.  
126. Kogan F, Haris M, Debrosse C, S ingh A, Nanga RP, Cai K, Hariharan H and Reddy R. In 
vivo chemical exchange saturation transfer imaging of creatine (CrCEST) in skeletal muscle 
at 3T. J Magn Reson Imaging. 2014;40:596- 602.  
127. Haris M, Singh A, Cai K, Kogan F, McGarvey J, Debrosse C, Zsido G A, Witschey WR, 
Koomalsingh K, Pilla JJ, Chirinos JA, Ferrari VA, Gorman JH, Hariharan H, Gorman RC and 
Reddy R. A technique for in vivo mapping of myocardial creatine kinase metabolism. Nature 
Medicine. 2014;20:209 -14.  
128. Kogan F, Haris M, Singh A, Cai K, D ebrosse C, Nanga RP, Hariharan H and Reddy R. 
Method for high- resolution imaging of creatine in vivo using chemical exchange saturation 
transfer. Magn Reson Med. 2014;71:164 -72.  
Efficacy of Potassium Nitrate in HFpEF    Page 69 of 79 
V12 – Date 07Oct2021  
 
 129. Yotti R, Bermejo J, Benito Y, Antoranz JC, Desco MM, Rodriguez -Perez D, Corti na C, 
Mombiela T, Barrio A, Elizaga J and Fernandez -Aviles F. Noninvasive estimation of the rate 
of relaxation by the analysis of intraventricular pressure gradients. Circ Cardiovasc Imaging . 
2011;4:94 -104.  
130. Stewart KC, Kumar R, Charonko  JJ, Ohara T, Vlachos PP and Little WC. Evaluation of LV 
diastolic function from color M -mode echocardiography. JACC Cardiovasc Imaging. 
2011;4:37 -46.  
131. Zhang KW, French B, May Khan A, Plappert T, Fang JC, Sweitzer NK, Borlaug BA, Chirinos 
JA, St John Sutto n M, Cappola TP and Ky B. Strain improves risk prediction beyond ejection 
fraction in chronic systolic heart failure. J Am Heart Assoc. 2014;3:e000550.  
132. Segers P, Rietzschel ER, De Buyzere ML, Vermeersch SJ, De Bacquer D, Van Bortel LM, 
De Backer G, Gilleb ert TC, Verdonck PR and Asklepios i. Noninvasive (input) impedance, 
pulse wave velocity, and wave reflection in healthy middle- aged men and women. 
Hypertension. 2007;49:1248- 55.  
133. Chirinos JA, Segers P, Raina A, Saif H, Swillens A, Gupta AK, Townsend R, Emm i AG, Jr., 
Kirkpatrick JN, Keane MG, Ferrari VA, Wiegers SE and St John Sutton MG. Arterial pulsatile 
hemodynamic load induced by isometric exercise strongly predicts left ventricular mass in hypertension. Am J Physiol Heart Circ Physiol. 2010;298:H320- 30.  
134. Westerhof N, Sipkema P, van den Bos GC and Elzinga G. Forward and backward waves in the arterial system. Cardiovascular research. 1972;6:648 -56.  
135. Swillens A and Segers P. Assessment of arterial pressure wave reflection: Methodological considerations. Artery Research. 2008;2:9.  
136. Quick CM, Berger DS and Noordergraaf A. Constructive and destructive addition of forward and reflected arterial pulse waves. Am J Physiol Heart Circ Physiol. 2001;280:H1519- 27.  
137. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczy k P, Cruickshank JK, De Backer T, 
Filipovsky J, Huybrechts S, Mattace- Raso FU, Protogerou AD, Schillaci G, Segers P, 
Vermeersch S and Weber T. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid- femoral pulse wave velocity. J Hypertens . 
2012;30:445 -8.  
138. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I and Struijker -Boudier H. Expert consensus document on arterial 
stiffness: methodological issues and clinical applications. Eur Heart J . 2006;27:2588605.  
139. Chirinos JA. Arterial stiffness: basic concepts and measurement techniques. J Cardiovasc 
Transl Res . 2012;5:243 -55.  
140. Munson DA, Grubb PH, Kerecman JD, McCurnin DC, Yoder BA, Hazen SL, Shaul PW and 
Ischiropoulos H. Pulmonary and systemic nitric oxide metabolites in a baboon model of 
Efficacy of Potassium Nitrate in HFpEF    Page 70 of 79 
V12 – Date 07Oct2021  
 
 neonatal chronic lung disease. American journal of respiratory cell and molecular biology . 
2005;33:582 -8.  
141. Allen JD, Stabler T, Kenjale A, Ham KL, Robbins JL, Duscha BD, Dob rosielski DA and Annex 
BH. Plasma nitrite flux predicts exercise performance in peripheral arterial disease after 
3months of exercise training. Free Radic Biol Med. 2010;49:1138 -44.  
142. Chirinos JA, Segers P, Duprez DA, Brumback L, Bluemke DA, Zamani P, Kronm al R, Vaidya 
D, Ouyang P, Townsend RR and Jacobs DR. Late systolic central hypertension as a 
predictor of incident heart failure: the multi -ethnic study of atherosclerosis. J Am Heart Assoc . 
2015;4.  
143. Chirinos JA, Rietzschel ER, Shiva -Kumar P, De Buyzere ML, Zamani P, Claessens T, Geraci 
S, Konda P, De Bacquer D, Akers SR, Gillebert TC and Segers P. Effective arterial elastance is insensitive to pulsatile arterial load. Hypertension. 2014;64:1022 -31.  
144. Shiva Kumar P, Medina- Lezama J, Morey -Vargas O, Zamani P,  Bolanos -Salazar JF, 
Chirinos DA, Haines P, Khan ZA, Coacalla- Guerra JC, Davalos -Robles ME, Llerena- Dongo 
GR, Zapata -Ponze M and Chirinos JA. Prospective risk factors for increased central 
augmentation index in men and women. Am J Hypertens . 2015;28:121 -6.  
145. Chirinos JA, Segers P, Gillebert TC, De Buyzere ML, Van Daele CM, Khan ZA, Khawar U, 
De Bacquer D, Rietzschel ER and Asklepios I. Central pulse pressure and its hemodynamic 
determinants in middle- aged adults with impaired fasting glucose and diabetes: the 
Asklepios study. Diabetes Care . 2013;36:2359 -65.  
146. Cai K, Singh A, Poptani H, Li W, Yang S, Lu Y, Hariharan H, Zhou XJ and Reddy R. CEST signal at 2ppm (CEST@2ppm) from Z -spectral fitting correlates with creatine distribution in 
brain tumor. NMR Biomed . 2015;28:1 -8.  
147. Haris M, Singh A, Mohammed I, Ittyerah R, Nath K, Nanga RP, Debrosse C, Kogan F, Cai K, Poptani H, Reddy D, Hariharan H and Reddy R. In vivo magnetic resonance imaging of tumor protease activity. Sci Rep . 2014;4:6081.  
148. Cai K, Singh A, Roalf DR , Nanga RP, Haris M, Hariharan H, Gur R and Reddy R. Mapping 
glutamate in subcortical brain structures using high- resolution GluCEST MRI. NMR Biomed . 
2013;26:1278 -84.  
149. Haris M, Singh A, Cai K, Nath K, Crescenzi R, Kogan F, Hariharan H and Reddy R. MICEST: a potential tool for non -invasive detection of molecular changes in Alzheimer's disease. J 
Neurosci Methods . 2013;212:87- 93.  
150. Cai K, Xu HN, Singh A, Haris M, Reddy R and Li LZ. Characterizing prostate tumor mouse 
xenografts with CEST and MT -MRI and redox s canning. Adv Exp Med Biol . 2013;765:39- 45.  
151. Kogan F, Singh A, Cai K, Haris M, Hariharan H and Reddy R. Investigation of chemical exchange at intermediate exchange rates using a combination of chemical exchange 
Efficacy of Potassium Nitrate in HFpEF    Page 71 of 79 
V12 – Date 07Oct2021  
 
 saturation transfer (CEST) and spin- locking me thods (CESTrho). Magn Reson Med. 
2012;68:107 -19.  
152. Haris M, Cai K, Singh A, Hariharan H and Reddy R. In vivo mapping of brain myo- inositol. 
NeuroImage. 2011;54:2079- 85.  
153. Cai K, Xu HN, Singh A, Moon L, Haris M, Reddy R and Li LZ. Breast cancer redox 
heterogeneity detectable with chemical exchange saturation transfer (CEST) MRI. Mol Imaging Biol . 2014;16:670- 9.  
154. Kogan F, Singh A, Debrosse C, Haris M, Cai K, Nanga RP, Elliott M, Hariharan H and Reddy R. Imaging of glutamate in the spinal cord using GluCEST. NeuroImage. 2013;77:262 -7.  
155. Singh A, Haris M, Cai K, Kassey VB, Kogan F, Reddy D, Hariharan H and Reddy R. Chemical 
exchange saturation transfer magnetic resonance imaging of human knee cartilage at 3 T 
and 7 T. Magn Reson Med. 2012;68:588 -94.  
156. Swank AM, H orton J, Fleg JL, Fonarow GC, Keteyian S, Goldberg L, Wolfel G, Handberg 
EM, Bensimhon D, Illiou MC, Vest M, Ewald G, Blackburn G, Leifer E, Cooper L and Kraus 
WE. Modest increase in peak VO
2 is related to better clinical outcomes in chronic heart failure 
patients: results from heart failure and a controlled trial to investigate outcomes of exercise training. Circ Heart Fail. 2012;5:579 -85.  
157. Hintze J. PASS 11. NCSS, LLC. Kaysville, Utah, USA . http://www.ncss.com/ . 2011 .  
158. Laird NM and Ware JH. Random -effects models for longitudinal data. Biometrics . 
1982;38:963 -74.  
159. Willan AR and Pater JL. Carryover and the two- period crossover clinical trial. Biometrics . 
1986;42:593 -9.  
160. Brown BW, Jr. The crossover experiment for clinical t rials. Biometrics . 1980;36:69 -79.  
161. Grizzle JE. The Two -Period Change- over Design an Its Use in Clinical Trials. Biometrics . 
1965;21:467 -80.  
162. Singer J. Using SAS PROC MIXED to Fit Multilevel Models, Hierarchical Models, and 
Individual Growth Models. Journal  of Educational and Behavioral Statistics 24:323 -355.  
163. Little RJ. Modeling the drop- out mechanism in repeated- measures studies. Journal of the 
American Statistical Association. 1995;90:1112 -1121.  
164. Rubin DB. Multiple Imputation for Nonresponse in Surveys. J Wiley & Sons, New York 1987.  
165. Molenberghs G, Verbeke G and Kenward MG. Multiple imputation. In: Fitzmaurice G, 
Davidian M, Verbeke G, Molenberghs G (eds) Longitudinal data analysis: a handbook of 
modern statistical methods. . Chapman & Hall/CRC, Boca Rato n. 2009;477- 500:477.  
Efficacy of Potassium Nitrate in HFpEF    Page 72 of 79 
V12 – Date 07Oct2021  
 
 166. Kaiser HF. The application of electronic computers to factor analysis. . Educational and 
Psychological Measurement . 1960:141 -151.  
167. Glorfeld LW. An improvement on Horn’s parallel analysis methodology for selecting the 
correct number of  factors to retain. Educational and Psychological Measurement . 
1995;55:377 -393.  
168. Horn J. A rational and test for the number of factors in factor analysis. . Psychometrika . 
1965;30:179 -185.  
169. Gregory RJ. Psychological testing: History, principles, and applic ations (5th ed.). Boston: 
Allyn and Bacon.  
170. Fabrigar LR. Evaluating the use of exploratory factor analysis in psychological research. .  
Psychological Methods . 4:272- 299.  
171. Velicer WF, Eaton CA and Fava JL. Construct explication through factor or component 
analysis: A review and evaluation of alternative procedures for determining the number of factors or components. In R. D. Goffin & E. Helms (Eds.), Problems and solutions in human 
assessment: Honoring Douglas N. Jackson at seventy (pp. 41 -71). New York: Guilford. 2000.  
172. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Jr., Ferdinand K, Taylor M, Adams 
K, Sabolinski M, Worcel M and Cohn JN. Combination of isosorbide dinitrate and hydralazine 
in blacks with heart failure. N Engl J Med. 2004;351:2049- 57.  
173. Franciosa JA, Taylor AL, Cohn JN, Yancy CW, Ziesche S, Olukotun A, Ofili E, Ferdinand K, Loscalzo J and Worcel M. African- American Heart Failure Trial (A -HeFT): rationale, design, 
and methodology. J Card Fail . 2002;8:128 -35.  
174. Cohn JN. Contemporary treatment of heart failure: is there adequate evidence to support a 
unique strategy for African -Americans? Pro position. Curr Hypertens Rep. 2002;4:307 -10.  
175. Carson P, Ziesche S, Johnson G and Cohn JN. Racial differences in response to therapy for 
heart failure: analysis of the vasodilator -heart failure trials. Vasodilator -Heart Failure Trial 
Study Group. J Card Fail . 1999;5:178 -87.  
176. Miller GD, Marsh AP, Dove RW, Beavers D, Presley T, Helms C, Bechtold E, King SB and 
Kim-Shapiro D. Plasma nitrate and nitrite are increased by a high -nitrate supplement but not 
by high- nitrate foods in older adults. Nutrition research. 2012;32:160- 8.  
177. Gilchrist M, Winyard PG, Aizawa K, Anning C, Shore A and Benjamin N. Effect of dietary nitrate on blood pressure, endothelial function, and insulin sensitivity in type 2 diabetes. Free radical biology & medicine. 2013;60:89 -97.  
178. Zamani P, Tan VX, Soto- Calderon H, Beraun M, Brandimarto J, Trieu L, Varakantam S, 
Doulias PT, Townsend RR, Chittams J, Margulies KB, Cappola TP, Poole DC, Ischiropoulos H and Chirinos JA. Pharmacokinetics and Pharmacodynamics of Inorganic Nitrate in Heart Failure With Preserved Ejecti on Fraction. Circ Res . 2016.  
Efficacy of Potassium Nitrate in HFpEF    Page 73 of 79 
V12 – Date 07Oct2021  
 
 179. Sobko T, Marcus C, Govoni M and Kamiya S. Dietary nitrate in Japanese traditional foods 
lowers diastolic blood pressure in healthy volunteers. Nitric Oxide . 2010;22:136- 40.  
180. Wright RO, Lewander WJ and Woolf AD. Methemoglobinem ia: etiology, pharmacology, and 
clinical management. Annals of emergency medicine. 1999;34:646- 56.  
181. Eichholzer M and Gutzwiller F. Dietary nitrates, nitrites, and N -nitroso compounds and 
cancer risk: a review of the epidemiologic evidence. Nutrition review s. 1998;56:95 -105.  
182. Lundberg JO, Weitzberg E, Cole JA and Benjamin N. Nitrate, bacteria and human health.  
Nature reviews Microbiology . 2004;2:593 -602.  
183. Al-Dabbagh S, Forman D, Bryson D, Stratton I and Doll R. Mortality of nitrate fertiliser 
workers. British journal of industrial medicine. 1986;43:507 -15.  
184. Fandrem SI, Kjuus H, Andersen A and Amlie E. Incidence of cancer among workers in a Norwegian nitrate fertiliser plant. British journal of industrial medicine. 1993;50:647 -52.  
185. Forman D, Al -Dabbagh S and Doll R. Nitrates, nitrites and gastric cancer in Great Britain. 
Nature. 1985;313:620 -5.  
186. Powlson DS, Addiscott TM, Benjamin N, Cassman KG, de Kok TM, van Grinsven H, L'Hirondel JL, Avery AA and van Kessel C. When does nitrate become a risk for humans? 
Journal of environmental quality . 2008;37:291- 5.  
187. van Loon AJ, Botterweck AA, Goldbohm RA, Brants HA, van Klaveren JD and van den 
Brandt PA. Intake of nitrate and nitrite and the risk of gastric cancer: a prospective cohort study. British journal of cancer . 1998;78:129- 35.  
188. McKnight GM, Duncan CW, Leifert C and Golden MH. Dietary nitrate in man: friend or foe? Br J Nutr . 1999;81:349- 58.  
189. Mensinga TT, Speijers GJ and Meulenbelt J. Health implications of exposure to environmental nitrogenous compounds. Toxicologi cal reviews . 2003;22:41- 51.  
190. Speijers G BP. Nitrate. Food Additives Series  Geneva: Joint FAO/WHO Expert Committee on Food Additives. 2003.  
191. Wiseman M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrit ion, physical activity, and the prevention of cancer: a 
global perspective. The Proceedings of the Nutrition Society . 2008;67:253 -6.  
192. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, Forman D, Franklin B, Guazzi M, Gulati M, Keteyian SJ, Lavie CJ, Macko R, Mancini D, Milani RV, American Heart 
Association Exercise CR, Prevention Committee of the Council on Clinical C, Council on E, Prevention, Council on Peripheral Vascular D, Interdisciplinary Council on Quality of C and Outcomes R. Clinician's  Guide to cardiopulmonary exercise testing in adults: a scientific 
statement from the American Heart Association. Circulation . 2010;122:191- 225.  
Efficacy of Potassium Nitrate in HFpEF    Page 74 of 79 
V12 – Date 07Oct2021  
 
 193. Myers J, Forman DE, Balady GJ, Franklin BA, Nelson- Worel J, Martin BJ, Herbert WG, 
Guazzi M, Arena R, American Heart Association Subcommittee on Exercise CR, Prevention 
of the Council on Clinical Cardiology CoL, Cardiometabolic Health CoE, Prevention, Council 
on C and Stroke N. Supervision of exercise testing by nonphysicians: a scientific statement 
from the Ameri can Heart Association. Circulation . 2014;130:1014- 27.  
194. Zakeri R, Borlaug BA, McNulty SE, Mohammed SF, Lewis GD, Semigran MJ, Deswal A, 
LeWinter M, Hernandez AF, Braunwald E and Redfield MM. Impact of atrial fibrillation on exercise capacity in heart failur e with preserved ejection fraction: a RELAX trial ancillary 
study. Circ Heart Fail. 2014;7:123 -30.  
195. Hadeli KO, Siegel EM, Sherrill DL, Beck KC and Enright PL. Predictors of oxygen desaturation during submaximal exercise in 8,000 patients. Chest . 2001;120:88 -92.  
196. Dempsey JA and Wagner PD. Exercise- induced arterial hypoxemia. Journal of applied 
physiology . 1999;87:1997- 2006.  
197. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf  JG and Thomsen HS. 
Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrastenhanced magnetic resonance imaging. J Am Soc Nephrol . 2006;17:2359- 62.  
198. Wright RO, Lewander WJ and Woolf AD. Methemoglobinemia: etiology, pharmacol ogy, and 
clinical management. Ann Emerg Med. 1999;34:646- 56.  
Efficacy of Potassium Nitrate in HFpEF    Page 75 of 79 
V12 – Date 07Oct2021  
 
 15. APPENDIX 1. SCHEDULE OF EVENTS  
 
SCHEDULE OF EVENTS  Baseline
 assessment  Phase  1 
1 wee
k 
6 week 1-week
 
washout  Phase  2 
1 wee
k 
6 week 
Informed Consent a X 
X 
X 
 X X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 X X 
X 
X  
X 
X 
 X X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X X X 
X Eligibility assessment  X 
Medical History  X 
Concomitant Medications  X 
Randomization  X 
Dietary counseling  X 
 Kansas City Cardiomyopathy Questionnaire  X 
Physical Exam (including orthostatic vital signs and 
anthropometric measurements)  X 
12-lead ECG  X 
Laboratory tests (CBC, chem 7, methemoglobin, pregnancy 
test as needed)  X 
RNA collection with PAXgene tubes    
G6PD test as needed  X  
Cognitive assessment  X  
6 minute walk test with O2 saturation  X  
Blood, urine and saliva collection and freezing  X  
2D echocardiogram  X  
Arterial tonometry  X  
Pill count    
Drug accountability    
Maximal effort exercise test with expired gas    
Exercise cardiac output measurements    
Plantar flexor exercise / MRI    
Assessment of Adverse events    
Placement of Aurora device and Actigraph  X  
Retrieval of Aurora device and Actigraph    
       
Note: For subjects participating in the ancillary study, a cardiac MRI will be performed 4 -6 weeks 
after drug initiation in each treatment phase, on a different day than the other study procedures.  
  
Efficacy of Potassium Nitrate in HFpEF    Page 76 of 79 
V12 – Date 07Oct2021  
 
 16. APPENDIX 2. ANTICIPATED STUDY TIMELINE AND KEY DATES  
 
 
KEY DATES  
 
 
 
17. APPENDIX 3 Instructions for wearing the Aurora Device (Pulse Watch)  
 
The Aurora device is designed to record your pulse throughout the day. We ask that you wear 
throughout the day and night, as you may wear a watch. During your first study visit, we will do 
a demonstration to teach you how t o place and secure the device to your wrist.  
 
Use of the Aurora Device is very safe. However, there are a few precautions of which you 
should be aware:  
 
- The wrist strap will need to be moderately tight for acquisition of good quality pulse 
signals. It should never be so tight, however, as to restrict circulation in the hand. If you 
feel a tingling sensation in the hand or wrist where the Aurora device is being worn, 

Efficacy of Potassium Nitrate in HFpEF    Page 77 of 79 
V12 – Date 07Oct2021  
 
 immediately loosen the wrist strap. If the sensation persists, take the device off and 
disco ntinue use.  
- The device will beep several times during the day. When you hear the beep, you should 
touch the two contacts on the front of the device with two fingers from the hand that is 
not wearing the device, as illustrated in the following image:  
 
 
 
- The device has been engineered to be robust to normal daily wear conditions, but it is 
not waterproof. Therefore, avoid submerging the device in water or using it outdoors in heavy rain.  
- The Aurora Device can be cleaned using standard isopropyl alcohol wipes. Do not use any other cleaning agents. Do not submerge the device in cleaning agents.  
- Do not attempt to open the housing of the device or to dismantle the device.  
    
18. APPENDIX 4. HISTORY OF CHANGES  
All changes after version V1 (dated 4/29/16), which was finalized after receiving input from all 
DSMB members and both IRBs, and before any subject enrollment, are documented below.  
Version 2 (Feb 2016): Amended to specifically include  
a) The administration of a low -nitrate diet with study medications duri ng Visit 2 and Visit 3.  
b) The use of the Aurora watch during the symptom -limited maximal effort exercise test  
c) Blood draw at peak exercise 
d) Minor grammatical changes and inconsistencies fixed throughout the protocol  
Version 3 (July 2016):  
a) Changed the language about the randomization procedure (direct communication 
between IDS and Jesse Chittams, without involvement of the study team.  
b) Specified that we will provide subjects with a 14 -day supply of study medication at the 
beginning of each phase.  
c) Minor changes in language to meet wording consistent with FDA regulations  

Efficacy of Potassium Nitrate in HFpEF    Page 78 of 79 
V12 – Date 07Oct2021  
 
 d) Added unanticipated device- related effects as potential adverse events.  
e) Replaced MEDWATCH format with CIOMS format for SAE reporting 
f) Added a section of potential risks of investigational devices.  
g) Removed DSMB as an appendix, as it is a stand- alone core document.  
h) Removed VaSera measurements to simplify the protocol.  
Version 4 (July 2016)  
a) Updated the chemistry and manufacturing document  
b) Updated the chemistry and manufacturing portion of the protocol  
Version 5 (August 2016)  
a) Altered the inclusion criteria to remove the stipulation that evidence for elevated filling 
pressures must have been demonstrated within the last 12 months.  
Version 6 (October 2016)  
a) Modified the inclusion criteria to include specific criteria for elevated intracardiac filling 
pressures at rest or with exercise.  
b) Modified the exclusion criteria to allow enrollment of individuals with rate -controlled 
(resting HR<100) atrial fibrillation.  
c) Included specific plans to ensure MRI safety for subject who may have metal in his/her body. This includes obtaining X -rays or X -ray reports and discussing the case with an 
attending radiologist prior the MRI scan.  
d) Updated the MRI protocol to include phase contrast imaging instead of ASL.  
e) Added the Philadelphia VAMC as an enrollment site, pending VA IRB/ACOS approval and site activation.  
f) In response to VA IRB stipulations:  
i. Reworded maximal exercise test to “symptom -limited maximal effort exercise test” 
throughout the protocol  
ii. Added additional monit oring of serum potassium for participants with a baseline 
serum K between 4.7 and 5.0 mEq/L in the presence of either: (a) 
potassiumsparing  diuretic use, or (b) Estimated glomerular filtration rate of 30- 39 
mL/min/1.73m2. In this instance, we will check a serum potassium 1 week after 
the implementation of the 18 mmol/d dose as a safety measure . 
iii. Added more explicit language about the purpose of KNO
3 in the study, in the 
specific aims section: “The purpose of the trial is to test the efficacy of KNO 3 on a 
number of clinical and physiologic endpoints in subjects with HFpEF…”  
Version 7 (January 2017)  
a. Clarified that the Aurora and Actigraph devices will be given to the subjects at 
approximately 5 weeks into each interventional phase.  
b. Clarified safety monitoring to be performed during the exercise study, including oxygen saturation monitoring.  
c. Added a section (4.3.3. Criteria that will prompt exclusion from the trial at the 6 week visit) 
in response to further VA IRB stipulations  
d. Updated figure 3. Overview of study design and procedures  
Efficacy of Potassium Nitrate in HFpEF    Page 79 of 79 
V12 – Date 07Oct2021  
 
 e. Added a sentence describing that a letter may be sent to potential subjects prior to initial 
contact  
f. Added Sujith Kuruvilla, M.D. to the protocol as a sub- investigator  
  
Version 8 (July 20177)  
a. Added cognitive assessments via Cogstat e tests.  
b. Added RNA collection (PAXGene tubes)  
c. Added cuff brachial and central BP measurements using BP+ Uscom device.  
d. Removed febuxostat/allopurinol as exclusion criteria.  
e. Removed NT -proBNP testing for visits 2 and 3.  
  
Version 9 (November 2017)  
a. Added ancillary study to perform vasodilatorvasodilator cardiac MRI’s in 20 subjects 
enrolled at CMC VA Medical Center and University of Pennsylvania. The cardiac MRI will be performed  ~4 -6 weeks into each phase. The ancillary study is designed to assess the 
effect of KNO
3 on myocardial perfusion (MP) and perfusion reserve (MPR) in 
HFpEFHFpEF subjects. Stress cardiac MRI’s will be performed at 1.5 T scanner. Subjects will be administered GBCA (Gadolinium Based Contrast Agent) and Regandenoson. The potential risks associated with these procedures and adequacy to protect against these 
risks are also added.  
b. Some minor typos were corrected.  
c. Ambulatory blood pressure monitoring was removed.  
d. The placement of Actigraph (activity monitor) was specified inin the wri st instead of hip.   
e. Addition of standardized low nitrate breakfast to baseline visit following the blood draw for 
labs and biomarker samples . 
f. SpecificationSpecification of cutpoints  for considering a quantitative G6PD activity test 
“positive” for clinically significant G6PD deficiency (<60% of normal).  
g. Increase of number of enrolled subjects to 84.  
Version 10 ( October  2018)  
a. Added laungage for recent FDA guidance regarding GBCA (Gadol inium Based Contrast 
Agent) administration. The potential risks associated with these procedures and adequacy to protect against these risks were also updated.  
b. Some minor typos and formatting  errors  were corrected.  
c. Clarification of the role of the DSM B and PI reporting requirements  
d. Clarification of some exclusion criteria.  
 
Version 11 (March 2020)  
a. Added Srinath Adusumalli, MD, M. SC, to protocol as sub -investigator  
 
Version 12  (07-Oct-2021 ) 
a. Added clarification of consent procedure  
 